Cover page  
 
 
Official Title:  
Multi -center, blinded, randomized, parallel -group, Phase 3 study with aprocitentan in 
subjects with resistant hypertension (RHT).  
Study Registry ID: [REMOVED]  
  
Brief Title:  
A Research Study to Show the Effect of Aprocitentan in the Treatment of Difficult to 
Control (Resistant) High Blood Pressure (Hypertension) and Find Out More About Its 
Safety  
(PRECISION)  
 
Date of protocol document:  
[ADDRESS_929969]-100601_v01  
Aprocitentan / ACT -132577  
Resistant Hypertension  
Protocol ID -080A301  
PRECISION  
Multi -center, blinded, randomized, PaRallEl-group, Phase 3 study with apro CItentan in 
Subjects with Res Istant Hypertensi ON (RHT)  
Study Phase:  [ADDRESS_929970] Number:  2017 -004393 -33 
Status and version:  Final  Version 3 
Date:  27 February  2020 
Document type : Amended g lobal protocol  
Idorsia document number 
(Doc No.):  D-20.[ADDRESS_929971]. It is understood that this information will not be disclosed to others without 
written authorization from Idorsia Pharmaceuticals Ltd, except to the extent neces sary to obtain informed 
consent from those persons to whom the study treatment may be administered.  
Aprocitentan / ACT -132577  
Resistant hypertension  
Protocol ID -080A301  
Version 3  
27 February  2020 , page  2/[ADDRESS_929972] DETA ILS 
Sponsor  Idorsia Pharmaceuticals Ltd  
Hegenheimermattweg 91  
CH-4123 Allschwil  
Switzerland  
 [PHONE_744] [ADDRESS_929973] details of the  Clinical Trial Physician can 
be found in the Investigator Site File.  
Medical Emergency Hotline  
Toll phone number:  Site-specific toll telephone numbers and toll -free 
numbers for the Medical Emergency Hotline can 
be found in the Investigator Site File.  
CONTRACT RESEARCH OR GANIZATIONS ’ INFORMATION  
Some study activities will be delegated to Contract Research Organizations (CROs). A 
list of site -specific contact [CONTACT_42886].  
Api-odtentan / ACT-132577 
Resistant hypertension 
Protocol ID-080A301 
Version 3 
27 Februaty 2020, page 3/[ADDRESS_929974] 2017-004393-33 
Doc No D-20.008 
SIGNATURE [CONTACT_686111] / number 
Aprocitentan / ACT-132577 
Indication 
Resistant hypertension 
Protocol number, study acronym, study title 
ID-080A301, PRECISION 
Multi-center, blinded, randomized, parallel-group, Phase 3 study with aprocitentan in 
subjects with resistant hype1iension (RHT). 
I approve the te1ms and
 conditions relating  to this study as defined in this protocol.  I 
confnm that the infonnation contained in this  protocol is consistent  with the cm-rent 
risk-benefit evaluation
 of aprocitentan, and with
 the ethical and scientific principles 
governing clinical research as set out in the Declaration of Helsinki and the International 
Council for Haimonisation (ICH) Good Clinical Practice (GCP) guidelines. 
Title Name [CONTACT_686112] =p=p=oc-'
[COMPANY_003] 
-======= ---
Aprocitentan / ACT -132577  
Resistant hypertension  
Protocol ID -080A301  
Version 3  
27 February  2020 , page  4/[ADDRESS_929975] 2017 -004393 -33 
Doc No D-20.008  
INVESTIGATOR SIGNATURE [CONTACT_180549] / number 
Aprocitentan / ACT-132577 
Indication 
Resistant hypertension  
Protocol number, study acronym, study title 
ID-080A301, PRECISION, 
Multi-ce
nter, blinde d, randomize d, parallel-grou p, Phase 3 study with aprocite ntan in 
subjects wit h resistant hypertension (RHT ). 
I agree to the terms and conditions relating to this study as defined in this protocol and any 
other  protocol-related  documents.  I fully  understand  that any  changes  instituted  by [CONTACT_1275](s)  without  previous  agreement  with the sponsor would constitute  a protocol 
deviation, including any ancillary studies or procedures performed on study subjects (other 
than those procedures necessary for the wellbeing of the subjects). 
I agree  to conduct  this study  in accordance  with the Declaration  of Helsinki  principles, 
International Council for Harmonisation (ICH) Good Clinical Practice (GCP) guidelines, 
and applicable regulations and laws. 
Country  Site 
number  Town  Date  Signature  
[INVESTIGATOR_97159]  
[INVESTIGATOR_685992] / ACT -132577  
Resistant hypertension  
Protocol ID -080A301  
Version 3  
27 February  2020 , page  5/[ADDRESS_929976] OF ABBREVIATION S AND ACRONYMS  ................................ .......................... 12 
SUBSTANTIAL GLOBAL A MENDMENT 2  ................................ ................................ .16 
PROTOCOL SYNOPSIS ID -080A301  ................................ ................................ ............. 21 
PROTOCOL  ................................ ................................ ................................ ...................... 32 
1 BACKGROUND  ................................ ................................ ................................ ......... 32 
1.1 Hypertension and  resistant hypertension  ................................ ...................... 32 
1.1.1  Current treatment of RHT  ................................ ................................ .33 
1.1.2  Unmet medical need in RHT  ................................ ............................ 34 
1.2 Aprocitentan  ................................ ................................ ................................ .34 
1.2.1  Mechanism of action and rationale for development in RHT  .......... 34 
1.2.2  Nonclinical summary  ................................ ................................ ........ 35 
1.2.3  Clinical summary  ................................ ................................ .............. 35 
1.2.4  Aprocitentan dose rationale  ................................ .............................. 39 
1.3 Rationale of the study  ................................ ................................ ................... 40 
1.4 Summary of known and potential risks and benefits  ................................ ....40 
2 STUDY OBJECTIVES  ................................ ................................ ............................... 41 
2.1 Primary objective  ................................ ................................ .......................... 41 
2.2 Secondary objectives  ................................ ................................ .................... 41 
2.3 Othe r objectives  ................................ ................................ ............................ 42 
3 OVERALL STUDY DESIGN  AND PLAN  ................................ ............................... 42 
3.1 Study design  ................................ ................................ ................................ .42 
3.1.1  Study peri ods ................................ ................................ .................... 42 
[IP_ADDRESS]  Screening period  ................................ ................................ ..... 43 
[IP_ADDRESS]  Placebo run -in period  ................................ .............................  43 
[IP_ADDRESS]  Randomized treatment period  ................................ ................  43 
[IP_ADDRESS]  Safety follow -up (FU) period  ................................ .................  44 
3.1.2  Study duration  ................................ ................................ ................... 45 
3.2 Overall study design rationale  ................................ ................................ ......45 
3.2.1  Rationale for DB part  ................................ ................................ ........ 45 
3.2.2  Rationale for SB aprocitentan part and  DB-WD part  ....................... 46 
3.3 Study committees  ................................ ................................ ......................... 46 
3.3.1  Independent Central Adjudication Committee  ................................ .46 
Aprocitentan / ACT -132577  
Resistant hypertension  
Protocol ID -080A301  
Version 3  
27 February  2020 , page  6/[ADDRESS_929977] 2017 -004393 -33 
Doc No D-20.008  
 
 3.3.2  Independent Data Monitoring Committee  ................................ ........ 46 
4 STUDY POPULATION  ................................ ................................ ............................. 47 
4.1 Selection of study population  ................................ ................................ .......47 
4.2 Rationale for the selection of the study population  ................................ ......48 
4.3 Inclusion criteria  ................................ ................................ ........................... 48 
4.4 Exclusion criteria  ................................ ................................ .......................... 49 
4.5 Criteria for women of childbearing potential  ................................ ............... 51 
4.5.1  Definition of childbearing potential  ................................ .................. 51 
4.5.2  Acceptable methods of contraception  ................................ ............... 52 
5 TREATMENTS  ................................ ................................ ................................ .......... 54 
5.1 Study treatment  ................................ ................................ ............................. 54 
5.1.1  Investigational treatment and matching placebo  .............................. 54 
5.1.2  Study treatment dosing and rationale  ................................ ................ 54 
5.1.3  Study treatment administration  ................................ ......................... 54 
5.1.4  Treatment assignment  ................................ ................................ .......54 
5.1.5  Blinding  ................................ ................................ ............................ 55 
5.1.6  Unblinding  ................................ ................................ ........................ 56 
[IP_ADDRESS]  Unblinding for final analyses  ................................ .................  56 
[IP_ADDRESS]  Unblinding for suspected unexpected serious adverse 
reactions  ................................ ................................ ..................  56 
[IP_ADDRESS]  Emergency procedure for unblinding  ................................ ..... 56 
5.1.7  Study treatment supply  ................................ ................................ .....56 
[IP_ADDRESS]  Study treatment packaging and labeling  ................................  57 
[IP_ADDRESS]  Study treatment distribution and storage  ................................  57 
[IP_ADDRESS]  Study treatment dispensing  ................................ ....................  57 
[IP_ADDRESS]  Study treatment return and destruction  ................................ .. 57 
5.1.8  Study treatment adherence  ................................ ................................ 57 
[IP_ADDRESS]  Study treatment adherence based on accountability  ...............  58 
[IP_ADDRESS]  Standardized background antihypertensive therapy 
adherence based on urine analysis  ................................ ..........  59 
5.1.9  Study treatment dose adjustments and interruptions  ........................ 59 
5.1.10  Premature discontinuation of study treatment  ................................ ..60 
5.1.11  Study -specific criteria for interruption / premature 
discontinuation of study t reatment  ................................ .................... 61 
[IP_ADDRESS]  Hypertension  ................................ ................................ ..........  61 
[IP_ADDRESS]  Renal failure  ................................ ................................ ...........  61 
[IP_ADDRESS]  Persistent fluid retention  ................................ .........................  61 
[IP_ADDRESS]  Hemoglobin abnormalities  ................................ .....................  61 
Aprocitentan / ACT -132577  
Resistant hypertension  
Protocol ID -080A301  
Version 3  
27 February  2020 , page  7/[ADDRESS_929978] 2017 -004393 -33 
Doc No D-20.008  
 
 [IP_ADDRESS]  Liver aminotransferases abnormalities  ................................ ... 62 
[IP_ADDRESS]  Pregnancy  ................................ ................................ ...............  63 
5.2 Previous and concomitant therapy  ................................ ................................ 63 
5.2.1  Definitions  ................................ ................................ ........................ 63 
5.2.2  Mandatory concomitant therapy  ................................ ....................... 63 
5.2.3  Allowed concomitant therapy  ................................ ........................... 64 
[IP_ADDRESS]  Antihypertensive rescue medication  ................................ ...... 65 
[IP_ADDRESS]  Diuretics for fluid retention  ................................ ....................  65 
5.2.4  Forbidden concomitant therapy  ................................ ........................ 65 
5.2.5  Reporting of previous / concomitant therapy in the eCRF  ............... 66 
[IP_ADDRESS]  Antihypertensive therapi[INVESTIGATOR_014]  ................................ .....................  66 
[IP_ADDRESS]  Other therapi[INVESTIGATOR_014]  ................................ ................................ ....... 66 
6 STUDY ENDPOINTS  ................................ ................................ ................................ 66 
6.1 Efficacy endpoints  ................................ ................................ ........................ 66 
6.1.1  Primary efficacy endpoint  ................................ ................................ .66 
6.1.2  Secondary efficacy endpoints  ................................ ........................... 67 
6.1.3  Other efficacy endpoints  ................................ ................................ ...67 
6.2 Safety endpoints  ................................ ................................ ........................... 67 
6.3 Pharmacokinetic endpoints  ................................ ................................ ........... 68 
6.4 Biomarker endpoints  ................................ ................................ ..................... 68 
6.5 Rationale for primary and secondary endpoints  ................................ ........... 68 
7 VISIT SCHEDULE AND S TUDY ASSESSMENTS  ................................ ................ 69 
7.1 Study visits  ................................ ................................ ................................ ...69 
7.1.1  Screening/re -screening  ................................ ................................ ......69 
[IP_ADDRESS]  Screening  ................................ ................................ ................  69 
[IP_ADDRESS]  Re-screening  ................................ ................................ ...........  69 
7.1.2  Placebo RI period  ................................ ................................ .............. 70 
7.1.3  Randomized treatment period  ................................ ........................... 70 
7.1.4  Unscheduled visits  ................................ ................................ ............ 70 
7.2 Study assessments  ................................ ................................ ......................... 75 
7.2.1  Baseline demographics and disease characteristics  .......................... 76 
[IP_ADDRESS]  Hypertension history  ................................ ..............................  76 
[IP_ADDRESS]  Data to be collected for screening failure subjects  .................  76 
7.2.2  Efficacy assessments  ................................ ................................ ......... 76 
[IP_ADDRESS]  Unattended automated office blood pressure 
measurement (AOBPM)  ................................ .........................  76 
[IP_ADDRESS]  Ambulatory blood pressure monitoring  ................................ . 77 
[IP_ADDRESS]  Home blood pressure measurement  ................................ ....... 78 
Aprocitentan / ACT -132577  
Resistant hypertension  
Protocol ID -080A301  
Version 3  
27 February  2020 , page  8/[ADDRESS_929979] 2017 -004393 -33 
Doc No D-20.008  
 
 7.2.3  Safety assessments  ................................ ................................ ............ 78 
[IP_ADDRESS]  Vital signs  ................................ ................................ ...............  79 
[IP_ADDRESS]  Physical examination  ................................ ..............................  79 
[IP_ADDRESS]  Weight and height  ................................ ................................ .. 79 
[IP_ADDRESS]  ECG assessment  ................................ ................................ ..... 80 
[IP_ADDRESS]  Laboratory assessments  ................................ ..........................  80 
7.2.4  Pharmacokinetic assessments  ................................ ........................... 83 
[IP_ADDRESS]  Sampling, labeling, storage and shipment  ..............................  83 
[IP_ADDRESS]  Bioanalysis  ................................ ................................ .............  [ADDRESS_929980] -STUDY TREATMEN T / MEDICAL 
CARE  ................................ ................................ ................................ .......................... 84 
8.1 Study completion as per protocol  ................................ ................................ .84 
8.2 Premature withdrawal from study  ................................ ................................ 84 
8.3 Premature termination or suspension of the study  ................................ ........ 85 
8.4 Medical care of subjects after study completion / withdrawal from 
study  ................................ ................................ ................................ .............. 86 
9 SAFETY DEFINITIONS A ND REPORTING REQUIRE MENTS  ........................... 86 
9.1 Safety definitions  ................................ ................................ .......................... 86 
9.1.1  Definition of adverse events  ................................ ............................. 86 
9.1.2  Definition of serious adverse events  ................................ ................. 87 
9.1.3  Definition of suspected unexpected s erious adverse reaction  .......... 87 
9.1.4  Definition of the intensity of adverse events  ................................ ....88 
9.1.5  Relationship to study treatment  ................................ ........................ 88 
9.1.6  Relationship to study design or protocol -mandated procedure  ........ 88 
9.2 Time period and frequency for AE/SAE assessment and foll ow-up ............ 88 
9.2.1  Follow -up of adverse events  ................................ ............................. 89 
9.2.2  Follow -up of serious adverse events  ................................ ................. 89 
9.3 Reporting procedures  ................................ ................................ .................... 89 
9.3.1  Reporting of adverse events  ................................ .............................. 89 
9.3.2  Additional reporting procedures for serious adverse events  ............. 89 
9.3.3  Additional reporting procedures for S[LOCATION_003]R  ................................ ....90 
9.4 Pregnancy  ................................ ................................ ................................ .....90 
9.4.1  Reporting of pregnancy  ................................ ................................ ....90 
9.4.2  Follow -up of pregnancy  ................................ ................................ ....90 
9.5 Reporting of study treatment overdose, misuse, and abuse  .......................... 91 
9.6 Study sa fety monitoring  ................................ ................................ ................ 91 
Aprocitentan / ACT -132577  
Resistant hypertension  
Protocol ID -080A301  
Version 3  
27 February  2020 , page  9/[ADDRESS_929981] 2017 -004393 -33 
Doc No D-20.008  
 
 10 STATISTICAL METHODS  ................................ ................................ ....................... 91 
10.1  Analysis sets  ................................ ................................ ................................ .91 
10.1.1  Screene d Set  ................................ ................................ ...................... 91 
10.1.2  Run-in Set  ................................ ................................ ......................... 91 
10.1.3  Full Analysis Set (FAS)  ................................ ................................ ....91 
10.1.4  Per Protocol Set  ................................ ................................ ................ 92 
10.1.5  Mod ified FAS  ................................ ................................ ................... 92 
10.1.6  ABPM FAS  ................................ ................................ ....................... 92 
10.1.7  Modified ABPM FAS  ................................ ................................ .......92 
10.1.8  Safety Analysis Set  ................................ ................................ ........... 92 
10.1.9  Modified Safety Analysis Set  ................................ ........................... 92 
10.1.10  Pharmacokinetic Set  ................................ ................................ ......... 92 
10.1.1 1 Usage of the analysis sets  ................................ ................................ .92 
10.2  Variables  ................................ ................................ ................................ .......93 
10.2.1  Primary efficacy variable  ................................ ................................ ..93 
10.2.2  Secondary efficacy variables  ................................ ............................ 93 
10.2.3  Safety variables  ................................ ................................ ................. 93 
10.3  Description of statistical analyses  ................................ ................................ .94 
10.3.1  Overall testing strategy  ................................ ................................ .....94 
10.3.2  Analysis of the primary efficacy variable  ................................ ......... 94 
[IP_ADDRESS]  Main analysis in the DB part  ................................ ..................  95 
[IP_ADDRESS]  Handling of missing data in the DB part  ................................  95 
[IP_ADDRESS]  Sensitivity analyses for missing data in the DB part  ..............  95 
[IP_ADDRESS]  Supportive analyses in the DB part  ................................ ........  96 
[IP_ADDRESS]  Subgroup analyses in the DB part  ................................ ..........  96 
10.3.3  Analysis of the key secondary efficacy variable  .............................. 96 
[IP_ADDRESS]  Main analysis in the DB -WD part  ................................ ..........  97 
[IP_ADDRESS]  Handling of missing data in the DB -WD part  ........................  97 
[IP_ADDRESS]  Sensitivity analyses for missing data in the DB -WD part  ...... 97 
[IP_ADDRESS]  Supportive analyses in the DB -WD part  ................................  97 
[IP_ADDRESS]  Subgroup analyses in the DB -WD part  ................................ .. 98 
10.3.4  Analysis of the other secondary efficacy variables  .......................... 98 
10.3.5  Analysis of other efficacy variables  ................................ .................. 98 
10.3.6  Analysis of the safety variables  ................................ ........................ 98 
[IP_ADDRESS]  Adverse events  ................................ ................................ ....... 98 
[IP_ADDRESS]  Laboratory data  ................................ ................................ ....... 99 
[IP_ADDRESS]  Vital  signs  ................................ ................................ ...............  99 
[IP_ADDRESS]  ECG  ................................ ................................ ......................  100 
[IP_ADDRESS]  Treatment -emergent MACE and MACE -plus .....................  100 
Aprocitentan / ACT -132577  
Resistant hypertension  
Protocol ID -080A301  
Version 3  
27 February  2020 , page  10/[ADDRESS_929982] 2017 -004393 -33 
Doc No D-20.008  
 
 [IP_ADDRESS]  Increase in dose of existing diuretic or addition of new 
diuretic due to fluid retention  ................................ ...............  100 
10.3.7  Analysis of other variables  ................................ ............................. 100 
10.4  Interim analyses  ................................ ................................ .......................... 100 
10.5  Sample size  ................................ ................................ ................................ .100 
11 DATA HANDLING  ................................ ................................ ................................ ..101 
11.1  Data collec tion ................................ ................................ ............................ 101 
11.2  Maintenance of data confidentiality  ................................ ........................... 102 
11.3  Database management  ................................ ................................ ................ 102 
12 PROCE DURES AND GOOD CLINI CAL PRACTICE  ................................ ........... 103 
12.1  Ethics and Good Clinical Practice  ................................ .............................. 103 
12.2  Independent Ethics Committee / Institutional Review Board 
(IEC/IRB)  ................................ ................................ ................................ ...103 
12.3  Informed consent  ................................ ................................ ........................ 103 
12.4  Compe nsation to subjects and investigators  ................................ ............... 104 
12.5  Protocol adherence/compliance  ................................ ................................ ..104 
12.6  Protocol amendments  ................................ ................................ ................. 104 
12.7  Essential documents and retention of documents  ................................ .......105 
12.8  Monitoring  ................................ ................................ ................................ ..106 
12.9  Investigator Site File  ................................ ................................ ................... 107 
12.10  Audit  ................................ ................................ ................................ ........... 107 
12.11  Inspections  ................................ ................................ ................................ ..107 
12.12  Reporting of study results  and publication  ................................ ................. 108 
13 REFERENCES  ................................ ................................ ................................ .......... 109 
14 APPENDICES  ................................ ................................ ................................ ........... 116 
 
Aprocitentan / ACT -132577  
Resistant hypertension  
Protocol ID -080A301  
Version 3  
27 February  2020 , page  11/[ADDRESS_929983] OF TABLES  
 
Table  1 BP thresholds for the definition of uncontrolled BP (i.e., 
hypertension)  ................................ ................................ .............................  [ADDRESS_929984] OF APPENDICES  
 
Appendix 1  Forbidden drugs  ................................ ................................ .......................  116 
 
 
Aprocitentan / ACT -132577  
Resistant hypertension  
Protocol ID -080A301  
Version 3  
27 February  2020 , page  12/[ADDRESS_929985] observed treatment  
ECG  Electrocardiogram  
eCRF  Electronic case report form  
eGFR  Estimated glomerular filtration rate  
EOS  End-of-Study  
Aprocitentan / ACT -132577  
Resistant hypertension  
Protocol ID -080A301  
Version 3  
27 February  2020 , page  13/[ADDRESS_929986]  
ESC European Society of Cardiology  
ESH  European Society of Hypertension  
ET Endothelin  
FAS Full Analysis Set  
FDA  Food and Drug Administration  
FU Follow -up 
GCP  Good Clinical Practice  
HCTZ  Hydrochlorothiazide  
HR Heart rate  
IB Investigator ’s Brochure  
ICF Informed c onsent form 
ICH International Council for Harmonis ation  
IDMC  Independent Data Monitoring Committee  
IEC Independent Ethics Committee  
IRB Institutional Review Board  
IRT Interactive Response Technology  
ISAC  Independent Statistical Analysis Center  
ISF Investigator Site File  
J2R Jump to Reference  
LSM  Least Squares Mean  
MACE  Major a dverse cardiac event(s) 
maFAS  Modified ABPM Full Analysis Set  
MAR  Missing at random  
MCH  Mean corpuscular hemoglobin  
MCHC  Mean corpuscular hemoglobin concentration  
MCV  Mean corpuscular volume  
MedDRA™ Medical Dictionary for Regulatory Activities  
mFAS  Modified Full Analysis Set  
MI Myocardial i nfarction  
Aprocitentan / ACT -132577  
Resistant hypertension  
Protocol ID -080A301  
Version 3  
27 February  2020 , page  14/[ADDRESS_929987]  
MR-proANP  Mid-regional pro -atrial natriuretic peptide  
mSAF  Modified Safety Analysis Set  
NT-proBNP  N-terminal pro -brain natriuretic peptide
NYHA  [LOCATION_001] Heart Association
PD Pharmacodynamic(s)
PI [INVESTIGATOR_244873](s)
PPS Per Protocol Set
QS Quality System
QTc Corrected QT
QTcB  QT corrected according to Bazett ’s formula
QTcF  QT corrected according to Fridericia ’s formula
RAS  Renin a ngiotensin system
RHT  Resistant hypertension
RI Run-in
RIS Run-in Set
RSI Reference safety information
SAE Serious adverse event
SAF Safety Analysis Set
SAP Statistical Analysis Plan
SB Single -blind
SBP Systolic blood pressure
SCR  Screened Set
SiDBP  Sitting diastolic blood pressure
SiSBP  Sitting systolic blood pressure
SIV Site initiation visit
SOC  System organ class
SSRI  Selective serotonin reuptake inhibitor
S[LOCATION_003]R  Suspected unexpected serious adverse reaction
Aprocitentan / ACT -132577  
Resistant hypertension  
Protocol ID -080A301  
Version 3  
27 February  2020 , page  15/[ADDRESS_929988]  Upper limit of normal  
US [LOCATION_002]  
USPI  [INVESTIGATOR_685993] / ACT -132577  
Resistant hypertension  
Protocol ID -080A301  
Version 3  
27 February  2020 , page  16/[ADDRESS_929989] 2017 -004393 -33 
Doc No D-20.008  
SUBSTANTIAL  GLOBAL AMENDMENT 2 
Amendment rationale 
This global  amendment applies to the global protocol ID -080A301 Version 2 dated 
19 September  2018. The resulting amended global  protocol is Version 3 dated 
27 February  2020.  
The main change s to the protocol in this amendment are: 
1.The inclusion  criteri a 4 and 11 , section 4.3.
2.The exclusion criteri a 5 and 11 , section 4.4.
3.The study -specific discontinuation criterion for renal failure, section [IP_ADDRESS].
4.The forbidden medication, appendix 1.
The changes are as follows:
1.The inclusion criteri a [ADDRESS_929990] been modifi ed (strikethrough  and/or bol d) to:
1a: Inclusion criterion 4:
 Treated with at least [ADDRESS_929991] 4 weeks before the screening visit (Visit 1).
Beta blockers are not coun ted as background antihypertensive medication.
This criterion was previously selected in line  with recent hypertension guidelines (e.g., 
ESH 2018 [Williams  2018 ], AHA [Whelton  2017 ] which  recommends a diuretic as one of 
the 3 background antihypertensiv e medications , and  beta-blockers  mainly as the 4th 
medication  or earlier (e.g., as the 2nd or 3rd medication) if it is prescribed for other 
indication s than hypertension  (e.g., heart failure, angina, post -myocardial infarction , atrial 
fibrillation ).  
Information collected during the screening  period in PRECISION show  that some subjects  
are not treated with a diuretic and/or that a beta-blocker  is used as an antihypertensive 
medication . Therefore, t o open the recruitment  for th ose patients  who have uncontrolled 
blood pressure ( BP) but are treated with a combination of medications that are not strictly 
aligned to the recent hypertension guidelines , this inclusion criterion was modified . 
This modification will not affect  the intended patient population in this study which 
remains true resistant hypertension ( RHT). The management of the subjects  as per current 
Version 2 of the protocol beyon d screening  is not altered as the background 
antihypertensive medication s of all screened subjects will be standardized by [CONTACT_667187] 
a fixed -dose combination of a calcium channel blocker ( CCB ; amlodipi[INVESTIGATOR_050]), an angiotensin 
Aprocitentan / ACT -132577  
Resistant hypertension  
Protocol ID -080A301  
Version 3  
27 February  2020 , page  17/[ADDRESS_929992] 2017 -004393 -33 
Doc No D-20.008  
receptor blocker  (ARB ; valsartan) and a diuretic (hydrochlorothiazide  [HCTZ ]) for at least 
[ADDRESS_929993] uncontrolled BP (i.e., mean  
trough sitting s ystolic blood press ure [SiSBP ] ≥ 140 mmHg measured by [CONTACT_686028] [ AOBPM ]) despi[INVESTIGATOR_12847] 3 antihypertensive 
medications including a diuretic (in line with the guidelines ’ recommendation) to continue 
in the study and enter the run -in period .  
1b: Inclusion criterion 1 1: 
 Stable dose of the standardized background antihypertensive therapy since the start
for at least 1 week before Day –1 (end  of the RI period ).
This inclusion criterion was previously put in place to ensure a stable dose of the 
standardized background antihypertensive therapy and consequently a stable blood 
pressure before randomization.  
The standardized background antihypertensive therapy  is a triple fixed -dose combination 
of amlodipi[INVESTIGATOR_050], valsartan and HCTZ. Two dose stre ngths will be available: 10/160/25 and 
5/160/25 mg (amlodipi[INVESTIGATOR_050], valsartan, HCTZ, respectively)  to account for potential edema 
which occurs in a dose -related manner  with amlodipi[INVESTIGATOR_050] . The protocol recommends use of 
amlodipi[INVESTIGATOR_050] 10 mg (section 5.2.2). Consequent ly, for subjects having tolerability issues 
with the higher dose of [ADDRESS_929994] ates Prescribing Information ( USPI ) 
patient ’s response to each dose level of amlodipi[INVESTIGATOR_685994] [ADDRESS_929995] been extended ( bold) to:
2a: Exclusion criterion 5:
 Clinically significant unstable cardiac disease at screening or in the past  in the
opi[INVESTIGATOR_871], e.g., uncontrolled symptomatic arrhythmia, atrial
fibrillation , congestive heart failure  NYHA stage II with relevant mitral valve
insufficiency and/ or aortic stenosis,  congestive heart failure  NYHA stage  III or
IV, congestive heart failure .
This criterion excludes subjects with significant or potential unstable cardiac disease. 
During the medical review of enrolled subjects, it was noticed that some subjects entered 
the study with [LOCATION_001] Heart Association  (NYHA ) stage II. However, their medical 
history suggested possible instability in their cardiac co ndition due to mitral valve 
insufficiency and/or aortic stenosis . Therefore, further explanation was added to the 
Aprocitentan / ACT -132577  
Resistant hypertension  
Protocol ID -080A301  
Version 3  
27 February  2020 , page  18/[ADDRESS_929996] the intended patient population in 
this study. It emphasizes exclusion of subjects with clinically significant unstable cardiac 
disease. 
2b: Exclusion criterion 11:  
 Treatment with any medication which may affect BP (e.g., treatment of psyc hiatric
diseases)  [see Appendix 1] and/or treatment with high dose of loop diuretics
(i.e., furosemide greater than 80 mg/day, or equivalent dosage of other loop
diuretics).
The third Independent Data Monitoring Committee (IDMC) meeting took place on 
[ADDRESS_929997] with cardiac failure with preserve d ejection 
fraction ( NYHA  stage II), post procedural pulmonary embolism and diabetes mellitus type 
2 who entered the study receiving background antihypertensive medications from different  
pharmacological classes including the following diuretics: high dose of loop diuretics (i.e., 
furosemide 80 mg twice a day) and thiazide diuretic (i.e., hydrochlorothiazide 25 mg). 
These background antihypertensive medications were switched to the standar dized 
background antihypertensive therapy (i.e., triple fixed-dose combination of amlodipi[INVESTIGATOR_050], 
valsartan and hydrochlorothiazide) according to the protocol. High dose of loop diuretics 
is normally prescribed for treatment of congestive heart failure (an exc lusion criterion for 
this study, see section 4.4, exclusion criterion 5) and its modification might destabilize 
clinical conditions of a subject. Therefore, further explanation was added to the criterion 
to emphasize subjects treated with high dose of loop  diuretics are not suitable for this study. 
3.The second component of the study -specific discontinuation criterion for renal failure
has been modified to :
 Confirmed (within one week)  decrease  increase  of ≥ 30%  > 2  from baseline  in
eGFR based on the CKD EPI [INVESTIGATOR_685995] .
This discontinuation criterion was previously based on estima ted glomerular filtration rate 
(eGFR ), since eGFR is a biomarker  for renal function. However, a  decline in eGFR might 
be related only to hemodynamic modifications  as observed with other antihypertensive 
therap ies, such  as renin angiotensin blockers [Palmer  2002 ] and not secondary to structural 
kidney injury . The BP decrease induces  a reduction of the intraglomerular pressure  which 
impact s the eGFR . Endothelin receptor antagonist indeed induces vasodilation on the 
afferent and efferent intra -glomerul ar arterioles with presumably a more pronounced effect 
on the efferent one [Kohan  2011 ]. Therefore, to avoid discontinuation of subjects due to 
potentially transient eGFR reduction this criterion was modified. The new criterion is using 
serum creatinine change . Serum creatinine is less influenced by [CONTACT_686029] / ACT -132577  
Resistant hypertension  
Protocol ID -080A301  
Version 3  
27 February  2020 , page  19/[ADDRESS_929998] s more organ damage of the kidney. This is in line with the Acute 
Kidney Injury score [Kellum  2013 ] which is based on serum creatinine level. This ensures 
appropriate monitor ing and discontinu ation of  subjects at risk of potential kidney injury .  
4.Changes of forbidden medication , appendix 1 .
Removal of erythropoiesis -stimulating agents  and psychiatric drugs from the list of the
forbidden medications  and adding them  to allowed medications with the provision that
they have been initiated and the dose has been stable  at least [ADDRESS_929999] been made to: 
Exclusion criterion 15 in section 4.4 : remo val of “planned treatment ”.
Clarif y and provide  the definition for overdose, abuse, and misuse in section  9.5.
Provide more guidance for the documentation of the informed consent process  in
section  12.3.
Clarify some inconsistencies and correct some minor errors and typos.
Changes to the protocol 
Two versions of the amended protocol will be prepared: 1) a clean version and 2) a Word 
comparison document showing deletions and insert ions in comparison to the previous 
protocol version.  
Amended protocol sections 
The sections of the protocol affected by [CONTACT_686030]. Where 
applicable, the same changes have also been made to the corresponding sections of the 
protocol synopsis:  
Section 1.4  Summary of known and potential risks and benefits  
Section 3.1  Study design  
Section 3.1.1 .1 Screening period  
Section 3.1.2   Study duration  
Aprocitentan / ACT -132577  
Resistant hypertension  
Protocol ID -080A301  
Version 3  
27 February  2020 , page  20/[ADDRESS_930000] 2017 -004393 -33 
Doc No D-20.008  
Section 4.3   Inclusion criteria  
Section 4.4   Exclusion criteria  
Section 4.5.2   Acceptable methods of c ontraception  
Section 5.1.10   Premature discontinuation of s tudy treatment  
Section 5. 1.11.2 Renal failure  
Section 5.2.2   Mandatory  concomitant therapy  
Section 5. 2.3  Allowed concomitant therapy  
Section [IP_ADDRESS]  Re-screening  
Section [IP_ADDRESS]  Hypertension history  
Section [IP_ADDRESS]  Weight and height  
Section 7.2.5   Biomarker assessments  
Section 9.5   Reporting of study treatment overdose, misuse, and abuse  
Section 1 1.3  Database management  
Section 12.3  Informed consent  
Section 13   Referen ces 
Section 14   Appendices  
Summary of previous amendments  
Amendment  Date  Main reason(s)  
1 19 September  2018   Merge components of several local 
amendments which were issued to address  the 
feedback from health authorities to the global 
protocol ID -080A301 Version 1 to  keep 
consistency in the performance of the study 
across  all countries .  
Modify the exclusion criteria 5 , 16 and 18 .
Removed the NT -proBNP criterion at
randomization .
Aprocitentan / ACT -132577  
Resistant hypertension  
Protocol ID -080A301  
Version 3  
27 February  2020 , page  21/[ADDRESS_930001] 2017 -004393 -33 
Doc No D-20.008  
PRO TOCOL SYNOPSIS ID -080A301  
TITLE  Multi -center, blinded, randomized, PaRallEl-group, Phase 3 study 
with apro CItentan in Subjects with Res Istant Hypertensi ON 
ACRONYM  PRECISION  
OBJECTIVES  The primary objective of the study is to demonstrate the blood 
pressure (BP) lowering effect of apro citentan when added to 
standard -of-care in true resistant h ypertension (RHT) subjects.  
The secondary objectives of the study are:  
 to demonstrate that the effect of aprocitentan on BP is durable
when added to standard -of-care in true RHT subjects ,
 to evaluate the long -term safety and tolerability of aprocitentan
in true RHT subjects  during 48 weeks of treatment.
DESIGN  The study consists of four periods: a screening period, a placebo 
run-in (RI) period, a randomized trea tment period and a safety 
follow -up (FU) period.  
Screening period  
This period lasts between [ADDRESS_930002] RHT subjects  and confirm the diagnosis 
of true RHT.  
During this period the background antihypertensive medication 
(except beta-blockers) of subjects will be standardized by [CONTACT_686031] a fixed combination of a calcium c hannel blocker (CCB), an 
angiotensin receptor blocker (ARB) and a diuretic.   
Placebo RI period  
This single -blind (SB) period lasts for 4 weeks during which  
placebo will be added to the standardized background 
antihypertensive therapy in  all subjects. The purpose of this period 
is to confirm that BP remains uncontrolled  despi[INVESTIGATOR_685996] 4  weeks.  
Randomized treatment period  
This period lasts for 48 weeks. The purpose of this period is to 
evaluate the primary and secondary objectives of the study.  
Aprocitentan / ACT -132577  
Resistant hypertension  
Protocol ID -080A301  
Version 3  
27 February  2020 , page  22/[ADDRESS_930003] 2017 -004393 -33 
Doc No D-20.008  
This period consists of 3 sequential parts: 
 In the first double -blind (DB) par t of 4 weeks subjects will be
randomized to  aprocitentan 25 mg, aprocitentan 12.5 mg or
placebo in a 1:1:1 ratio;
 In the second SB part of 32 weeks all subjects will receive
aprocitentan 25 mg;
 In the third DB withdrawal (WD) part of 12 weeks subjects
will be re -randomized to  aprocitentan 25 mg or placebo in a
1:1 ratio.
The End -of-Treatment (EOT) visit will take place at Week 48 
(i.e., end of DB -WD part) or earlier in the event  of premature 
discontinuation of study treatment. The EOT visit should preferably 
take place on the day of the last dose of study treatment but , in any 
case, no later than [ADDRESS_930004] dose of study treatment.  
Follow -up (FU) Period  
The safety FU period starts on the day after the last dose of study 
treatment and ends at least 30 days thereafter. For subjects who 
discontinued during the RI period there will be a safety FU call. For 
randomized subjects , it will be a safety FU visit.  
The End-of-Study (EOS) is reached when the subject has completed 
the safety FU visit/call.  
NUMBER OF 
SUBJECTS  Approximately [ADDRESS_930005] ete the DB treatment part 
(Week  4) and at least 380 subjects should enter the DB -WD part 
(Week 36). It is expected that at least 300 subjects will complete the 
DB-WD part (Week 4 8).  
PLANNED 
DURATION  Approximately [ADDRESS_930006] Visit 
(i.e., screening visit of first subject) to Last Subject Last Visit 
(i.e., safety FU visit of last subject).  
Aprocitentan / ACT -132577  
Resistant hypertension  
Protocol ID -080A301  
Version 3  
27 February  2020 , page  23/[ADDRESS_930007] 2017 -004393 -33 
Doc No D-20.008  
SITE(S)  
/ COUNTRY(IES)  Approximately 200 sites in approximately 25 countries in Asia, 
Australia, Europe, and North America (planned).  
INCLUSION 
CRITERIA  The complete list of inclusion criteria is provided in the core text. 
The main criteria per study period are:  
Screening criteria  
This study will enroll adult male and female subjects > 18 years old 
with RHT defined as:  
Mean s itting systolic BP (SiSBP) ≥ 140 mmHg measured by 
[CONTACT_686032] 
(AOBPM) despi[INVESTIGATOR_040] a background antihypertensive medicatio n of at 
least [ADDRESS_930008] 4 weeks before 
the screening visit (Visit 1).   
RI entry  criteria  
Subjects with a confirmed diagnosis of RHT who are on 
standardized background antihypertensive therapy for at least 
4 weeks will  enter the placebo RI period if their mean trough SiSBP 
is ≥ [ADDRESS_930009] a mean trough 
SiSBP ≥ [ADDRESS_930010] of exclusion criteria is provided in the core text. 
The main exclusion criteria are:  
 Apparent/pseudo RHT due to white coat effect, medical
inertia, poor therapeutic adherence, or secondary causes of
hypertension (except sleep apnea)
 Confirmed severe hypertension (grade 3) : mean
SiSBP  ≥ 180 mmHg  and/or  sitting diastolic blood pressure
(SiDBP ) ≥ 110 mmHg, measured by [CONTACT_686033] .
STUDY 
TREATMENTS  Placebo tablets will be administered during the RI period.  
Aprocitentan / ACT -132577  
Resistant hypertension  
Protocol ID -080A301  
Version 3  
27 February  2020 , page  24/[ADDRESS_930011] 2017 -004393 -33 
Doc No D-20.008  
Investig ational treatment  
During the DB part, aprocitentan 12.5 and 25 mg tablets will be 
administered.  
During the SB part, aprocitentan 25 mg tablets will be administered. 
During the DB -WD part, aprocitentan 25 mg tablets will be 
administered.  
Comparator  
Placebo tablets will be administered during the DB and DB -WD 
parts of the study.  
Placebo tablets, aprocitentan 12.5 mg tablets and aprocitentan 
25 mg tablets will be indistinguishable.  
CONCOMITANT 
THERAPY  Mandatory therapy  
Background antihypertensive medication will be standardized to a 
fixed combination of a CCB  (amlodipi[INVESTIGATOR_050]), an ARB  (valsartan) and 
a diuretic (hydrochlorothiazide, HCTZ).  
The standardized background antihypertensive therapy will be 
initiated during the scree ning period, at the latest 4 weeks before the 
start of the RI period , and will be continued until EOS.  
Two dose strengths of amlodipi[INVESTIGATOR_050], 5 and 10 mg, will be available in 
the fixed combination. The standardized background 
antihypertensive therapy  will be 10/160/25 or 5/160/25 mg of 
amlodipi[INVESTIGATOR_050]/valsartan/HCTZ, respectively. The selection of the 
amlodipi[INVESTIGATOR_685997] (either 5 or 
10 mg) is at the investigator ’s discretion and may vary during the 
screening period . It is required to use the maximal tolerated dose of 
the background antihypertensive therapy (i.e., 10 mg amlodipi[INVESTIGATOR_050], if 
there is no tolerability issue) from start of the RI period. The dose 
strength  must be kept stable for at least 1 week before Day  –1 (end 
of the RI period ) until the end of  the DB part (i.e., Week 4) and 
during the DB -WD part. The dose strength might be adjusted later 
on, during the SB aprocitentan part .  
Aprocitentan / ACT -132577  
Resistant hypertension  
Protocol ID -080A301  
Version 3  
27 February  2020 , page  25/[ADDRESS_930012] ’s wellbeing and not 
categor ized as forbidden concomitant medications are allowed 
during the study.  
In particular, t he following therapi[INVESTIGATOR_685998] 4 weeks prior to the screening 
visit and that the dose is kept stable unti l the EOT:  
Beta blockers ;
Alfuzosin and tamsulosin (alpha-adrenergic receptors blockers )
for prostatic symptoms ;
Hormonal contraceptives ;
Estrogen -replacement treatment ;
Sodium -glucose co -transporter 2 inhibitors;
Low dose acetylsalicylic acid for cardiovascular prevention ;
Erythropoiesis -stimulating agents ;
Psychiatric drugs .
In addition, the following therapi[INVESTIGATOR_685999] 4 weeks prior to the screening 
visit and that the d ose is kept stable until the end of the DB part  
(i.e., Week 4) :  
Non-steroidal anti -inflammatory drugs;
Selective serotonin reuptake inhibitors and anxiolytics  (such as
benzodiazepi[INVESTIGATOR_050]) .
During the SB aprocitentan part and DB -WD p art, if, in the 
investigator ’s opi[INVESTIGATOR_1649] , the BP of a subject is not sufficiently 
controlled, antihypertensive rescue medication can be added as 
described in Section [IP_ADDRESS] . 
After R andomization, the dose of the existing diuretic (HCTZ) can 
be increased or a new diuretic can be added in the event  of fluid 
retention as judged by [CONTACT_467395]  [IP_ADDRESS] . 
Forbidden concomitant therapy  
From the s creening visit until the EOT visit any drug which may 
affect BP (other than those mentioned above)  is forbidden . A list of 
medication s is provided in Appendix 1. 
Aprocitentan / ACT -132577  
Resistant hypertension  
Protocol ID -080A301  
Version 3  
27 February  2020 , page  26/[ADDRESS_930013] 2017 -004393 -33 
Doc No D-20.008  
ENDPOINTS  Primary efficacy endpoint  
The primary efficacy endpoint is t he change from baseline to 
Week  4 of DB treatment in mean trough SiSBP measured by 
[CONTACT_686034].  
Secondary efficacy endpoints  
The key secondary endpoint is the change from Week 36 (i.e., start 
of DB -WD) to Week 40 in  mean  trough  SiSBP measured by 
[CONTACT_686034].  
The other secondary efficacy endpoints are:  
Change from baseline to Week 4 of DB treatment in mean
trough SiDBP measured by [CONTACT_686035];
Changes from baseline to Week 4 of DB treatment in 24  h mean
systolic BP (SBP)  and diastolic BP (DBP)  measured by
[CONTACT_686036]  (ABPM );
Change from Week 36 to Week 40 of DB -WD treatment in mean
trough SiDBP measured by [CONTACT_686034];
Changes from Week 36 to Week 40 of DB -WD treatment in 24  h
mean SBP and DBP measured by [CONTACT_44117].
Other efficacy endpoints  
Other efficacy endpoints are described in Section 6.1.3 . 
Main safety endpoints  
Treatment -emergent1 adverse events (AEs);
Treatment -emergent1 serious AEs;
Treatment -emergent1 AEs leading to premature discontinuation
of study treatment;
Treatment -emergent1 major adverse cardiac events (MACE),
defined as cardiovascular death, non -fatal myocardial infarction
(MI) , and non -fatal stroke;  only those events confirmed by
[CONTACT_686037]  (CAC)  will be considered;
Treatment -emergent1 MACE -plus, defined as cardiovascular
death, no n-fatal MI, non-fatal stroke  and hospi[INVESTIGATOR_678629] ; only those events confirmed by [CONTACT_686038];
Increase of the dose of an existing diuretic or addition of a new
diuretic due to fluid retention ;
Aprocitentan / ACT -132577  
Resistant hypertension  
Protocol ID -080A301  
Version 3  
27 February  2020 , page  27/[ADDRESS_930014] 2017 -004393 -33 
Doc No D-20.008  
1Any AEs/abnormalities temporally associated with the use of study 
treatment (from RI placebo initiation until 30 days after study 
treatment discontinuation) whether or not considered by [CONTACT_42929].  
Pharmacokinetic endpoints  
Trough plasma concentration o f aprocitentan at Week 4  of the
DB part .
ASSESSMENTS  Refer to the schedule of assessments in Table 2 and Table  3. 
STATISTICAL 
METHODOLOGY  Analysis sets  
The Full Analysis Set (FAS) includes all subjects who were 
randomized and have a baseline SiSBP, measured by [CONTACT_686034]. This 
data set will be used for the evaluation of the primary endpoint.  
The Per Protocol Set (PPS) includes all subjects from the FAS 
without a major protocol deviation (to be defined in the Statistical 
Analysis P lan).  
The modified FAS (mFAS) includes all subjects in the FAS who 
were re -randomized in the DB -WD part of the study  and have a 
Week 36 SiSBP, measured by [CONTACT_686034]. This data set will be used 
for the evaluation of the key secondary endpoint.  
The ABPM FAS (aFAS) includes all subjects from  the FAS who 
have a baseline 24  h mean SBP, measu red by [CONTACT_44117].  
The modified aFAS (maFAS) includes all subjects from the aFAS 
who were re -randomized in the DB -WD part of the study and have 
a Week 36 24  h mean SBP, measured by [CONTACT_44117].  
The Safety Analysis Set (SAF) includes all randomized subjects 
who received  at least one dose of study treatment in the DB part.  
The modified SAF (mSAF) includes subjects from the SAF who 
received at least one dose of study treatment in the DB -WD part.  
Statistical hypotheses  
Three null hypotheses will be tested in this study. The  first two 
hypotheses (H 10 and H 20) will be tested in parallel using the 
Bonferroni correction. The third hypothesis (H 30) will only be tested 
if H10 or H [ADDRESS_930015] null hypothesis H 10 is that there is no difference between 
aprocitentan 25 mg and placebo in the DB part in the mean change 
Aprocitentan / ACT -132577  
Resistant hypertension  
Protocol ID -080A301  
Version 3  
27 February  2020 , page  28/[ADDRESS_930016] null hypothesis H 30 is that there is no difference between 
aprocitentan 25 mg and placebo in the DB -WD part in the mean 
change from Week 36 to Week 40 in mean  trough SiSBP. This 
hypothesis will only be tested if H 10 or H 20 has been rejected: at a 
two-sided significance leve l of 0.[ADDRESS_930017] the overall type I error 
is protected at 0.05.  
Type I error and power  
The power is set to 90% for the  third null hypothesis  (H30) which 
(under  the assumptions made in the sample size calculations) 
implies >  90% power for the first and second null hypothesis.  
Analysis of the primary efficacy variable  
The main analysis for the DB part will be conducted on t he FAS. 
AOBPM measurements obtained after premature discontinuation of 
DB treatment will be excluded from  this analysis  (i.e., considered 
as missing) . 
Changes from baseline to post -baseline visits up to Week [ADDRESS_930018] Squares M ean (LSM)  differences vs placebo at Week 4 and 
their 9 7.5% confidence intervals (CIs) will be obtained from the 
model. The associated P -values will be used to test the first and 
second null hypothes es.  
Aprocitentan / ACT -132577  
Resistant hypertension  
Protocol ID -080A301  
Version 3  
27 February  2020 , page  29/[ADDRESS_930019] 2017 -004393 -33 
Doc No D-20.008  
Based on the Phase 2 study, AC -080A201, it is expected that 5% of 
subjects will have a missing Week 4 AOBPM. Missing data will not 
be imputed but will be handled by [CONTACT_686039] (MAR). The impact of devia tions 
from the MAR assumption will be investigated in sensitivity 
analyses using control -based multiple imputation assuming the data 
in the aprocitentan  groups are  missing not at random .  
Analysis of the key secondary efficacy variable  
The main analysis fo r the DB -WD part  will be conducted on the 
mFAS. AOBPM measurements obtained after premature 
discontinuation of DB -WD treatment or initiation of 
antihypertensive rescue medication in the DB -WD part will be 
excluded from  this analysis  (i.e., considered as mi ssing) . 
Changes from Week 36 to visits up to Week 48 in mean  trough 
SiSBP will be analyzed using a mixed model with factors for 
stratum ( in the  re-randomization), treatment group, time, and 
treatment by [CONTACT_6491] , covariates for Week 36 SiSBP and th e 
interaction between Week 36 and time and an unstructured 
covariance matrix.  
LSM  differences vs placebo for the change from Week  36 to 
Week  40 and their 95% CIs will be obtained from the model. The 
associated P -values will be used to test the third null h ypothesis.  
It is expected that 10% of subjects in the mFAS will have a missing 
Week 40 AOBPM. The missing data handling and sensitivity 
analyses will be similar to those described for the analysis of the 
primary efficacy endpoint.  
Analysis of the other secondary efficacy variables  
The other secondary efficacy variables will be analyzed at α=0.05 
(two-sided) using 95% CIs.  
 Change from baseline to Week 4 of DB treatment in mean
trough SiDBP measured by [CONTACT_686040].
 Changes from baseline to Week 4 of DB treatment in 24  h
mean SBP and DBP measured by [CONTACT_686041] (ANCOVA) with a
Aprocitentan / ACT -132577  
Resistant hypertension  
Protocol ID -080A301  
Version 3  
27 February  2020 , page  30/[ADDRESS_930020] 2017 -004393 -33 
Doc No D-20.008  
factor for treatment group and a covariate for baseline 24  h 
mean SBP (or DBP).  
 Change from Week 36 to Week 40 of DB -WD treatment in
mean  trough SiDBP measured by [CONTACT_686042]-WD part.
 Changes from Week 36 to Week 40 of DB -WD treatment in
24 h mean SBP and DBP measured by [CONTACT_686043] 4 of DB treatment.
Safety  analyses  
Safety analyses in the DB and SB aprocitentan parts will be 
performed on the SAF. Safety analyses in the DB -WD part will be 
performed on the mSAF.  
Safety endpoints will be summariz ed by [CONTACT_16051] (DB, SB and 
DB-WD; DB+SB combined where appropria te) and treatment 
group (within study part) using descriptive statistics 
(e.g.,  percentages of subjects).  
Specific safety endpoints  will be analyzed using time -to-event 
methods (Kaplan -Meier plot, Cox  model), with time starting at 
Randomization and account ing for treatment switching (as part of 
the study design).  
Interim analysis  
No interim analysis is planned.  
Sample Size  
The sample size is driven by [CONTACT_686044]. The within -group standard deviation for the change from 
Week 36 t o Week 40 in mean  trough SiSBP (measured by [CONTACT_686034]) 
is expected to be around 15 mmHg based on study AC -080A201. A 
difference vs placebo ( ‘delta ’) of at least 5 mmHg in the DB -WD 
part is considered clinically relevant.  
With a type I error of 0.05 (two -sided ; if both H10 and H [ADDRESS_930021] been 
rejected ), the size of the mFAS needed for 90% power to detect a 
difference of 5 mmHg between aprocitentan 25 mg and placebo 
Aprocitentan / ACT -132577  
Resistant hypertension  
Protocol ID -080A301  
Version 3  
27 February  2020 , page  31/[ADDRESS_930022] 2017 -004393 -33 
Doc No D-20.008  
would be 380 subjects (190 in each of the two groups in the DB -WD 
part).  
In order to have 380 subj ects in the DB -WD part , a total of 
600 subjects will be randomized (200 in each of the three groups in 
the DB part of the study).  
For the change from baseline to Week 4 in mean  trough SiSBP 
measured by [CONTACT_686034] (primary endpoint) , the clinically relevant 
difference vs placebo is around [ADDRESS_930023] this 
difference is well over 90%:  
Delta (mmHg)  5.5 6.0 6.5 
Power * 92% 96% 98% 
*alpha=0.[ADDRESS_930024] be tested at alpha=0.025 (two -sided). In 
that case the power for the DB-WD part is 84%.  On average 
(assuming that testing at 0.025 is less likely than at 0.05), the power 
for the DB -WD part is app roximately 88%.  
If the drop -out rate is greater than anticipated the sample size may 
be increased in order to ensure sufficient  power for the DB -WD part. 
The sample size will not be decreased below 600.  
STUDY 
COMMITTEES  An independent CAC will review and confirm all reported cases of 
MACE  and MACE -plus in a blinded fashion. The composition and 
operation of the CAC is described in  the CAC charter.  
An Independent Data Monitoring Committee (IDMC) has the 
overall responsibility for safeguarding the interests o f subjects by 
[CONTACT_686045] -risk ratio and making appropriate 
recommendations based on all the reported data and thus ensuring 
that the study is being conducted with the highest scientific and 
ethical standards. The IDMC will be fully operational prior to 
enrollment of the first subject into the study. The composition and 
operation of the IDMC is described in the IDMC charter.  
Aprocitentan / ACT -132577  
Resistant hypertension  
Protocol ID -080A301  
Version 3  
27 February  2020 , page  32/[ADDRESS_930025] 2017 -004393 -33 
Doc No D-20.008  
PROTOCOL 
1 BACKGROUND 
1.1 Hypertension and resistant hypertension 
Hypertension  (i.e., elevated  blood pressure  [BP])  is a “silent”  killer  that rarely  causes 
symptoms. Hypertension is defined in adults by (office) systolic/diastolic  BP (SBP/DBP ) 
≥ 140/90 mmHg and is sub-classified into grade 1 (mild): 140/90 ≤ BP < 160/100, grade 2 
(moderate): 160/100 ≤ BP < 180/110, or grade 3 (severe): BP ≥ 180/110 [ Williams 2018, 
Chobanian 2003 ]. This condition represents a significant global public health concern, as 
it contributes  to vascular  and renal  morbidity,  cardiovascular  mortality,  and economic 
burden [ Lim 2012 , Go 2 013].  
Despi[INVESTIGATOR_040]  c
urrent  knowledge  on the  management  of hypertension  and the availability  of 
numerous effective antihypertensive drugs, hypertension remains inadequately controlled 
in many patients. A number of these uncontrolled patients are considered to have so-called 
“resistant hypertension” (RHT) or “difficult- to-control hypertension”, which is defined as 
uncontrolled BP (i.e., failure to lower BP to a pre-defined threshold) in patients adhering 
to lifestyle modifications and to an appropriate regimen of three or more antihypertensive 
drugs  from  different  pharmacological  classes,  including  a diuretic,  in the  absence  of 
secondary cause of hypertension [ Calhoun 2008 , Williams 2018 ].  
“True” RHT should not be confused with “pseudo” or “apparent” RHT, which is far more 
common  than true  RHT.  White  coat effect,  improper  BP measurement,  poor patient 
adherence, drug-related hypertension, and physician’ s clinical inertia (i.e., inadequate dose 
of antihypertensive  medications  or inappropriate  combinations)  are frequent  causes  of 
pseudo  RHT  and need  to be  ruled  out before  the diagnosis  of true  RHT  is made 
[White 2014, Sheppard  2017 ]. Secondary  causes  of hypertension  (e.g.,  renovascular 
disease, hyperaldosteronism due to aldosterone-producing adenoma, pheochromocytoma, 
and thyroid  disease)  can also cause  apparent  RHT  and require  specific  targeted  therapy. 
Diagnosis of true RHT requires exclusion of these various medical situations according to 
local medical practice. 
The estimated  prevalence  of RHT  varies  from  2 to 30%  of the hypertensive  population 
[Sheppard  2017 , Williams 2012].  This broad  range  of the  estimate  is mainly  due to the 
different  sources  of information  (e.g.,  insurance  healthcare  systems,  registries, 
well-controlled therapeutic clinical trials). It is not always clear from these reports whether 
the prevalence is for “apparent” or “true” RHT.  
A critical  characteristic  of most  “true”  RHT  patients  is their  complex  medical  condition. 
Compared  to the hypertensive  population, RHT  patients  are more  likely  to be  older 
(> 75 years), to be of black race, to have a higher body mass index, albuminuria, reduced 
renal  fun
ction,  self-reported  co-morbidities  of diabetes  mellitus  (DM),  coronary  heart 
Aprocitentan / ACT -132577  
Resistant hypertension  
Protocol ID -080A301  
Version 3  
27 February  2020 , page  33/[ADDRESS_930026] 2017 -004393 -33 
Doc No D-20.008  
disease, and sleep apnea [ Myat  2012 , White  2014 ]. Chronic kidney disease (CKD) and 
DM, in particular, amplify the RHT patients ’ vulnerability and increase the complexity of 
RHT treatment [ De Nicola  2013 , Solini 2014 , Rossignol  2015 ]. In addition, in RHT 
patients, the risk of cardiovascular events is much higher than in th e rest of the hypertensive 
population. This has been consistently sho wn in different settings (i.e.,  clinical trials, 
observational studies, and international registries) comparing RHT vs non-RHT patients 
[Daugherty  2012 , Kumbhani 2013 , Bangalore  2014 , Tsioufis 2014 ]. Consequently, it is  
import ant to control BP in the RHT population . 
1.1.[ADDRESS_930027] clinical 
guidelines, include: an angiotensin -converting enzyme inhibitor (ACEI) or an angiotensin 
receptor blocker (ARB), a long -acting thiazide diuretic and a calcium channel blocker 
(CCB), which is the most commonly used type of third background agent in RHT 
[Poulter  2015 ]. For some patients, individualization of therapy is needed; e.g., for patients 
with ischemic heart disease, a beta -blocker is often used in addition to the aforementioned 
medication s.  
The cho ice of the fourth -line therapy prescribed to control BP in RHT patients has not been 
unequivocally determined. The first therapeutic option recommended by [CONTACT_686046] (ESH ) / European Society of Cardiology (ESC) guidelines [ Williams  2018 ] 
is to reinforce the diuretic therapy, by [CONTACT_686047] e background therapy.  
Potassium -sparing diuretics, such as a mineralocorticoid receptor antagonists (MRAs), are 
recommended. The most commonly used MRA in RHT  is spi[INVESTIGATOR_8407]. The effect of 
this drug as a fourth -line antihypertensive medication in RHT has been brought to the  
forefront by [CONTACT_686048] -2. This study showed 
a larger BP decreasing effect of spi[INVESTIGATOR_8407] (25 mg i ncreased to 50 mg after 6 to 
12 weeks) compared to bisoprolol (beta -blocker), and doxazosin (alpha -[ADDRESS_930028]),  in 
RHT patients [ Williams  2015 ]. However, the insufficient representation of patients with 
CKD stage [ADDRESS_930029] frequent comorbidities associated  with RHT challenges the 
external validity of this study [ Rossignol  2015 ]. The use of spi[INVESTIGATOR_686000] (RAS ) blocking medication might potentially increase the 
risk of hyperkalemia in RHT patients as reported in heart failure [Juurlink  2004 ] and 
consequently,  might limit the safe use of spi[INVESTIGATOR_686001] [Krogager 2017 ]. 
Other available antihypertensive therapeutic classes not used in the alrea dy prescribed 
background therapi[INVESTIGATOR_686002] -line therapi[INVESTIGATOR_686003] 
(e.g.,  alpha -[ADDRESS_930030] vasodilators). These 
Aprocitentan / ACT -132577  
Resistant hypertension  
Protocol ID -080A301  
Version 3  
27 February  2020 , page  34/[ADDRESS_930031] well -known limitations, especially due to their adver se effects, which often 
lead to discontinuation of therapy [ Lancet 1981 , Thomopoulos  2016a ].  
An alternative therapeutic approach in the management of RHT is catheter -based renal 
denervation. However, there are several limitations in its development program such as 
small sample sizes, lack of sham -control groups, suboptimal background or comparative 
antihypertensive therapi[INVESTIGATOR_014], lack of strict ambulatory blood pressure monito ring (ABPM) 
assessment, and requirement of specialized expertise by [CONTACT_686049]. Due to 
these limitations, a definitive conclusion cannot be dr awn on its efficacy and applicability 
in RHT [ Cai 2017 ].  
1.1.2 Unmet medical need in RHT  
As outlined above, even with the current knowledge on the management of hypertension 
and availability of numerous antihypertensive therapi[INVESTIGATOR_014], hypertension and particularly 
RHT re mains  a global public health concern , because:  
 Uncontrolled BP despi[INVESTIGATOR_12847] 3 or more antihypertensive medications 
triggers deleterious cardiovascular  outcomes;  
 Comorbidities such as CKD and DM associated with RHT trigger poor prognosis and 
induc e therapeutic challenges;  
 RHT patients are polymedicated; any new therapy proposed in fourth line must  be safe 
on top of existing mandatory background therapi[INVESTIGATOR_014];  
 All current therapi[INVESTIGATOR_686004] -line therapi[INVESTIGATOR_686005], triggering discontinuation and amplifying t he 
well-known poor adherence in this population.  
There is a medical need for additional pharmacological therapy acting on pathway(s) 
different from those currently used [ Dhaun 2 008, Oparil 2015 ] in line with the 
pathophysiology of RHT  [see Section 1.2.1 ].  
1.2 Aprocitentan  
1.2.1 Mechanism  of action and rationale for develo pment  in RHT  
Aprocitentan is an orally active dual endothelin (ET) receptor antagonist (ERA), selected 
for clinical development for the treatment of RHT. The peptide ET -1 is a potent 
vasoconstrictor that can also cause ne urohormonal activation, increased aldosterone 
synthesis and secretion, induce vascular hypertrophy and remodeling, and endothelial 
dysfunction. ET -1 and its two receptors, ET A and ET B, mediate biological processes that 
may contribute to the pathogenesis of  hypertension.  
RHT had been frequently associated with volume expansion [ Gaddam 2008 , 
Aprocitentan  IB], which is a feature of salt -sensitive hypertension. Plasma ET -1 
Aprocitentan / ACT -132577  
Resistant hypertension  
Protocol ID -080A301  
Version 3  
27 February  2020 , page  35/[ADDRESS_930032] 2017 -004393 -33 
Doc No D-20.008  
concentrations are increased in hypertensive African -Americans [ Ergul 1996 ], a population 
with an increased prevalence of salt -sensitive, low -renin hypertension and also RHT 
[Chrysant  1979 , Luft 1979 ]. ET -1 production is also increased in patients with risk factors 
to RHT such as obesity, DM, and CKD. RHT may therefore represent an “ET-depe ndent 
form ” of hypertension. Accordingly, ERAs demonstrate greater efficacy in salt -dependent 
/ low renin than in high/normal renin animal models of hypertension [ Schiffrin 1998 ]. 
Nonclinical data with aprocitentan have confirmed these expectations and findings 
[Aprocitentan  IB]. 
The mechanism of action of aprocitentan seems appropriate to the RHT pathophysiological 
profile [ Dhaun 2 008] and is distinct from drugs interfering with the RAS or producing 
sodium depletion [ Davenport  2016 ]. Therefore, it is anticipated that  it can be combined 
with background therapy including RAS blockers and diuretics without increasing their 
risks while providing additional BP lowering potential [ Weber 2009 ].  
1.2.[ADDRESS_930033] been conducted to characterize the pharmacology and 
pharmacokinetics (PK) of aprocitentan. In rat models of systemic hypertension, single and 
chronic oral administration of aprocitentan dose -dependently decreased mean arterial BP 
without increasing heart rate (HR) and showed synergistic BP -lowering effects in two 
different animal models (spontaneously hypertensive rats, deoxycorticosterone acetate -salt 
rat model) when combined with an  ARB.  
More  detailed information on the nonclinical data generated on aprocitentan can be found 
in the I nvestigator ’s Brochure (IB)  [Aprocitentan  IB]. 
1.2.[ADDRESS_930034] been clinically completed; these studies characterized 
the safety, tolerability, PK, and pharmacodynamics (PD) of aprocitentan in 144 male and 
female subjects. In these studies, aprocite ntan was given as single doses of up to 600 mg 
and multiple doses up to 100 mg once daily.  
Pharmacokinetics  
After absorption of aprocitentan, with peak plasma concentrations reached at 3 –9 h for the 
different doses, elimination was slow, with an apparent elimination half -life of 
approximately 44  h. The PK properties of aprocitentan after single and multiple dosing 
were similar and support once -daily dosing. Steady -state conditions were reached by [CONTACT_2006]  8 
of dosing with an accumulation of aprocitentan by [CONTACT_41672] 3 -fold. Based on PK, 
aprocitentan can be administered with or without food and no dose adjustment is required 
Aprocitentan / ACT -132577  
Resistant hypertension  
Protocol ID -080A301  
Version 3  
27 February  2020 , page  36/[ADDRESS_930035] 2017 -004393 -33 
Doc No D-20.008  
for sex, elderly subjects, and subjects with mild, moderate, or severe (i.e., estima ted 
glomerular filtration rate [ eGFR ] ≥15 mL/min) re nal function impairment.  
A clinical drug -drug interaction (DDI) study with midazolam showed that aprocitentan did 
not influence the PK of drugs that are substrates of any cytochrome P450 and, therefore, 
these drugs can be administered concomitantly withou t need for dose adaptation. Likewise, 
a clinical DDI study with rosuvastatin showed that aprocitentan did not influence the PK 
of drugs that are substrates of the efflux transporter breast cancer resistance protein , 
therefore these drugs can be administere d concomitantly without need for dose adaptation. 
The primary results of the human absorption, distribution, metabolism, elimination  study 
showed that urine represented the most important elimination route of aprocitentan and its 
metabolites. Formation of  the two most abundant metabolites of aprocitentan in urine and 
feces, respectively , is not expected to be dependent on cytochrome P450  (CYP )3A4. 
Therefore, aprocitentan can be concomitantly administered with drugs that are inhibitors 
or inducers of CYP3A4 .  
More detailed information on nonclinical and clinical PK data generated on aprocitentan 
can be found in the IB [ Aprocitentan  IB]. 
Pharmacodynamics  
PD were investigated in the mechanistic Phase  1 study AC -080-102 in which healthy male 
subjects received a twice daily ( o.d.) dose of aprocitentan (10, 25 or 50 mg) or placebo for 
[ADDRESS_930036] cross -over design [D-18.046 ]. An extra sodium load was given from 
Day 3 to Day 9 to ensure that subjec ts had a sodium excretion >  170 mmol/day. PK and 
PD variables were assessed on Day 1 and Day 9 with aprocitentan  at steady -state 
conditions.  
The primary endpoint was the change from baseline (Day 1) to Day 9 in body weight (kg). 
A non -inferiority approach was applied in which at least one aprocitentan dose had to be 
non-inferior to placebo with respect to change fro m baseline to Day 9 in body weight, 
defined as the upper limit of the 90% confidence interval ( CI) for the difference excluding 
1 kg.  
The 10 mg aprocitentan dose was considered non -inferior to placebo, despi[INVESTIGATOR_040] a (statistically 
non-significant) mean increa se in body weight of [PHONE_14288] kg since the upper limit of the 
90% CI did not exceed [ADDRESS_930037], for both the 25 and 50 mg doses, the upper limit 
of the 90% CI exceeded 1 kg, therefore, for both non -inferiority was not concluded. The 
mean body weight i ncreases were [PHONE_14289] and [PHONE_14290] kg with [ADDRESS_930038], with a minimal 
difference between 25 and 50 mg aprocitentan, and were not associated with peripheral 
edema in these healthy subjects. In addition, decreases in hemoglobin vs placebo were 
Aprocitentan / ACT -132577  
Resistant hypertension  
Protocol ID -080A301  
Version 3  
27 February  2020 , page  37/[ADDRESS_930039] transiently been present.  
Plasma hormones were measured in study AC -080-102 to assess any possible development 
of adaptive mechanisms. Due to the high salt inta ke, plasma aldosterone and renin activity 
levels were low, and there were no clear patterns of changes in body fluid regulating 
hormones between baseline and Day 9.  
Tolerability and safety 
In the entry -into-human study AC -080-101, aprocitentan was well to lerated at single oral 
doses of up to and including 600 mg, and multiple oral doses of up to and including 100  mg 
o.d. for 10 days. No deaths or serious adverse events (SAEs) were reported.
After single -dose administration, under fasted conditions, more s ubjects reported adverse 
events (AEs) with increasing dose. The most frequently reported AEs were headache 
(10/30 subjects on aprocitentan 2/8 subjects on placebo with headache reported by [CONTACT_686050] 600 mg aprocitentan), nausea (3 and 1, re spectively), postural 
orthostatic tachycardia (3 and 1, respectively), and nasal congestion (2 and 1, respectively).  
There were no relevant differences in safety findings between subjects in fed and fasted 
conditions.  
After multiple -dose administration, w hilst at lower doses there were no apparent 
differences in proportion of subjects reporting AEs compared with placebo  (ranging from 
57–67% of the subjects on aprocitentan compared to 67% of the subjects on placebo). A 
larger proportion of healthy subjects (71%) and elderly subjects  (83%) treated with 
100 mg/day aprocitentan reported AEs  when compared to it s matching placebo (67 % and 
50%, respectively). The most frequently reported AE was headache. Reporting of headache 
increased with dose and was not observ ed in subjects treated with placebo.  
Compared with placebo and lower  doses of aprocitentan , 100 mg aprocitentan appeared to 
increase body weight in both  healthy adult and healthy elderly subjects . 
Aprocitentan / ACT -132577  
Resistant hypertension  
Protocol ID -080A301  
Version 3  
27 February  2020 , page  38/[ADDRESS_930040] 2017 -004393 -33 
Doc No D-20.008  
The safety profiles of subsequent Phase 1 studies were in line with observations in study 
AC-080-101. 
More detailed information on clinical safety data generated on aprocitentan can be found 
in the IB [ Aprocitentan  IB]. 
Phase 2 dose -finding study AC -080A201  
A Phase  2 placebo - and active -controlled, dose -finding study explored four  doses of 
aprocitentan (5,  10, 25, and 50  mg o.d.) on s itting DBP (SiDBP) me asured at trough by 
[CONTACT_686051] (AOBPM) in subjects with 
grade  1 or 2 essential hypertension with no background therapy. Additionally, sitting S BP 
(SiSBP) and 24  hour SBP/DBP measured by [CONTACT_44117], as well as the safet y and tolerability 
of the four  aprocitentan doses were evaluated. The active reference was 20  mg lisinopril 
o.d. The study consisted of a single -blind (SB) placebo period of 4 –6 weeks, followed by
a double -blind (DB) treatment period of 8 weeks. A withdraw al (WD) period of [ADDRESS_930041] dose of the
SB WD study treatment, there was a safety follow -up (FU) period of at least 2  weeks.
A total of 490  subjects were randomized to placebo, aprocitentan 5, 10, 25 or 50  mg, or 
20 mg lisinopril in a 1:1:1:1:1:1 ratio. Overall, the key demographic and clinical 
characteristics of the study population at baseline were representative of the general 
essential hypertension population and well -balance d across all groups.  
At baseline, the average SiSBP/SiDBP was 149.7/97.6 mmHg ( Per Protocol Set [PPS] ). 
The mean changes from baseline to Week 8 in SiSBP/SiDBP in the placebo and 
aprocitentan 5, 10, 25 and 50 mg groups were –7.7/–4.9, –10.3/ –6.3, –15.0/ –9.9, 
–18.5/ –12.0, –15.1/ –10.0 mmHg, respectively. In the lisinopril 20 mg group the mean
change fr om baseline in SiSBP/SiDBP was –12.8/–8.4.
The differences vs placebo for SiSBP/SiDBP were –2.45/ –1.31, –7.05/ –4.93, 
–9.90/ –6.99, –7.58/ –4.95 mmHg for aproc itentan 5 , 10, 25 and 50 mg respectively.
The primary efficacy objective for this study was met in that a dose -response relationship 
was detected among the placebo and aprocitentan groups for the change from baseline to 
Week 8 in mean SiDBP (primary endpoi nt; P < 0.0001). A quadratic model fitted the data 
best. A similar dose -response relationship was detected for the change from baseline to 
Week 8 in mean  SiSBP (secondary endpoint). The results of the analyses for the ABPM 
endpoints were consistent with those for the primary endpoint.  
As observed with other ERAs, a dose -dependent decrease in hemoglobin (as well as 
hematocrit, protein and albumin) was obser ved at Week  8 in the aprocitentan groups, as 
compared to placebo and lisinopril 20 mg groups. Additionally, a dose -dependent increase 
Aprocitentan / ACT -132577  
Resistant hypertension  
Protocol ID -080A301  
Version 3  
27 February  2020 , page  39/[ADDRESS_930042] 2017 -004393 -33 
Doc No D-20.008  
in estimated plasma volume (calculated based on changes in hemoglobin  and hematocrit 
[Strauss  1951 ]) was detected ranging from 3.0% to 9.5% in the aprocitentan groups vs 
1.6% in the lisinopril 20 mg group and –0.3% in the placebo group. No change of weight 
was observed across  all doses of aprocitentan.  
All four doses of aprocitentan were well tolerated. The proportions of subjects in the 
aprocitentan dose groups who had at least one AE during the DB study treatment period 
ranged from 22.0% to 40.2% and showed no apparent dose response. The incidences in the 
placebo (36.6%) and lisinopril (32.1%) groups were within the same range.  The most 
frequently reported AEs in the 6  treatment groups were: headache, nasopharyngitis, upper 
respi[INVESTIGATOR_1092], arthralgia, dizziness a nd pain in extremity. Edema AEs were 
reported for 4  subjects, 2  subjects each in the aprocitentan 25  mg (2.4%)  and 50  mg (2.5%) 
groups.  
More detailed information can be found in the IB [ Aprocitentan  IB]. 
1.2.4 Aprocitentan dose rationale  
The doses of aprocitentan for clinical development in RHT were identified based on the 
results of the Phase 2 dose -finding study (AC -080A201) and were supported by [CONTACT_686052] -080-102 study in healthy subjects on a high sodium diet.  
In the Phase 2 dose -finding study placebo -corrected differences in the change from 
baseline to Week 8 in mean  SiSBP/SiDBP were statistically significant for aprocitentan 
10 mg (P <  0.05 / P  < 0.01), aprocitentan 25 mg (P  < 0.001/ P  < 0.0001) and aprocitentan 
50 mg (P  < 0.01/ P  < 0.01). Numerically, the 25 mg dose was the bes t dose 
(–9.90/ –6.99 mmHg). The 10 mg ( –7.05/ –4.93 mmHg) and 50 mg ( –7.58/ –4.95 mmHg) 
doses were similar, indicating that a “plateau ” of the dose response curve may have been 
reached.  
In the Phase 1 study AC-080-102, [Section 1.2.3 ] non-inferiority vs placebo in change from 
baseline to Day [ADDRESS_930043] benefit (reduction 
of BP) / risk (h emoglobin decrease, weight increase) profile. Therefore,  aprocitentan doses 
of 12.[ADDRESS_930044] been selected for further development.  
Aprocitentan / ACT -132577  
Resistant hypertension  
Protocol ID -080A301  
Version 3  
27 February  2020 , page  40/[ADDRESS_930045] 2017 -004393 -33 
Doc No D-20.008  
1.3 Rationale of the study  
The rationale for this Phase 3 study is based on (i) the mechanism of action of ap rocitentan 
that addresses the RHT pathophysiological mechanism  [Dhaun 2 008 and S ection 1.2.1 ], 
and (ii) the recognition of an unmet medical need for these patients  [see S ection  1.1.2 ]. 
1.4 Summary of known and potential risks and benefits  
Based on the mechanism of action of aprocitentan, current nonclinical data, and clinical 
data from the Phase 1 studies and Phase 2 study in adult subjects with essential 
hypertension on mono -thera py, it is anticipated that aprocitentan will reduce the BP of 
subjects participating in this study in a durable and safe manner.  
During the study s ubjects will be carefully followed at regular visits for up to 68 weeks in 
hypertension specialized centers. All visit assessments (e.g., BP measurement, blood 
sampling, electrocardiogram [ECG]) are part of the routine standard -of-care for subjects 
with RHT, although their frequency may be higher in the study. The most invasive 
procedure repeated at each visit wi ll be blood sampling, which requires the use of needles. 
All subjects will be treated with aprocitentan [ADDRESS_930046] 4 weeks before entering the run -in (RI) period until the End-of-Study 
(EOS; i.e., for at least 60 weeks ) to standardize their background antihypertensive 
medication. This fixed combination medication has been  approved and commercialized for 
severa l years in different countries for treatment of hypertension. For detail ed information 
refer to the package insert provided in the site file.  
The potential risks for subjects participating in this study are related to those based on the 
pre-clinical and cl inical findings of aprocitentan [see Sections 1.2.2  and 1.2.3 , and 
section  1.5 of the  Aprocitentan  IB].  
There is a potential risk in both placebo and aprocitentan treatment groups that BP  may not 
be reduced.  However, the placebo period s are  limited to short period s of time [see 
Section  [IP_ADDRESS]  and [IP_ADDRESS] ]. It should be noted that no harm was reported when placebo 
was used for a similar ly short period of time [see S ection 3.2]. In addition, b ased on the 
Phase 2 data  it is anticipated that aprocitentan  will decrease  BP. 
The following measures will contribute to minimize the risks for the subjects participating 
in the study:  
Exclusion of subjects with confirmed severe hypertension (i.e., grade 3), recent severe
cardiovascular disease (heart failure [LOCATION_001] Heart Association [NYHA ] stage III
and IV), N-terminal pro -brain natriuretic peptide (NT -proBNP)  ≥ 500 pg/mL,  stroke,
Aprocitentan / ACT -132577  
Resistant hypertension  
Protocol ID -080A301  
Version 3  
27 February  2020 , page  41/[ADDRESS_930047] 2017 -004393 -33 
Doc No D-20.008  
severe CKD (i.e., grade 5), low hemoglobin, and high alanine  and aspartate  
aminotransferase  (ALT /AST ) [see Section 4.4].  
Use of a highly effective method of contraception for women of childbearing potential.
Laboratory tests performed prior to initiation of study treatment and frequently
thereafter [as defined in Table 2 and Table  3] until EOS .
Close follow -up of the subjects throughout the study with site visits see Section  7.1.
Possibility to add antihypertensive rescue medication at the discretion of the
investigator during the SB aprocitentan and DB -WD part s of the study in the event
that BP is not satisfactorily controlled (confirmed by [CONTACT_686053]),  despi[INVESTIGATOR_686006] e therapy  [see
Section [IP_ADDRESS] ].
Study -specific criteria for interrupting or  stoppi[INVESTIGATOR_262] [see
Section  5.1.11 ].
Monitoring of safety and efficacy data by [CONTACT_223233]
(IDMC) [see Section 3.3.2 ].
It is the investigator ’s responsibility to monitor the risk -benefit ratio of study treatment 
administration, as well as the degree of distress caused by [CONTACT_686054], and to discontinue study trea tment or the study if, based on medical 
judgment, he/she believes that continuation would be detrimental to the subjects ’ 
well-being.  
For further information on the efficacy and safety profile of aprocitentan, please refer to 
the IB [ Aprocitentan  IB]. 
[ADDRESS_930048] -of-care in true RHT subjects.  
2.2 Secondary objective s 
The secondary objectives of the study are 
to demonstrate that the effect of aprocitentan on BP is  durable when added to
standard -of-care in true RHT subjects
to evaluate the long -term safety and tolerabilit y of aprocitentan in true RHT subjects
during 48 weeks of treatment.
Aprocitentan / ACT -132577
Resistant hypertension
Protocol ID- 080A301
Version 3
27 February 2020 , page 42/117ConfidentialEudraCT 2017 -004393 -33
Doc No D- 20.008
2.3 Other objectives
Evaluate steady-state trough plasma concentrations of aprocitentan after 4 weeks of
treatment.
Evaluate the ETsystem activity and the effect of aprocitentan on micro- and
macrovascular complications based on specific biomarkers.
3 OVERALL STUDY DESIGN AND PLAN
3.1 Study design
This is a prospective, multicenter, randomized, parallel-group, blinded Phase 3 study with 
aprocitentan in subjects with true RHT. 
The overall study design is depi[INVESTIGATOR_123614] [ Figure 1]. 
Figure [ADDRESS_930049] 300 subjects are expected to complete the study (i.e., the 
30 day safety follow-up period). The study will be conducted in approximately 200 sites in 
approximately 25 countries.
Once the randomization target has been met, the sponsor might decide to close the 
recruitment. In such a case, study participants still in the screening period may not enter the run-in period and be randomized.
3.1.1 Study p eriods
The study comprises the following consecutive periods:

Aprocitentan / ACT -132577  
Resistant hypertension  
Protocol ID -080A301  
Version 3  
27 February  2020 , page  43/[ADDRESS_930050] 2017 -004393 -33 
Doc No D-20.008  
[IP_ADDRESS]  Screening period  
This period lasts between 4 and 12 weeks. It starts at the screening visit with the signing 
of the informed consent form (ICF) and ends the day before the subject enters the RI period.  
The purpose of the screening period is to select RHT subjects and confirm the diagnosis of 
true RHT.  
At least 4 weeks before the start of the RI period, the background antihypertensive 
medication (except beta-blockers) of subjects with diagnosis of true RHT and having mean  
trough SiSBP ≥ 140 mmHg measured by [CONTACT_686055] a 
fixed combination of a CCB (amlodipi[INVESTIGATOR_050]), an ARB (valsartan) and a diuretic 
(hydrochlorothiazide  [HCTZ ]).  
In case a beta-blocker is used  as one of the background antihypertensive medication s or for 
any other indication ( e.g., heart failure, angina, post -myocardial infarction  [MI], atrial 
fibrillation ), this can be kept, with the provision that it has been initiated and the dose kept 
stable for at least 4 weeks prior to the screening v isit and that the dose is kept stable until 
the End-of-Treatment ( EOT ). 
The number of site visits is flexible during this period and depends on tests/ass essments 
needed to be performed .  
[IP_ADDRESS]  Placebo  run-in period  
This SB period lasts for [ADDRESS_930051] dose of SB placebo and ending 
at Randomization (after completion of the [ADDRESS_930052] dose of SB 
placebo).  It consists of 3 site visits: Visit 2 at the start of the RI (i.e., 4 weeks before 
Randomization ), Visit 3 (i.e., 2 weeks before Randomization ) and Visit 4 at the end of the 
RI (Day –1; i.e., 1 day before Randomization ). 
The purpose of this period is to c onfirm that mean  trough SiSBP measured by [CONTACT_686056] ≥ 140 mmHg despi[INVESTIGATOR_686007] 4 weeks on top of the 
standardized background antihypertensive therapy. The rationale for administering placebo 
during the RI is discussed in Section 3.2. 
[IP_ADDRESS]  Randomized treatment period  
This period lasts for 48 weeks . It starts at Randomization (i.e., Day 1 of the DB part) and 
ends at the EOT visit (i .e., at end of the DB -WD part) . 
This period consists of 3 sequential parts: 
Part 1 is DB, randomized, parallel -group and placebo -controlled and lasts for 4 weeks. 
Subjects will receive aprocitentan 12.5 mg, aprocitentan 25 mg, or placebo in a 1:1:1  ratio. 
It starts at Randomization (i.e., Day 1) with the first dose of DB study treatment and ends 
Aprocitentan / ACT -132577  
Resistant hypertension  
Protocol ID -080A301  
Version 3  
27 February  2020 , page  44/[ADDRESS_930053] dose of DB study 
treatment . It consists of 3 site visits: Visit 4 at Randomization (i.e., Day 1), Vi sit 5 at 
Week  2 and Visit 6 at Week 4 (i.e., end of the DB part).  
The purpose of this period is to demonstrate the BP lowering effect of aprocitentan in true 
RHT subjects (i.e., the primary objective of the study ). 
Part [ADDRESS_930054] dose of the SB study treatment (after  completion of the Week  4 
24 h ABPM) and ends after completion of the Week [ADDRESS_930055] 
dose of SB treatment.  It consists of 5 site visits: Visit 7 at Week 6, Visit 8 at Week 12, 
Visit  9 at Week 20, Visit 10 at Week 28 and Visit 11 at Week 36 (i.e., end of the SB 
aprocitentan part).  
Part 3 is DB-WD, randomized, parallel -group and placebo -controlled and lasts for 
12 weeks. S ubjects will be re -randomized to aprocitentan 25 mg or placebo in a 1:[ADDRESS_930056] dose of the DB -WD study treatment (after completion of the  
Week 36 24 h ABPM recording) and ends after completion of the Week 48  (i.e., D B-WD 
EOT) assessments. It consists of 4 visits: Visit 12 at Week  38, Visit 13 at Week 40, Visit  14 
at Week 44 and Visit 15 at Week 48 (i.e., EOT).  
The purpose of parts [ADDRESS_930057] of aprocitentan 
on BP is sustaine d over a period of 36 weeks in true RHT subjects (i.e., the key secondary 
objective).  
EOT is at Week 48 (i.e., end of DB -WD part) or earlier in the event  of premature 
discontinuation of study treatment. The EOT visit should preferably take place as soon as  
possible after the last dose of study treatment but , in any case , no later than 7 days. 
Premature discontinuation of study treatment is described in Section 5.1.10 . 
[IP_ADDRESS]  Safety follow -up (FU) period  
The safety FU period starts on the day after the last dose of study treatment and ends at 
Visit 16 with a safety FU visit/call:  
 For subjects who entered the RI period, but who were not randomized (i.e., who 
received only SB placebo) it will be a safety FU call.  
 For randomized subjects it will be a safety FU visit.  
The safety FU visit/call must take place 30 (+3) days after the last dose of study treatment.  
For an individual subject, EOS corresponds to the safe ty FU call or safety FU visit.  
The visit schedule and protocol -mandated procedures will be performed according to the 
tables of assessments [ Table 2 and Table  3] and as described in Section  7. 
Aprocitentan / ACT -132577  
Resistant hypertension  
Protocol ID -080A301  
Version 3  
27 February  2020 , page  45/[ADDRESS_930058] is sustained 
(durable) in subjects with RHT.  
This study has a RI period of [ADDRESS_930059] -the-mean phenomenon. 
[EMA  2016a ]. 
3.2.[ADDRESS_930060] o f 2 doses of aprocitentan 
(12.5  and 25 mg) on BP at Week 4, compared to placebo. The analysis after [ADDRESS_930061] 80% of the expected BP reduction was already observed in the first 
4 weeks of treatment. Placebo is used as the control group  due to high variability of BP, 
especially on top of background therapi[INVESTIGATOR_686008].  
The use of placebo does not create an unethical situation due to the following reasons: 
Subjects are already on background antihypertensiv e medications and severe  (grade  3)
hypertensive subjects will not be allowed to enter into this study.
Subjects are closely followed during these 4 weeks with visits at Week  2 and Week  4.
Study -specific discontinuation criteria have been set -up [see Section 5.1.11 ].
Subjects who experience (confirmed) essential hypertension grade [ADDRESS_930062] permanently
stop the study treatment.
Use of placebo in numerous recent placebo - or sham-controlled studies in similar
population (i.e., RHT) on stable triple background antihypertensive medications didn ’t
report safety concern [ Václavík 2011 , Williams  2015 , Bhatt  2014 ].
No irreversible harm was reported d uring this short -term period (4 –8 weeks) by [CONTACT_686057] -analysis of 590 individual hypertension clinical trials involving
64,438 subjects randomized to experi mental drug and 21,699 randomized to placebo
[DeFelice  2008 ].
Aprocitentan / ACT -132577  
Resistant hypertension  
Protocol ID -080A301  
Version 3  
27 February  2020 , page  46/[ADDRESS_930063] of aprocitentan. 
In chronic diseases (e.g. , heart failure) or special population (e.g., pediatric) placebo cannot 
be administered for a long period of time or not at all. For these cases , a randomized WD 
design is now standard when the objective is to demonstrate that the long-term effect on 
BP is sustained  [O’Neill 2012 ]. In a randomized WD design, a long -term SB active 
treatment part is followed by a DB -WD part in which subjects are randomized to 
investigational drug or placebo.  
In this study, all subjects who enter into the SB aprocitentan part will be treated for 
32 weeks with aprocitentan 25 mg. Th is period is followed by [CONTACT_171744] -WD p art where subjects 
will remain either on aprocitentan 25 mg or switch to placebo in a 1:1 ratio for 12 weeks.  
The BP will be analyzed at W eek 4 of the DB -WD period ( i.e., Week 40) key secondary 
endpoint). This duration is select ed and justified based on the h alf-life of aprocitentan 
(i.e., 44 hours). The total duration of the DB-WD part will be 12 weeks to be able to also 
explore the durability at Week 8 and Week 12.  
3.3 Study committee s 
3.3.1 Independent Central Adjudication Committee  
An independent Central Adjudication Committee (CAC ) provides ongoing review of all 
reported cases of major adverse cardiac events (MACE) and MACE -plus in a blinded 
fashion. To ensure the proper and comprehensive review and adjudication of MACE 
events, additio nal subject data may be requested by [CONTACT_575826].  
The composition and operation of the CAC is described in the CAC charter.  
3.3.[ADDRESS_930064] into the study. The composition and 
operation of the IDMC are described in the IDMC charter.  
Unblinded data will be delivered to the IDMC by [CONTACT_686058] (ISAC).  
Aprocitentan / ACT -132577  
Resistant hypertension  
Protocol ID -080A301  
Version 3  
27 February  2020 , page  47/[ADDRESS_930065] 2017 -004393 -33 
Doc No D-20.008  
4 STUDY POPULATION  
4.1 Selection of study  population  
RHT is defined as BP that is not controlled to a pre -defined threshold  [described in Table  1] 
in patients adhering to lifestyle modifications and to an appropriate regimen  of three or 
more  antihypertensive drugs from different pharmacological classes including a diuretic, 
in the abse nce of a secondary cause of hypertension [ Calhoun  2008 , Williams  2018 ].  
The definition of uncontrolled BP varies with the method of measurement, as shown in 
Table  1. 
Table  1 BP thresholds for the definition of uncontrolled BP (i.e., 
hypertension)  
Method of measurement  SBP and/or DBP (mmHg)  
Automated office BP measurement*  ≥ 135/85 * 
Ambulatory BP monitoring ** 
-Daytime (or awake) ≥ 135/85 ** 
-Night time (or sleep) ≥ 120/70 ** 
-24 hour ≥ 130/80 ** 
Home BP monitoring ** ≥ 135/85 ** 
*The term automated office BP measurement (AOBPM) refers to BP measurement obtained using a fully automated
electronic sphygmomanometer that records multiple BP readings with the patient resting undisturbed in a quiet place
without medical staff being presen t [Leung 2017 , Myers 2010 ].
** Extracted from [ Williams  2018 ]. 
ABPM = ambulatory blood pressure monitoring; AOBPM = automated office blood pressure measurement; BP = blood 
pressure; DBP = diastolic blood pressure; SBP = systolic blood pressure.  
In order  to minimize the rate of screening and RI failures, the investigator is encouraged to 
have a comprehensive medical history available for patients they intend to screen. Review 
of subject charts allows the identification of apparent RHT and help s avoid inap propriate 
subject screening. Subjects with any of the chronic conditions mentioned in the exclusion 
criteria list [see Section 4.4] should not be considered for screening.  
This study will enroll adult male and female subjects with a diagnosis of true RHT 
[Section  1.1 and Section 4.2] having a  mean  SiSBP measured by [CONTACT_686034] ≥  140 mmHg. 
This higher threshold (as compared to the table above) was chosen in order to minimize 
screening failures that are likely to occur following  the switch to the standardized 
background antihypertensive therapy. The BP randomization criterion will also be mean  
trough  SiSBP ≥  140 mmHg in order to increase the sensitivity of the study to observe 
treatment effects.  
Aprocitentan / ACT -132577  
Resistant hypertension  
Protocol ID -080A301  
Version 3  
27 February  2020 , page  48/[ADDRESS_930066] 2017 -004393 -33 
Doc No D-20.008  
4.2 Rationale for the selection of the  study population  
Among the hypertensive population, RHT was selected as the targeted study population 
[see Section 4.1]. No antihypertensive thera py has been specifically developed and 
approved for the treatment of this population. Furthermore, all existing antihypertensive 
therapi[INVESTIGATOR_686009] -line therapy in this population have some limitations with respect 
to adverse drug reactions. This is one of the major causes of treatment discontinuation. 
This, consequently cause uncontrolled BP which is one of the main reason s for increased 
cardiovascular outcomes [Thomopoulos  2016a , Thomopoulos  2016b ]. Hence, there is an 
unmet need for this vulnerable and complex patient population who are  at high 
cardiovascular risk.  
In this study, subjects with true RHT are included in order to demo nstrate the efficacy, 
durability of the effect, and safety of aprocitentan in a hypertensive population with high 
medical need. Subjects with “pseudo ” or “apparent ” (terms are used interchangeably) RHT, 
which is far more common than “true” RHT will be excl uded from the study.  
The selection criteria for this patient population follow the recommendation of the ESH  
and ESC joint guideline [ Williams  2018 ], the American Heart  Association Guideline for 
the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults 
[Whelton  2017 ], as well as several other national guidelines [ Denolle  2014 , 
McCormack  2013 ].  
Subjects with confirmed severe hypertension (grade 3), recent major cardiovascular, renal, 
cerebrovascular medical complications, and heart failure NYHA stage III-IV are excluded 
from the study. This is because these patients could potentially be at gr eater risk of 
experiencing side effects, and/or their conditions could interfere with the  evaluation of the 
treatment effect, study assessments and interpretation of study results.  
4.[ADDRESS_930067]:  
Screening criteria  
1. Signed and dated ICF prior to any study -mandated procedure.
2. Male and female subjects; 18 years (or year of country specific majority) or older.
3. Historical documentation in the subject ’s medical records of uncontrolled BP
despi[INVESTIGATOR_111776] [ADDRESS_930068] 4 weeks before the screening visit (Visit 1).
Aprocitentan / ACT -132577  
Resistant hypertension  
Protocol ID -080A301  
Version 3  
27 February  2020 , page  49/[ADDRESS_930069] 2017 -004393 -33 
Doc No D-20.008  
5. Mean SiSBP ≥ [ADDRESS_930070] ’s medical records of diagnosis of RHT accor ding to
the site ’s medical practice:
Exclusion of secondary causes of hypertension (e.g., serum aldosterone,
plasma renin activity , duplex/doppler ultrasonography, computer tomography
angiography  assessments are performed  to exclude the secondary cause s of
hypertension [Rimoldi 2013 ]),
Adherence to medication (e.g., how the adherence was checked and/or
monitored ) to eliminate apparent RHT .
7. A woman of childbearing potential [see definition in Section 4.5.1 ] is eligible only
if the following applies:
Negative pregnancy test at S creening and at baseline (i.e., end of RI  period ).
Agreement to undertake pregnancy tests during the study and up to 30 days
after randomized study treatment discontinuation.
Agreement to use methods of birth control as described in Section 4.[ADDRESS_930071] 30 days after randomized study treatment
discontinuation.
8. Mean  trough SiSBP ≥ 140 mmHg measured by [CONTACT_686034] a t the switch from
background antihypertensive medications  (i.e., at least  3 medications from different
pharmacological classes]) to the standardized back ground antihypertensive
therapy.
RI entry criteria  
9. Switched  to the standardized background anti hypertensive therapy at least [ADDRESS_930072] RI visit.
10. Mean trough SiSBP ≥ 140 mmHg measured by [CONTACT_686034].
Randomization criteria  (end of RI)
11. Stable dose of the standardized background antihypertensive therapy for at least
1 week before Day –1 (end of the RI period ).
12. Mean trough SiSBP ≥ 140 mmHg measured by [CONTACT_686034].
13. Subjects demonstrating ≥ 80% compliance (pi[INVESTIGATOR_686010]) to study treatment
(i.e., placebo) as well as ≥ 80% compliance (pi[INVESTIGATOR_63720]) to the standardized
background antihypertensive therapy  during the RI period.
4.[ADDRESS_930073]:  
Aprocitentan / ACT -132577  
Resistant hypertension  
Protocol ID -080A301  
Version 3  
27 February  2020 , page  50/[ADDRESS_930074] 2017 -004393 -33 
Doc No D-20.008  
 
 Screening period criteria  
Disease/condition:  
1. Pregnant or lactating subjects.  
2. Apparent/pseudo RHT due to white coat effect, me dical inertia, poor therapeutic 
adherence, or secondary causes of hypertension (not including obstructive sleep 
apnea).  
3. Confirmed severe hypertension (grade 3) defined as mean SiSBP ≥ 180 mmHg 
and/or SiDBP ≥ 110 mmHg measured by [CONTACT_686059] e points.  
The BP re -measurement can be during the screening v isit (e.g., after at least 3 h), 
or at the next planned visit, or at an un scheduled visit. The time of re -measurement 
is at the investigator ’s discretion, taking into consideration the subject ’s medical 
history . 
4. Known and documented transient ischemic attack, stroke, unstable angina or MI 
within [ADDRESS_930075] in the 
opi[INVESTIGATOR_871], e.g., uncon trolled symptomatic arrhythmia,  atrial 
fibrillation , congestive heart failure  NYHA  stage  II with relevant mitral valve 
insufficiency  and/or aortic stenosis , congestive heart failure  NYHA stage  III or IV .  
6. Severe renal insufficiency defined as an eGFR per the CKD Epi[INVESTIGATOR_623] 
(CKD -EPI) collaboration  creatinine equation <  15 mL/min/1.[ADDRESS_930076] or interpretation of the results.  
10. Known concomitant life -threatening disease with a life expectancy <  18 months of 
Screening.  
Treatments:  
11. Treatment with any medication which may affect BP [see Appendix 1] and/or 
treatment with high dose of loop diuretics (i.e., furosemide greater than 80 mg/day, 
or equivalent dosage of other loop diuretics) .  
12. Treatment with any o ther ERAs.  
13. Contraindication and/or known hypersensitivity to any of the three components of 
the standardized background antihypertensive therapi[INVESTIGATOR_014] (fixed combination of CCB 
Aprocitentan / ACT -132577  
Resistant hypertension  
Protocol ID -080A301  
Version 3  
27 February  2020 , page  51/[ADDRESS_930077] 2017 -004393 -33 
Doc No D-20.008  
[amlodipi[INVESTIGATOR_050] ], ARB [ valsartan ] and diuretic [HCTZ ]) according to their labels or 
drugs of the same class, or to any of the excipi[INVESTIGATOR_840].  
14. Known hypersensitivity to aprocitentan or drugs of the same class, or any of the
excipi[INVESTIGATOR_840].
15. Treatment  with another investigational trea tment within 3  months prior to
Screening .
16. Laboratory assessments bas ed on central laboratory
ALT or AST > 3 times the upper limit of normal range , or severe hepatic
impairment .
Hemoglobin < 100 g/L.
NT-proBNP ≥ 500 pg/mL.
If one of these criteria is not met based on central laboratory report, a re -test must 
be performed before Visit 2 (e.g., at the next screening visit , or at an unscheduled 
visit). If the value is confirmed, the subject must discontinue from screening.  
RI period exclusion criteria 
17. Confirmed severe hypertension (grade 3) defined as mean  SiSBP ≥ 180 mmHg
and/or SiDBP ≥ [ADDRESS_930078] RI Visit (e.g., after at least 3 h), or at the 
next planned visit, or at an unscheduled visit. The time of re -measurement is at the 
invest igator ’s discretion, taking into consideration the subject ’s medical history.  
Randomization exclusion criteria 
18. Laboratory  assessments  based on local laboratory.
ALT or AST > 3 times the upper limit of normal range.
Hemoglobin < 100 g/L.
eGFR per the CKD -EPI [INVESTIGATOR_144326] <  15 mL/min/1.73 m2.
At any time between Screening and Randomization the investigator/delegate must verify 
that the subject does not fulfill the exclusion criteria checked at the screening visit (as 
applicable).  
4.[ADDRESS_930079] one of the 
following criteria:  
Previous bilateral salpi[INVESTIGATOR_1656], bilateral salpi[INVESTIGATOR_8936] -oophorectomy or hystere ctomy,
Aprocitentan / ACT -132577  
Resistant hypertension  
Protocol ID -080A301  
Version 3  
27 February  2020 , page  52/[ADDRESS_930080] 2017 -004393 -33 
Doc No D-20.008  
Postmenopausal (defined as 12 consecutive months with no menses without an
alternative medical cause [ ICH M3  definition ]),
Premature ovarian failure (confirmed by a specialist), XY genotype, Turner syndrome,
uterine agenesis,
Childbearing potential status will be assessed at each visit and recorded in the electronic 
case report form (eCRF). 
4.5.2 Acceptable methods of contraception  
The methods of birth control used (including non -pharmacological methods) must be 
recorded in the eCRF.  
Note: The documentat ion of method of contraception can be based on the site personnel ’s 
review of the subject ’s medical records, medical examination or medical history interview 
of the subject . 
The use of one of the following options is regarded as a highly effective method o f 
contraception:  
Aprocitentan / ACT -132577  
Resistant hypertension  
Protocol ID -080A301  
Version 3  
27 February  2020 , page  53/[ADDRESS_930081] 4 weeks prior to the screening visit (Visit 1)  [see Section 5.2.3 ]. 
Option 3: vasectomiz ed partner is a highly effective birth control method provided that the 
partner is the sole sexual partner of the woman of childbearing potential trial par ticipant 
and that the vasectomiz ed partner has  received medical assessment of the surgical success.  

Aprocitentan / ACT-132577 
Resistant hypertension 
Protocol ID-080A301 
Version 3 27 Februar
y 2020, pa ge 54/[ADDRESS_930082] 2017-004393-33 
Doc No D-20.008 
5 TREATMENTS 
5.1 Study treatment 
This section applies to study treatment (aprocitentan/placebo).  The standardized 
background antihypertensive thera py is described in Section 5.2.2. 
5.1.1 Investigational treatment and matching placebo 
Aprocitentan is currently available for clinical study use as i dentical tablets of 12.5 and 
25 mg containing aprocitentan a nd inactive ex cipi[INVESTIGATOR_840].  
Placebo tablets will be identical  in appearance to the aprocite ntan tablets, and will contain 
inactive excipi[INVESTIGATOR_840]. 
5.1.2 Study treatment dosing and rationale  
For this confirmatory study in RHT, dosages of 12.5 and 25 mg ( o.d.) are selected. The 
rationale has been provided in Section 1.2.4. 5.1.3 Study treatment administration  
Study treatment is supplied in bot tles containing 36 tablets to  cover a 4-week treatment 
period accounting for one extra week (if needed). 
The subjects must be instructed to take one tablet from the bottle orally o.d. irrespective of 
food intake every morning and not to take it on the morning of study visit days. On the day 
of the study visits, study treatment must be administered only after the completion of the 
visit assessments as indicated in Section 7.2.  
The study personnel must remind subjects at each visit of the study treatment intake 
requirements. The reminders must be documented in the subject’s  chart. 
5.1.4 Treatment assignment 
After the informed consent has been signed the investigator/del egate gets a subject number 
through the Interactive Response Technology (IRT) system at Vis it 1 (screening visit).  
During the screening period, subjects will be switched to the s tandardized background 
antihypertensive therapy [see Section 5.2.2], which will be dis pensed via the IRT system. 
At the first RI visit the invest igator/delegate contacts the IR T system to get a study 
treatment number (i.e., bottle number) for the 4 weeks of the R I period. In the RI period all 
subjects will receive placebo in a SB fashion.  
At Visit 4 / Randomization (Day 1) the investigator/delegate co ntacts the IRT system to 
randomize the subject to aprocitentan 12.5 mg, aprocitentan 25 mg or placebo in a 
Aprocitentan / ACT -132577  
Resistant hypertension  
Protocol ID -080A301  
Version 3  
27 February  2020 , page  55/[ADDRESS_930083] 2017 -004393 -33 
Doc No D-20.008  
1:1:[ADDRESS_930084].  
At the end of the DB part (Week 4) the investigator/delegate contacts the IRT system  to 
get the treatment number (i.e., bottle number) for the SB aprocitentan part. All subjects in 
this period will be assigned to 25 mg aprocitentan.  
At the end of the SB treatment part (Week 36), the investigator/delegate contacts the IRT  
system  to re -randomize the subject to aprocitentan 25 mg or placebo in a 1 :1 ratio. The 
re-randomization will be stratified by [CONTACT_686060] , which will not 
be revealed.  The IRT system  assigns a (scrambled) re -randomization number to the subject 
and a bottle number to match the treatment arm assigned by [CONTACT_238522]-randomization list. 
The IRT system is handled by [CONTACT_686061], one for the DB part and another for the DB -WD part.  
5.1.[ADDRESS_930085] two SB parts: the SB placebo RI period prior to Randomization  and 
the SB aprocitentan part of [ADDRESS_930086] of the treatment received during these parts.  
Parts 1 (DB) and 3 (WD -DB) of the study will be performed in a DB fashion. The 
investigator and study personnel,  the subjects, the Clinical Research Associates (CRAs), 
sponsor personnel, and vendor/CRO personnel involved in the conduct of the study will 
remain blinded to the study treatment received by [CONTACT_686062] . To ensure adequate supply of study treatment, the IRT vendor 
personnel responsible for clinical study supply distribution and the sponsor individuals 
contributing to clinical supply distribution will need to be unblinded at subject level and 
depot level,  respectively. These persons will be clearly identified, their unblinding will be 
documented in the trial master file, and they will not take part in any Clinical Trial Team 
(CTT) meetings after study set -up has been completed.  
Until the time of unblinding  for final data analysis, the randomization list will be  kept 
strictly confidential, and accessible only to IRT vendor and sponsor authorized persons 
(i.e., Pharmaceutical Development department, Bioanalytical Laboratory group , ISAC  and 
IDMC ), who are not involved in the conduct of the study.  
The investigational treatment and its matching placebo are indistinguishable, and all 
treatment bottles will be packaged in the same way.  
To minimize the possibility of systematic unblinding, the PK results will be 
communicated/transferred by [CONTACT_686063].  
Aprocitentan / ACT -132577  
Resistant hypertension  
Protocol ID -080A301  
Version 3  
27 February  2020 , page  56/[ADDRESS_930087] 2017 -004393 -33 
Doc No D-20.008  
5.1.6 Unblinding  
[IP_ADDRESS]  Unblinding for final analyses  
Full randomization information will be made available for data analysis only after database 
lock, in accordance with the sponsor ’s Quality System (QS) documents.  
[IP_ADDRESS]  Unblinding for suspected unexpected serious adverse reactions  
If a suspected unexpected serious adverse reaction (S[LOCATION_003]R) see definition in 
Section  9.1.3 occurs in a subject participating in the study, the sponsor ’s Global Drug 
Safety department will request the unblinding of the treatment assignm ent to meet 
regulatory reporting requirements.  
The treatment assignment will not be communicated to site personnel or subjects, or to the 
sponsor CTT or any vendor/CRO personnel involved in the conduct of the study.  
Unblinded S[LOCATION_003]R information will be prov ided to respective health authorities and  
Independent Ethics Committee s / Institutional Review Board s (IECs/IRBs ) only. S[LOCATION_003]Rs 
will be reported to investigators in a blinded fashion.  
[IP_ADDRESS]  Emergency procedure for unblinding  
The investigator, study personnel, sub jects, CRAs, sponsor personnel, and any CRO 
personnel involved in the conduct of the study must remain blinded to the subject ’s 
treatment assignment.  
The identity of the study treatment may be revealed only if the subject experiences a 
medical event, the management of which would require knowledge of the blinded treatment 
assignment. In this case, the investigator can receive the unblinded treatment assignment 
through the IRT system. In these situations, the decision to unblind resides solely with the 
investigator. Whenever it is possible, and if it does not interfere with (or does not delay) 
any decision in the best interest of the subject, the investigator is invited to discuss the 
intended unblinding with the sponsor personnel.  
The occurrence of any unbl inding during the study must be clearly justified and explained 
by [CONTACT_093]. In all cases, the sponsor personnel must be informed as soon as possible 
before or after the unblinding.  
The circumstances leading to unblinding must be documented in the hospi[INVESTIGATOR_1332], the 
Investigator Site File (ISF) and in the eCRF.  
5.1.7 Study treatment supply  
Manufacturing, labeling, packaging, and supply of study treatment will be conducted 
according to Good Manufacturing Practice, GCP, and any local or national regulator y 
requirements.  
Aprocitentan / ACT -132577  
Resistant hypertension  
Protocol ID -080A301  
Version 3  
27 February  2020 , page  57/[ADDRESS_930088] 2017 -004393 -33 
Doc No D-20.008  
All study treatment supplies are to be used only in accordance with this protocol, and not 
for any other purpose.  
[IP_ADDRESS]  Study treatment packaging and labeling  
Study treatment is provided as tablets in childproof bottles.  Study treatment is labeled to 
comply with the applicable laws and regulations of the countries in which the study sites 
are located.  
[IP_ADDRESS]  Study treatment distribution and storage  
Study treatment supplies must be kept in an appropriate, secure area and stored according 
to the cond itions specified on the label.  The storage condition s must be explained to the 
subject.  
[IP_ADDRESS]  Study treatment dispensing  
The subjects will receive sufficient study treatment to cover the period up to the next 
scheduled visit. Subjects are asked to return all use d, partially used, and unused study 
treatment bottles at each visit. Should the treatment bottle dispensed at a scheduled visit be 
lost or damaged, a replacement bottle can be requested v ia the IRT system. The 
protocol -mandated study treatment dispensing p rocedures may not be altered without prior 
written approval from the sponsor. In exceptional circumstances (e.g., if the subject lost 
the study treatment between two visits, or if the subject is unable to return to the site due 
to a medical emergency/hospi [INVESTIGATOR_42853]), unscheduled dispensing and 
delivery of study treatment may occur outside of a scheduled visit. An accurate study 
treatment record of the date and amount of study treatment dispensed to each subject must 
be available at the site for inspection at any time.  
[IP_ADDRESS]  Study treatment return and destruction  
The protocol -mandated study treatment return procedures may not be altered without prior 
written approval from the sponsor. On an ongoing basis and/or on termination of the study, 
the CRA will collect used and unused treatment kits, which will be sent to the warehouse, 
where the sponsor personnel or a deputy will check treatment reconciliation. In certain 
circumstances, used and unused study treatment containers may be destroyed at the site 
once study treatment accountability is finalized and has been checked by [CONTACT_605988], and written permission for destruction has been obtained from the 
sponsor.  
5.1.8 Study treatment adherence 
Adherence to medications is one of the key elements in the treatment of chronic diseases 
such as hypertension/RHT. In this study, study t reatment adherence will be assessed 
throughout the study based on study treatment accountability  (tablets count) for study 
treatment and the standardized back ground antihypertensive therapy, monitoring of the 
Aprocitentan / ACT -132577  
Resistant hypertension  
Protocol ID -080A301  
Version 3  
27 February  2020 , page  58/[ADDRESS_930089] observed treatment (DOT) at the four  planned ABPM assessments [see 
Section  [IP_ADDRESS] ]. 
[IP_ADDRESS]  Study treatment adherence based on accountability 
The inventory of study treatment and the standardized background antihypertensive 
therapy dispensed to and returned by [CONTACT_941] s ubject (i.e., study treatment accountability) must 
be performed by [CONTACT_686064]. It is to be recorded by [CONTACT_686065], and checked by [CONTACT_686066]. The study treatment accountability log in the eCRF will include at least 
the following information for each study treatment unit (i.e., bottle)  dispensed to the 
subject:  
Dispensed bottle (study treatment) / blister or bottle (standardized background
antihypertensive therapy) ID number;
Date dispensed / number of tablets dispensed (pre -populated in eCRF);
Date returned / number of tablets returned.
All supplies, including p artially used or empty bottles/blisters must be retained at the site 
until they are verified by [CONTACT_2689].  
If the subject omits to bring the remaining study treatment to a study visit,  at which  new 
study treatment will be dispensed [see Table 2 and Table  3], he/she mu st be instructed to 
not take any tablets from the forgotten  study treatment bottle and to return it at the next 
visit.   
For each time interval between two visits (i.e., “period ”), the adherence to study treatment 
and, separately , the standardized background antihypertensive therapy based on study 
treatment accountability will be calculated by [CONTACT_686067]:  
Adherence based on study treatment accountability =  
(number of tablets dispensed at visit n – number of tablets returned at Visit n  + 1) / number 
of tablets that should have been taken during the period )] × 100 
The period is defined as the number of days between Visit n (or date of first study treatment 
intake if randomization visit) and Visit n  + 1 (or date of last study treatment intake if EOT 
visit).  
Between visits, ad herence based on study treatment and the standardized background 
antihypertensive therapy accountability is expected to be at least 80%.  
Aprocitentan / ACT -132577  
Resistant hypertension  
Protocol ID -080A301  
Version 3  
27 February  2020 , page  59/[ADDRESS_930090] 2017 -004393 -33 
Doc No D-20.008  
 
 Adherence at the end of the RI period is one of the randomization criterion. Subjects with 
adherence values below 80% for study treatment and/or  the standardized background 
antihypertensive therapy will be considered as RI failure and cannot be randomized. In 
order to minimize misuse of study medication by [CONTACT_423] (e.g., throwing out tablets 
from the returned bottles)  and to properly evaluate this randomization criterion, the study 
staff must not inform the subject about this criterion.  
Adherence values below 80% for the study treatment and/or the standardized background 
antihypertensive therapy without a medical just ification (e.g., AE) after the randomization 
visit is considered a protocol deviation, which will be reported as such to the sponsor by 
[CONTACT_2689].  In such cases, t he investigator /delegates  must discuss and clarify the reasons for 
non-compliance  with the subj ect and take appropriate actions to avoid re -occurrence. This 
discussion must take place prior to providing the next study treatment to the subject. The 
outcome of the discussion must be documented in the source documents . 
[IP_ADDRESS]  Standardized background antihyper tensive therapy  adherence based on urine 
analysis  
Urine samples will be collected throughout the study from initiation of the standardized 
background antihypertensive therapy. The samples must be collected at trough, i.e., before 
taking the study treatment  and the standardized background antihypertensive  therap y. The 
urine will be analyzed  for the presence of valsartan (one of the components of the 
standardized triple combination). The results of urine analysis from each visit will be used 
to discuss the im portance of study treatment intake with poor ly adherent subjects.  
In such cases, t he investigator /delegates  must call the subject within [ADDRESS_930091] ’s chart.  
5.1.9 Study treatment dose adjustments and interruptions  
Study treatment dose adjustments are not permitted. Study treatment may be temporarily 
interrupted in response to an AE, or other r easons (e.g., diagnostic or therapeutic procedure, 
a laboratory abnormality, study treatment forgotten).  
If study treatment is interrupted by [CONTACT_194666], he/she must immediately 
inform the investigator. Interruptions of study treatment sho uld be no longer tha n 
7 consecutive days during DB part and DB -WD p art. During the SB aprocitentan part the 
interruptions of study treatment could be 14 consecutive days. Otherwise, permanent study 
treatment discontinuation should be considered.   
Aprocitentan / ACT -132577  
Resistant hypertension  
Protocol ID -080A301  
Version 3  
27 February  2020 , page  60/[ADDRESS_930092], the 
investigator, or sponsor personnel. The main reason (e.g., AE, hype rtension grade 3) must 
be documented in the eCRF.  
A subject has the right to prematurely discontinue study treatment  at any time, without any 
justification, by [CONTACT_686068] (i.e., premature WD from the study [see  Section 8.2]). Although 
a subject is not obliged to give his/her reason for prematurely withdrawing from the 
treatment or the study, it is recommended that the investigator makes a reasonable effort to 
ascertain the reason(s), while fully respecting the subject ’s rights.  
The investigator must discontinue study treatment for a given subject if, on balance , he/she 
believes that continued administration would be contrary to the best interests of the subject.  
Study -specific criteria for discontinuation of study treatment (aprocitentan/placebo) are 
described in Section  5.1.[ADDRESS_930093] ’s consent for this limited participation in the stud y 
has not been withdrawn.  
 If a subject discontinues study treatment during the RI period the subject will be
asked to perform the end of RI visit and a safety FU call 30 (+3) days thereafter. The
standardized background antihypertensive therapy  will only be provided until the end
of RI visit. Thereafter, a ntihypertensive medication(s) should be administe red
according to local standard -of-care at the investigator ’s discretion.
 If a randomized subject discontinues study treatment the subject will be asked t o
perform the EOT visit (i.e., Visit 15) as soon as possible after the last dose of study
treatment but , in any case , no lat er than 7 days and a safety FU v isit 30 (+3) days
thereafter. Antihypertensive medication(s) should be administered according to loc al
standard -of-care at the investigator ’s discretion. The standardized background
antihypertensive therapy may be continued until the completion of the safety FU
visit.
The following visits must  be performed for subjects who prematurely discontinued
during  the DB part and DB -WD part:
–If a randomized subject discontinues study treatment during the DB part the
subject will be asked to perform the scheduled Week 4 visit. If the scheduled
Week 4 visit is within 7 days of the EOT or safety FU visit, the Week 4 v isit can
be skipped.
Aprocitentan / ACT -132577  
Resistant hypertension  
Protocol ID -080A301  
Version 3  
27 February  2020 , page  61/[ADDRESS_930094] 2017 -004393 -33 
Doc No D-20.008  
–If a randomized subject discontinues study treatment during the DB -WD part the
subject will be asked to stay in the study and to perform the remaining visits of
the DB -WD period. If a scheduled Week 40, Week  44 or Week 48 visit is with in
7 days of the EOT or safety FU visit, this Week 40/44/[ADDRESS_930095] to follow -up are also considered as withdrawn from 
the study. WD from the study and follow -up medical care of subjects withdrawn from the 
study are described in Sections 8.2 and 8.4, respectively.  
5.1.11  Study -specific criteria for interruption / premature discont inuation of study 
treatment  
All the following criteria apply after Randomization . 
[IP_ADDRESS]  Hypertension  
If mean SiSBP ≥ 180 mmHg and/or mean SiDBP ≥ 11 0 mmHg measured by [CONTACT_686034], 
i.e., essential hypertension grade 3 [ Williams  2018 ], BP  must be re -measured. The BP
re-measurement can be at the next planned visit, or at an un scheduled visit. The time of
re-measurement is at the investigator ’s discretion, taking into consideration th e subject ’s
medical history.
If grade [ADDRESS_930096] be permanently 
discontinued.  
[IP_ADDRESS]  Renal failure  
Study treatment must be permanently discontinued in the event  of: 
Confirmed (within one week) eGFR< 15mL/min/1 .73m2 or
Confirmed (within one week)  increase of > 2  from baseline in serum creatinine .
[IP_ADDRESS]  Persistent fluid retention  
Study treatment must be permanently discontinued if the symptom(s)  of fluid retention are 
not tolerable  after increasing the dose of the existing diuretic or the addition of a new 
diuretic [ Section [IP_ADDRESS] ].  
[IP_ADDRESS]  Hemoglobin abnormalities 
In the event of hemoglobin decrease from baseline of > 20 g/L, a hemoglobin retest must 
be performed within one week, with additional laboratory evaluations that include, but are 
not limited to, any of the following:  
Red blood cell cellular indices (mean corpuscular volu me [MCV] , mean corpuscular 
hemoglobin  [MCH] , mean corpuscular hemoglobin concentration  [MCHC] ), reticulocyte 
Aprocitentan / ACT -132577  
Resistant hypertension  
Protocol ID -080A301  
Version 3  
27 February  2020 , page  62/[ADDRESS_930097] 2017 -004393 -33 
Doc No D-20.008  
count, iron status (iron level, serum ferritin, total iron binding capacity, transferrin 
saturation).  
Study treatment must be permanently disconti nued if clinically mandated based on the 
investigator ’s judgment, or in any of the following situations:  
A decrease in hemoglobin to < 80 g/L (< 4.9 mmol/L),
A decrease in hemoglobin from baseline of > 50 g/L,
The need for transfusion.
[IP_ADDRESS]  Liver aminotrans ferases abnormalities  
Interruption of study treatment  
Study treatment must be interrupted in the following case: 
 Aminotransferases (i.e., ALT and/or AST) ≥ 3 and ≤ 8 × the upper limit of normal
(ULN )
Perform a re -test of aminotransferases (ALT and AST),  total and direct bilirubin, and 
alkaline phosphatase within one week. If AST and/or ALT e levation is confirmed, the 
re-test must be performed weekly until the value is within normal range or has returned to 
pre-treatment levels. Interruptions of study treatment are allowed up to 7 consecutive days  
during the DB part and the DB-WD p art, and 14 consecutive days  during the SB  
aprocitentan part [see Section 5.1.9].  
Aminotransferases, total and direct bilirubin, and alkaline phosphatase levels must be 
monitored weekly after study trea tment discontinuation until values  return to pre -treatment 
levels or within normal ranges.  
Permanent discontinuation of study treatment 
Study treatment must be permanently discontinued and its re -introduction is not to be 
considered in the following cases :  
Aminotransferases > 8 × ULN.
Aminotransferases ≥ 3 × ULN and associated clinical symptoms of liver injury, e.g.,
nausea, vomiting, fever, abdominal pain, jaundice, unusual lethargy or fatigue, flu like
syndrome (arthralgia, myalgia, fever).
Aminotrans ferases ≥ 3 × ULN and associated increase in total bilirubin ≥ 2 × ULN.
Aminotransferases, total and direct bilirubin, and alkaline phosphatase levels must be 
monitored weekly after study treatment discontinuation until values return to pre -treatment 
levels or within normal ranges.  
Aprocitentan / ACT -132577  
Resistant hypertension  
Protocol ID -080A301  
Version 3  
27 February  2020 , page  63/[ADDRESS_930098] 2017 -004393 -33 
Doc No D-20.008  
Other diagnoses (e.g., viral hepatitis, mononucleosis, toxoplasmosis, cytomegalovirus) 
and/or etiologies (e.g., acetaminophen -related liver toxicity) should be considered and 
ruled out by [CONTACT_180495]. To en sure the proper and comprehensive 
evaluation of hepatic events, additional subject data might be collected via the Idorsia 
Global Drug Safety  department.  
[IP_ADDRESS]  Pregnancy  
At any time during the study, i f a subject becomes pregnant, study treatment  must be 
permanently discontinued. The investigator/delegate must counsel the subject and discuss 
the risks of continuing with the pregnancy and the possible effects on the fetus.  
5.[ADDRESS_930099] be 
switched to a standardized background antihypertensive therapy which is a triple fixed 
combination of CCB (amlodipi[INVESTIGATOR_050]), ARB (vals artan) and diuretic (HCTZ). Th e dose 
strength  must be stable during  the RI period.  
Two dose strengths will be available: 10/160/25 and 5/160/25 mg (amlodipi[INVESTIGATOR_050], valsartan, 
HCTZ, respectively). The fixed combination will be provided to all subjects from tim e of 
the switch until EOS. The selection of the dose strength of the standardized background 
antihypertensive  therapy  for an individual subject  (either 5 or 10 mg)  is at the investigator ’s 
discretion and may vary during the screening period . It is required  to use the maximal 
tolerated dose of the background antihypertensive therapy (i.e., 10 mg amlodipi[INVESTIGATOR_050], if there 
is no tolerability issue) from the start of the RI period. The dose strength  must be kept 
stable for at least 1 week before Day –1 (end of the R I period ) until the end of DB part (i.e., 
Week 4) a nd during the DB -WD part. The dose strength might be adjusted later on, during 
the SB aprocitentan part . If the highest  dose of amlodipi[INVESTIGATOR_050] (i.e., 10 mg) cannot be used, the 
reason should be documented in the eCRF. If standardized background antihypertensive 
therapy is interrupted by [CONTACT_194666], he/she must immediately inform the 
investigator. All interruptions m ust be recorded in the eCRF.  
Aprocitentan / ACT -132577  
Resistant hypertension  
Protocol ID -080A301  
Version 3  
27 February  2020 , page  64/[ADDRESS_930100] be instructed to take one 
tablet orally o. d. irrespective of food int ake every morning and not to take it on the morning 
of study visit days.  The standardized background antihypertensive therapy will be supplied 
to all subjects by [CONTACT_686069]  [see Section 5.1.4 ]. The protocol -mandated dispensing procedures for 
the standardized background antihypertensive therapy may be different in  some countries 
depending on the number of tablets in one blister/bottle. In such a case, the detail on 
dispensing procedure will be provided in the site file.  
Subjects are asked to return all used, partially used, and unused bottles/blisters at each visi t. 
It must be kept in an appropriate, secure area and stored according to the conditions 
specified on the label.  The storage condition must be explained to the subject.  
Treatment adherence will be performed as st udy treatment, for details see S ection 5.1.[ADDRESS_930101] ’s well -being and not categorized as 
forbidden concomitant medications are allowed duri ng the study and must be documented 
in the medical charts.  
The following therapi[INVESTIGATOR_686011] 4 weeks prior to the s creening visit and that the dose is kept stable 
until the EO T:  
Beta blockers;
Alfuzosin and tamsulosin (alpha -adrenergic receptor blockers) for prostatic
symptoms;
Hormonal contraceptives;
Estrogen -replacement treatment;
Sodium -glucose co -transporter 2 inhibitors;
Erythropoiesis -stimulating agents ;
Psychiatric drugs ;
For selective serotonin reuptake inhibitors  (SSRIs ) and anxiolytics  the instruction
provided in the next paragraph must be followed ;
Low dose acetylsalicylic acid for preve ntion of cardiovascular disease.
In addition, the following therapi[INVESTIGATOR_686012] 4 weeks prior to the screening v isit and that the dose is kept stable until 
the end of  DB part (i.e., Week 4 ):  
Aprocitentan / ACT -132577  
Resistant hypertension  
Protocol ID -080A301  
Version 3  
27 February  2020 , page  65/[ADDRESS_930102] 2017 -004393 -33 
Doc No D-20.008  
Non-steroidal anti -inflammatory drugs;
SSRIs and anxiolytics  (such as benzodiazepi[INVESTIGATOR_050]) .
After Week 4 (end of DB part) these medications can be used , if necessary,  for the subject ’s 
well-being.   
[IP_ADDRESS]  Antihypertensive rescue medication 
In the SB aprocitentan part and DB -WD part (i.e., part 2 and part 3, respectively), if , in the 
investigator ’s opi[INVESTIGATOR_1649] , the BP of a subject is not sufficiently controlled, antihypertensive  
rescue medication can be added according to local medical practice to the study treatment 
and the standardized background antihypertensive therapy, but onl y after confirmation of 
the BP value by a second measurement. The second measurement should  be performed 
either at the next planned visit or at an unscheduled v isit at the investigator ’s discretion. In 
addition, the urine analysis for detection of valsarta n must confirm adherence to the 
standardized background antihypertensive therapy, otherwise additional antihypertensive 
medication should not be added.  
Antihypertensive rescue medication is not allowed in the DB part of the study.  
Antihypertensive rescue  medication must be recorded in the eCRF.  
[IP_ADDRESS]  Diuretics for fluid retention  
After Randomization , the dose of the existing diuretic (HCTZ) can be increased or a new 
diuretic can be added in the event  of fluid retention judged by [CONTACT_686070] . The investigator ’s judgment should be guided by  [CONTACT_686071] ’s weight gain, NT -proBNP, and/or signs and symptoms.  
The fluid retention must be reported as  an AE in the eCRF. In this case fluid retention must 
be repo rted as the indication for the diuretic. If the symptom(s) of fluid retention  are not 
tolerable  the subject must discontinue  the study treatment . 
5.2.[ADDRESS_930103] on BP, or trigger BP 
reduction or elevation, the following concomitant therapi[INVESTIGATOR_686013]:  
Any drug which may affect BP  (except rescu e and allowed medication s described
above) , see Appendix 1;
ERAs ;
Investigational drug, other than ID -080A301 study treatment .
Aprocitentan / ACT -132577  
Resistant hypertension  
Protocol ID -080A301  
Version 3  
27 February  2020 , page  66/[ADDRESS_930104] takes any of these forbidden medications, the investigator/delegate 
must contact [CONTACT_686072] -up actions, including stoppi[INVESTIGATOR_007]/interrupting 
study treatment as appropriate.  
For subjects who permanently discontinued s tudy treatment the investigator/delegate will 
explain to subjects what treatment(s) / medical care is necessary and available according 
to local practice.  
5.2.5 Reporting of previous / concomitant therapy in the eCRF  
The generic name, start/end dates of adminis tration, route, dose regimen, and indication 
will be recorded in the eCRF.  
[IP_ADDRESS]  Antihypertensive therapi[INVESTIGATOR_686014]/or ongoing at S creening will be 
recorded in the eCRF, i.e., start/end dates of administration, rea son for discontinuation and 
dose regimen.  
Antihyp ertensive  treatments stopped in the last 12 mo nths prior to S creening, start/end 
dates, dose regimen, and reason for discontinuation should be available in the hospi[INVESTIGATOR_686015].  
If a new antihypertensive therapy other than mandatory background therapy (i.e., the fixed 
combination of CCB, ARB and diuretic) and study treatment is (re -)initiated during the 
course of the study, the date of initiation, dose and detailed reason fo r (re-)initiation must 
be recorded in the eCRF.  
[IP_ADDRESS]  Other therapi[INVESTIGATOR_686016] -concomitant therapy (including traditional and alternative 
medicines, e.g., plant -, animal -, or mineral -based medicines) must be recorded in the eCRF.  
Any other pre vious therapy must be recorded in the eCRF if discontinued less than [ADDRESS_930105] available measurement before the start of DB treatment.  
Aprocitentan / ACT -132577  
Resistant hypertension  
Protocol ID -080A301  
Version 3  
27 February  2020 , page  67/[ADDRESS_930106] 2017 -004393 -33 
Doc No D-20.008  
6.1.2 Secondary efficacy endpoints  
The key secondary efficacy endpoint is the change from Week 36 to Week 40 of DB -WD 
treatment in mean trough SiSBP measured by [CONTACT_686034].  
The other secondary efficacy endpoints are:  
Change from baseline to Week 4 of DB treatment in mean  trough SiDBP measured by
[CONTACT_686034];
Changes from baseline to Week 4 of DB treatment in 24  h mean SBP and DBP
measured by [CONTACT_44117];
Change from Week 36 to Week 40 of DB -WD treatment in mean  trough SiDBP
measured by [CONTACT_686034];
Changes from Week 36 to Week 40 of DB -WD treatment in 24  h mean SBP and DBP
measured by [CONTACT_44117].
6.1.3 Other efficacy endpoints  
Change s from baseline to Week 2 of DB treatment  in mean trough SiSBP and SiDBP
measured by [CONTACT_686034];
Changes from baseline to Week 4 in daytime and nighttime mean SBP and DBP;
Changes from Week 36 to Week 38, Week 44 and Week 48 of DB -WD treatment in
mean  trough SiSBP/SiDBP measured by [CONTACT_686034];
Changes fro m Week 36 to Week 40 in daytime and nighttime mean SBP and DBP;
Changes from baseline to all assessed time points of DB, SB and DB -WD parts in
urine albumin -to-creatinine ratio (UACR);
Discontinuation of randomized study treatment due to confirmed grade 3 (i.e., mean
SiSBP/SiDBP ≥ 180/110 mmHg, respectively) hypertension.
Initiation of antihypertensive rescue medication in the SB aprocitentan part  or DB -WD
part.
6.2 Safety endpoints  
Treatment -emergent AEs;
Treatment -emergent SAEs ;
Treatment -emergent AEs leadi ng to premature discontinuation of study treatment;
Treatment -emergent MACEs, defined as cardiovascular death, non -fatal MI, and
non-fatal stroke  [EMA  2016b ]. Only those events confirmed by [CONTACT_686073];
Aprocitentan / ACT -132577  
Resistant hypertension  
Protocol ID -080A301  
Version 3  
27 February  2020 , page  68/[ADDRESS_930107] 2017 -004393 -33 
Doc No D-20.008  
Treatment -emergent M ACE -plus,  defined as cardiovascular death, non -fatal MI,
non-fatal stroke and hospi[INVESTIGATOR_19934];  only those events confirmed by
[CONTACT_686074];
Increase of the dose of an existing diuretic or addition of a new diuretic due to fluid
retention ;
Changes from baseline to each visit up to EOS in body weight and HR;
Treatment -emergent marked laborator y abnormalitiesa at each visit up to EOS;
Changes from baseline to each visit up to EOS in laboratory variables;
Changes from baseline to each visit up to EOS in [ADDRESS_930108] definitions and described in the Statistical Analysis Plan (SAP).  
6.3 Pharmacokinetic endpoints  
Trough plasma concentration of aprocitentan at Week 4 of the DB part.
6.4 Biomarker endpoints
Characterization of ET system activity b iomarkers  (e.g., CT-proET -1, ET -1, ET -3,
renin and aldosterone) and NT -proBNP in the study population at S creening as well
as at the end of RI;
Changes from baseline to Week 4 in these biomarkers;
Change s from baseline to time points up to Week 36 in NT -proBNP, mid-regional
pro-atrial natriuretic peptide ( MR-proANP ) and Troponin I;
Changes from Week 36 to time points up to Week 4 8 in NT -proBNP, MR-proANP
and Troponin I .
6.5 Rationale for primary and secondary endpoints  
Hypertension is an important public -health chall enge worldwide. There is global 
recognition that favorable effects of antihypertensive agents on BP reduction translate into 
morbidity/mortality benefits, as acknowledged in the FDA ’s approved labels for all 
antihypertensive products. BP  is a valid surroga te endpoint accepted by [CONTACT_686075] [ Desai 2006 ].  
SBP is the main accepted target nowadays, especially i n a population with an average age 
of around [ADDRESS_930109] -2 are based on SBP as the primary endpoint [ Wright 2015 , Williams  2015 ]. 
SBP measured by [CONTACT_686076] s study. DBP 
is correlated with SBP and will be analyzed  as a secondary endpoint.  
Aprocitentan / ACT -132577  
Resistant hypertension  
Protocol ID -080A301  
Version 3  
27 February  2020 , page  69/[ADDRESS_930110] [ Myers 2010 ] and allows immediate 
teletransmission of the BP readings and therefore offers better monitoring. In addition, 
AOBPM has less missing data compared to ABPM, which is known to be a burden for 
subjects. ABPM will be used for 24  h SBP/DBP recording as secondary endpoint.  
7 VISIT SCHEDULE AND S TUDY ASSESSMENTS  
7.1 Study visits  
The study visits, their respective time windows and the assessments to be performed at 
each visit are listed in Table 2 and Table  3. 
7.1.1 Screening/re -screening  
[IP_ADDRESS]  Screening  
The date of the screening visit is the date when the ICF is signed see Section  12.3 for the 
informed consent procedure .  
The subjects who agree to participate in the study and the investigator/delegate must sign  
the ICF prior to any study -related assessment or procedure.  
If the signing of the ICF and performance of the first study -specific procedures or  
assessments take place on the same day, it must be clear from the source documents that  
informed consent was obtained prior to any study -specific procedures being performed.  
If a study -specific procedure or assessment has been performed as part of routine  
assessments on the day of the screening visit prior to the  subject signing the ICF, such 
procedure or assessment may be used and does not have to  be repeated (e.g., vital signs). 
In such cases, it must be clear from the source documents  when and for which reason the 
assessment was done prior to the signing of the ICF.  
For convenience reasons, study -specific procedures or assessments can take place on 
different days/visits during the s creening period.  
Subjects who sign the ICF wh en the enrollment target has already been met may still be 
randomized.  
[IP_ADDRESS]  Re-screening  
Subjects who did not meet the criteria for participation in the study (i.e., screen failure) 
may be re -screened once, if the reason for  non-eligibility was transient ( e.g., abnormal 
laboratory test, insu fficient time for optimization [ i.e., maximal tolerated dose ] of 
background antihypertensive medications, insufficient time window for allowed 
Aprocitentan / ACT -132577  
Resistant hypertension  
Protocol ID -080A301  
Version 3  
27 February  2020 , page  70/[ADDRESS_930111] 2017 -004393 -33 
Doc No D-20.008  
medications, BP measurement technical issue [s]). Subjects w ho have switched to the  
standardized background antihypertensive therapy cannot be re -screened.  
A new ICF must be signed prior to re -screening the subject if more than [ADDRESS_930112] dose of RI study treatment (i.e., placebo)  and a safety FU call 30 (+ 3) 
days thereafter. The reason of the RI failur e must be recorded in the eCRF.  
7.1.3 Randomized treatment period  
At end of RI visit (Day –1) all eligibility criteria for randomization must be checked [see 
Section 4.3]. If these criteria are met, the subject will be randomized the following day.  
In case of premature discontinuation of randomized study treatment, the EOT visit must 
take place as soon as possible and no later than [ADDRESS_930113] dose of randomized 
study treatment and a safety FU visit 30 (+  3) days thereafter.  
Subjects who prematurely discontinue randomized study treatment for any reason will not 
be replaced.  
7.1.[ADDRESS_930114] continue according to 
the planned visit and assessment schedule.  
Aprocitentan / ACT -132577  
Resistant hypertension  
Protocol ID -080A301  
Version 3 
27 February  2020 , page  71/[ADDRESS_930115] 2017 -004393 -33 
Doc No D-20.008  
 
 Table 2 Visit and assessment schedule up to randomization  
PERIODS  Name / Duration  Screening  
4-[ADDRESS_930116]  Week -4 Week -2 End of Run -in Randomization  
Additional visits  as needed  Day -28 
( 4 d) Day -14 
( 2 d) Day –1 Day 1  
Informed consent  X      
Eligibility including confirmation of diagnosis of true RHT  X X X13  X15  
Demographic s / Medical history  X      
Physical examination  X X X X X  
Concomitant medications  X X X X X X 
Body weight, height2 X X X X X16  
12-lead ECG3 X    X16  
Laboratory tests4  X    X16,[ADDRESS_930117]  X X X  X16,17  
Urinalysis5       X16  
Urine sampling to monitor treatment adherence6   X6 X  X16  
AOBPM (incl. HR) X X X X X  
Hom e BP monitoring7    
ABPM      X16 X 
Blood  sampling for biomarkers8 X    X  
Accountability of study t reatment  and standardized background 
antihypertensive therapy9   X X X16  
Dispensing/return  of study treatment and standardized background  
antihypertensive  therapy10  X X14  X X 
SAE11 and AE11 X X X X X X 
Aprocitentan / ACT -132577  
Resistant hypertension  
Protocol ID -080A301  
Version 3 
27 February  2020 , page  72/[ADDRESS_930118] 2017 -004393 -33 
Doc No D-20.008  
1 Unscheduled visits may be performed at any time during the study. See Section  7.1.4  for details . 
2 Body weight is measured at each visit with  the same weight scale. Height is only measured at Screening.  
3 ECGs are read centrally.  
4 Hematology and clinical chemistry.  
5 For UACR determination.  
6 Urine sampling at trough (i.e., before intake of study treatment and standardized background antihypertensive therapy). For subjects who do no t fulfill Run-in eligibility criteria no urine 
sample to be collected.  
7 Upon investigator ’s judgment, a home BP monitoring device will be dispensed, if necessary.  
8 Blood sampling at trough (i.e., before intake of study treatment and standardized background antihypertensive therapy) , see S ection  7.2.5  for details . 
9 Drug accountability (pi[INVESTIGATOR_686017]).  
[ADDRESS_930119] be reported.  
12 Switch to the standardized background antihypertensive therapy. Visit 1 .1 may be at the same day as Visit 1. Additional v isits may be performed  for further  assessments (e.g ., to adjust the 
dose of the standardized background antihypertensive therapy , taking urine samples to monitor adherence ).  
[ADDRESS_930120] be kept stable.  
15 Randomization eligibility criteria.  
16 For subjects who permanently discontinue prior to Randomization  due to any reason or do not fulfill  the randomization eligibility criteria, these tests are not mandatory.  
17 Two samples will be drawn: one sample for central laboratory and one sample for local laboratory to measure hemoglobin, creat inine (to determine  eGFR ), and AST/ALT and to perform a  
pregnancy test to confirm eligibility of subjects for randomization.  
ABPM = ambulatory blood pressure monitoring; AE = adverse event; ALT = alanine aminotransferase; AOBPM = automated office blo od pressure measurement; AST = aspartate 
aminotransferase; BP = blood pressure; ECG = electrocardiogram; eGFR = estimated glomerular filtration rate; HR = heart rate; RHT = resistant h ypertension; RI = run -in; SAE = serious 
adverse event; UACR = urine albumin -to-creatinine ratio.  
Aprocitentan / ACT -132577  
Resistant hypertension  
Protocol ID -080A301  
Version 3 
27 February  2020 , page  73/[ADDRESS_930121] 2017 -004393 -33 
Doc No D-20.008  
Table  3 Visit and assessment schedule from start of DB Treatment period up to EOS  
PERIODS  Name / 
Duration  DB Treatment  
4 weeks  SB Treatment  
32 weeks  DB-WD Treatment  
12 weeks  FU12 
30 days  
VISITS1 Number  5 6 7 8 9 10 11 12 13 14 15 16 
Time  Week 2  Week 4  Week 6  Week 12  Week 20  Week 28  Week 36  Week 38  Week 40  Week 44  EOT11 
Week 48  EOS  
(EOT+30 d)  
Day 14  
( 2 d) Day 28  
( 2 d) Day 
29 Day 42  
( 2 d) Day 84  
( 10 d)  Day 140 
( 10 d)  Day 196  
( 10 d)  Day 252  
( 12 d)  Day 
253 Day 266  
( 4 d) Day 280 
( 4 d) Day 
281 Day 308  
( 4 d) Day 336  
( 4 d) Day 366  
(+ 3 d)  
Physical examination  X X X X X X X X X X X X 
Concomitant medications  X X X X X X X X X X X X X X X12 
Body weight2 X X X X X X X X X X X X 
12-lead ECG3X X X X X X 
Laboratory tests4 X X X X X X X X X X 
Urinalysis5 X X X X X X X X X 
Urine sampling  to monitor treatment adherence6 X X X X X X X X X X X 
AOBPM (incl. HR) X X X X X X X X X X X X 
Home BP monitoring7 
ABPM  X X X X X X 
Blood  sampling for PK8 X 
Blood sampling for biomarkers8 X X X X 
Accountability of study t reatment  and 
standardized background antihypertensive 
therapy9 X X X X X X X X X X X X 
Dispensing/return of s tudy treatment and 
standardized background antihypertensive 
therapy   X X X X X X X X X X X X 
SAE10 and AE10 X X X X X X X X X X X X X X X12 
Aprocitentan / ACT -132577  
Resistant hypertension  
Protocol ID -080A301  
Version 3 
27 February  2020 , page  74/[ADDRESS_930122]. During SB aprocitentan part, urine pregnancy tests will be performed monthly (i.e., between scheduled 
visits) at home with kits that are provided to the subject.  
5 For UACR determination.  
6 Urine sampling at trough (i.e., before intake of study treatment and standardized background antihypertensive therapy).  
7 Upon investigator ’s judgment, a home BP monitoring device will be dispensed, if necessary.  
8 Blood sampling at trough (i.e., before intake of study treatment and st andardized background antihypertensive therapy) , see Section  7.2.5  for details . 
9 Study treatment including standardized background antihypertensive  therapy should be brought back at each visit for d rug accountability (pi[INVESTIGATOR_10685]).  
[ADDRESS_930123] be reported.  
11 Randomized subjects who  prematurely discontinue prior to Week 48/Visit [ADDRESS_930124] adver se events and concomitant medications only.  
ABPM = ambulatory blood pressure monitoring; AE = adverse event; AOBPM = automated office blood pressure measurement; BP = bl ood pressure; DB = double -blind; 
ECG  = electrocardiogram; EOT = End -of-Treatment; HR =  heart rate;  NT-proBNP = N-terminal pro -brain natriuretic peptide ; PK = pharmacokinetic(s);  RI = run -in; SAE = serious adverse 
event; UACR = urine albumin -to-creatinine ratio.  
Aprocitentan / ACT -132577  
Resistant hypertension  
Protocol ID -080A301  
Version 3  
27 February  2020 , page  75/[ADDRESS_930125] 2017 -004393 -33 
Doc No D-20.008  
7.2 Study assessments  
The study assessments are listed in Table 2 and Table  3. The assessments that are 
mandatory during a visit are marked with an ‘X’. 
All study assessments performed during study visits (scheduled or unscheduled) are to be 
done by [CONTACT_093]/delegate and are recorded in the eCRF, unless otherwise specified.  
The following order of assessments is recommended:  
Date and time of the last study treatment and standardized background
antihypertensive therapy  intake (i.e., the day prior to  each study visit),
AOBPM and HR measurements at trougha;
Blood sampling including PK and biomarker samples at trougha;
Urine sa mpling including sampling for drug monitoring at trougha;
Physical examination (including assessment of AEs/SAEs), and body weight ;
ECG ;
Start ABPM ;
Intake of the study treatment and standardized background antihypertensive therapy at
the site in the  presence of the study staff .
a Before taking the study treatment and the standardized background antihypertensive 
therapy.   
If the Principal Investigator (PI) delegates any study procedure/assessment for a subject 
(e.g., ECG, blood / urine sampling)  to an  external facility, he/she should inform the sponsor 
to whom these tasks are delegated. The set -up and oversight will be agreed upon with the 
sponsor. The supervision of any external facilities remains the responsibility of the PI.  
Calibration certificates  / evidence of equipment maintenance for the below -listed 
equipment used to perform study assessments must be available prior to the screening of 
the first subject:  
BP monitoring devices (i.e., AOBPM and ABPM) ;
Body weight scale ;
ECG devices ;
Temperatur e measurement devices for study treatment storage area and laboratory
sample storage (e.g., freezer) ;
Calibration certificates of other equipment must be available as per local requirements.
Aprocitentan / ACT -132577  
Resistant hypertension  
Protocol ID -080A301  
Version 3  
27 February  2020 , page  76/[ADDRESS_930126] 2017 -004393 -33 
Doc No D-20.008  
7.2.1 Baseline demographics and disease characteristics  
Demographic and  baseline characteristic data to be collected on all subjects include: age, 
sex, race, ethnicity (if allowed in the country), weight and heigh t. Relevant medical 
history  / current medical conditions (e.g., chronic and ongoing acute conditions, serious 
past conditions) present before signing of the ICF will be recorded in the eCRF. In 
particular, the following conditions must be considered: DM, angina pectoris, heart failure,  
CKD, obstructive sleep apnea syndrome. Where possible, main diagnoses , instead of 
symptoms , will be recorded .  
[IP_ADDRESS]  Hypertension history  
True RHT disease characteristics, evidenced by [CONTACT_686077], as 
defined below will be recorded at Screening:  
Date of first diagnosis  of hypertension ;
Secondary causes of hypertensi on that have been excluded;
Current antihypertensive medications; i.e., ongoing at Visit 1 and stopped o r modified
if required at this v isit.
[IP_ADDRESS]  Data to be collected for screening failure subjects  
Blood samples for biomarker evaluation must be collected.  The following data will be 
recorded in the eCRF if available:  
Date / t ime of ICF signature ;
Demographics (age, sex, race and ethnicity) ;
Medical history ;
Reason for screen failure and associated assessments, if applicable ;
Antihypertensive medications;  i.e., ongoing at Visit 1 ;
All AEs and SAEs that occur after signing the ICF ;
7.2.2 Efficacy assessments
[IP_ADDRESS]  Unattended automated office blood pressure measurement (AOBPM)
Accurate measurement of BP is essential to diagnose subjects with RHT and demonstrate 
the BP l owering effect of aprocitentan in true RHT subjects.  
Fully automated BP measurement has several advantages over manual BP measurements, 
especially in routine clinical practice, by [CONTACT_686078] -induced increases in 
BP (i.e. , white coat effe ct), improving accuracy, minimizing observer error, and providing 
a more standardized measurement technique [ Myers 2010 ]. Therefore, BP will be 
measured throug hout the study with an automatic oscillometric sphygmomanometer which 
will be provided to each site by [CONTACT_686079].  
Aprocitentan / ACT -132577  
Resistant hypertension  
Protocol ID -080A301  
Version 3  
27 February  2020 , page  77/[ADDRESS_930127] resting undisturbed, alone 
(unattended) in a quiet place. At each assessment, SiSBP and SiDBP will be measured 
using a pre -defined number of readings with preset time interval between them (timed from 
the start of one reading to the st art of the next one). The BP device /system  generates  the 
average of the readings  for SiSBP and SiDBP.  
BP must always be measured at trough (i.e., before taking the study treatment and the 
standardized background antihypertensive therapy) at around the sam e clock time. In case 
an unscheduled visit is performed, BP must be measured using the AOBPM device.  
The AOBPM device must be managed by [CONTACT_686080], the 
same person should use the BP device for a given subject at each visit. It should be 
attempted to perform BP measurements at each visit always using the same arm of the 
subject and the appropriate cuff size, as determined during Screening.  
Details on BP procedure including device to be used, subject preparation (e.g., arm 
selection, arm position, cuff size) will be provided in the BP laboratory manual and will 
follow the American Heart Association guidelines / Canadian Education Program on 
Hypertension [ Pi[INVESTIGATOR_11721] 2005 , Daskalopoulou  2012 ]. AOBPM data will be electronically 
transferred to the central BP laborator y and subsequently to the sponsor.  
Standing BP measurement  
BP must also be measured in the standing position to monitor orthostatic hypotension [see 
Section [IP_ADDRESS].1 ]. Standing SBP/DBP is measured twice, with the AOBPM device, 
approximately one and three minutes after standing.  
Pulse rate   
Pulse rate  will be measured at each visit, at the same time as BP  measurements, with the 
AOBPM device, in a s itting position. The last pulse rate  measurement will be used for 
analysis.  
[IP_ADDRESS]  Ambulatory blood pressure monitoring  
ABPM is performed over a [ADDRESS_930128] BP at a 
pre-defined  inflation sequence over the 24  h period at the following visits:  
 Baseline: At the end of the SB placebo RI period, i.e., Visit 4 / Day –1.  
 End of DB part: At Visit 6 / Week 4 (Day 28, ± 2 days)  
 End of the SB aprocitentan part: At Visit 11 / Week 36 (Day 252, ± 12 days).  
 During the DB -WD part: At Visit 13 / Week 40 (Day 280, ± 4 days)  
Aprocitentan / ACT -132577  
Resistant hypertension  
Protocol ID -080A301  
Version 3  
27 February  2020 , page  78/[ADDRESS_930129] will take the study 
treatment at the site, in the presence of study personnel ( i.e., DOT). The following day 
(i.e., second day), the subject will come back to site to have the ABPM device removed.  
The ABPM device will be provided to each site by [CONTACT_686081]. ABPM data will be electronically  transferred to the central BP 
laboratory and subsequently to the sponsor.  
Details on ABPM procedure (installation, recording and transfer of data) including subject 
preparation will be provided in the BP laboratory manual.  
[IP_ADDRESS]  Home blood pressure measurement  
Each site will be provided with home BP monitoring devices. These can be lent to the 
subjects for the entire duration of the study, upon investigator ’s judgment, to monitor BP 
at home, if necessary.  
The following instructions must be given to subjects wh o receive a home BP device:  
 Explain how to use the device to measure the BP ; 
 Explain to measure BP if there are severe symptoms related to hypertension like 
headache, vomiting, nose bleeding, or symptoms related to orthostatic hypotension 
e.g., light-head edness, pre -syncope, dizziness, as follows:  
– Sit in a calm place for 5 minutes  
– Measure the SBP/DBP:  
o Three readings within 5 –10 minutes in the morning before taking your study 
medications  
o Three readings within 5 –10 minutes in the evening  
– Record the SBP/ DBP values, time of measurement and time of study treatment 
intake in the subject ’s card, which will be provided with the device ;  
– Measure the BP as descr ibed above for 3 days in a row;  
– If the symptoms are still present on the third day, contact [CONTACT_779].  
The data recorded by [CONTACT_686082] l be filed in the hospi[INVESTIGATOR_1332]. It will not be 
recorded in the eCRF or transferred to the sponsor.  
The subject must give back the device at the EOS.  
7.2.3 Safety assessments  
The definitions, reporting and follow -up of AEs, SAEs and pregnancies are described in 
Section 9. 
Aprocitentan / ACT -132577  
Resistant hypertension  
Protocol ID -080A301  
Version 3  
27 February  2020 , page  79/[ADDRESS_930130] 2017 -004393 -33 
Doc No D-20.008  
 
 [IP_ADDRESS]  Vital signs  
[IP_ADDRESS].1  Orthostatic hypotension  
At each study visit, standing and sitting SBP and DBP will be measured with the AOBPM 
device [see Section [IP_ADDRESS] ].  
Symptomatic orthostatic hypote nsion is defined as a SBP decrease of ≥ 20 mmHg or a DBP 
decrease of ≥ 10 mmHg from sitting to standing position, with symptoms of cerebral 
hypo -perfusion (e.g., light -headedness, dizziness, pre -syncope). The last sitting BP values 
(SBP and DPB) measured b y AOBPM are compared to the last measured standing BPs.  
Symptomatic orthostatic hypotension must be recorded as an AE in the eCRF.  
[IP_ADDRESS]  Physical examination  
Physical examination at S creening includes the examination of the general appearance, 
heart, lungs, abd omen, skin, extremities/peripheral vascular assessment, eyes, ears, nose, 
throat, neck, and lymph nodes . At subsequent visits, physical examination includes as a 
minimum the examination of general appearance, heart, and peripheral vascular 
assessment.  
Other examinations will be performed if indicated, based on medical history and/or  
symptoms.  
Information for all physical examinations must be included in the source documentation at 
the study site.  
The physical examination will be reported in the eCRF as  either normal or abnormal ; in 
the latter case, the investigator should specify whether it is clinically relevant. Clinically 
relevant physical abnormalities present at the time of signing off the ICF must be reported 
on the medical history form of the eCR F. Physical examination findings, which meet the 
definition of an AE [Section 9.1.1 ] and are made after signing off the ICF, must be recorded 
on th e AE form of the eCRF.  
[IP_ADDRESS]  Weight and height  
Height wil l be measured without shoes at S creening only.  
Body weight must be carefully monitored during the study  since it  is one of the s afety 
endpoints. Body weight must be measured at all visits in a standardize d way, as follows: 
subjects should always be weighed under similar conditions, e.g., same scale, similar 
clothing (i.e., underwear only), and similar interval between weighing and last meal. The 
investigator will be asked to indicate on the body weight for m in the eCRF whether an 
increase in body weight from the previous visit is judged to be clinically relevant and 
whether it could be a sign of fluid retention. In addition, subjects will be instructed  to 
Aprocitentan / ACT -132577  
Resistant hypertension  
Protocol ID -080A301  
Version 3  
27 February  2020 , page  80/[ADDRESS_930131] the study site if  they 
notice an unusual weight increase since the start of the  study .  
Body weight and height data measured at site will be recorded in the eCRF.  
[IP_ADDRESS]  ECG assessment  
ECGs will be performed with the subject in a fully rested supin e position after the subject 
has been allowed to rest for a minimum of 5 minutes prior to the measurement.  
The following variables will be evaluated: HR (bpm), PR (ms), QRS (ms), QT (ms), QTc 
(ms), and any ECG findings. QTc (ms) will be calculated accordin g to Bazett ’s and 
Fridericia ’s formula (QTcB = QT/(RR) ½ and QTcF = QT/(RR) ⅓, respectively).  
Digital [ADDRESS_930132] be reviewed, signed and dated by [CONTACT_093] /delegate within 
10 working days of receipt and filed with the source documentation. The 
investigator/delegate must indicat e on the ECG report whether abnormal values or findings 
are considered clinically relevant or not. Clinically relevant ECG findings that are known 
at the time of signing of the ICF must be recorded in the medical history form of the eCRF. 
Any clinically re levant ECG abnormalities detected after signing of ICF must be reported 
as an AE or SAE as appropriate [see Sections 9.1.1 , 9.1.2 ], and must be followed until the 
value returns to within the normal range or is stable, or until the change is no longer 
clinically relevant.  
Details on ECG procedur e (recording, transfer of data and reporting to the site) will be 
provided in the ECG manual.  
[IP_ADDRESS]  Laboratory assessments  
[IP_ADDRESS].1  Type of laboratory  
A central laboratory or designated laboratory (see laboratory manual for contact [CONTACT_8972]) 
will be used for all protocol -mandated laboratory tests (except PK and urine pregnancy 
tests), including re -tests due to laboratory abnormalities and laboratory tests performed at 
unscheduled visits.  
At the end of the RI period (Day –1), two samples will be drawn: 
One sample for cent ral laboratory, and
Aprocitentan / ACT -132577  
Resistant hypertension  
Protocol ID -080A301  
Version 3  
27 February  2020 , page  81/[ADDRESS_930133] 2017 -004393 -33 
Doc No D-20.008  
One sample for local laboratory: to measure hemoglobin, creatinine (to determine
eGFR ), AST/ALT and pregnancy test for women of childbearing potential to confirm
eligibility of subject for randomization. Decision on eligibility and randomization will
be based on local laboratory results. These local laboratory results (with the
corresponding normal ranges) must be recorded in the eCRF.
For other exceptional circumstances (e.g., subject is hospi[INVESTIGATOR_42868] a different hospi[INVESTIGATOR_686018] a medical emergency, or missing central laboratory results 
from a scheduled or unscheduled visit), local laboratory results of the parameters described 
in Section [IP_ADDRESS].[ADDRESS_930134] results are available (in which case they must be recorded in 
the eCRF) . 
Laboratory reports will be provided by [CONTACT_686083]/delegate. 
All laboratory reports must be reviewed, signed and dated by [CONTACT_093]/delegate 
within 10 working days of receipt and filed with the source documentation. The 
investigator/delegate must indicate on the laboratory report whether abnormal values are 
considered clinically relevant or not. Clinically relevant laboratory findings that are known 
at the time of signing of ICF must be recorded in the medical history  form of the eCRF. 
Any clinically relevant laboratory abnormalities detected after signing of the ICF must be 
reported as an AE or SAE as appropriate [see Sections 9.1.1  and 9.1.2 ], and must be 
followed until the value returns to within the normal range or is stable, or until the change 
is no l onger clinically relevant.  
In the event of specific (pre -defined) laboratory abnormalities, the central laboratory will 
alert the sponsor and the site personnel. Alert flags that will trigger such notifications are 
displayed in the laboratory guidelines.  
Details about the collection, sampling, storage, shipment procedures, and reporting of 
results and abnormal findings can be found in the laboratory manual.  
[IP_ADDRESS].[ADDRESS_930135] per visit will be described in t he 
laboratory manual.  
Aprocitentan / ACT -132577  
Resistant hypertension  
Protocol ID -080A301  
Version 3  
27 February  2020 , page  82/[ADDRESS_930136] 2017 -004393 -33 
Doc No D-20.008  
Hematology  
Hemoglobin
Hematocrit
Erythrocyte count
Reticulocyte count
Leukocyte count with differential counts
Platelet count
MCV, as part of a standard complete  blood  count , is used along with other red blood
count  indices (MCH and  MCHC)
Blood chemistry  
ALT, AST, Alkaline phosphatase
Total and direct bilirubin
Cholesterol, triglyceride, high density lipoprotein , low density lipoprotein
Creatinine, creatine kinase
eGFR (estimated using the CKD -EPI [INVESTIGATOR_144326] Levey  2009)
Uric acid
Albumin, Protein total
Glucose
Sodium, potassium
NT-proBNP [see Section 7.2.5 ]
[IP_ADDRESS].[ADDRESS_930137] urine collection tube for 
shipment to central laboratory. Details about the collection, sampling, storage, shipment 
procedures, transfer and reporting of results can be found in the laboratory manual.  
[IP_ADDRESS].3.1  UACR determination  
A midstream, clean -catch urine specimen will be collected for the determination of UACR 
(mg/g).  
Aprocitentan / ACT -132577  
Resistant hypertension  
Protocol ID -080A301  
Version 3  
27 February  2020 , page  83/[ADDRESS_930138] 2017 -004393 -33 
Doc No D-20.008  
 
 [IP_ADDRESS].3.2  Study treatment adherence  
Urine samples will be analyzed by a designated central laboratory for the presence of 
valsartan (one of the component s of the standardized background antih ypertensive 
therapy).  
[IP_ADDRESS].4  Pregnancy tests  
Serum pregnancy tests for women of childbearing potential will be performed during the 
study according to Table  3. Serum pregna ncy tests will be sent to the central lab for analysis 
and the result will be sent to the investigator/delegate (see laboratory manual for details on 
collection, sampling, storage, shipment procedures, and reporting of results). Reporting 
procedures of pre gnancy are described in Section 9.4.1 . 
During the SB aprocitentan part urine pregnancy tests will be performed between 
scheduled visits (i.e., mont hly) with approved kits provided by [CONTACT_686084] 
[see Table  3]. If pregnancy is suspected, the subject must immediately contact  [CONTACT_5753] 
a serum pregnancy test must be performed immediately at the site. The urine kit will be 
provided by [CONTACT_686085]. The results of the urine pregnancy tests will not 
be collected in the eCRF.  
Reporting procedures for pregnancy are described in Section 9.4.1 . 
7.2.4 Pharmacokinetic assessments  
Pre-dose (i.e., trough) blood samples for determination of PK will be collected for all 
subjects to provide information about the concentration of aprocitentan  in the target 
population. Blood samples will be dr awn at trough (before dose of study treatment and the 
standardized background antihypertensive therapy) as defined in Section 7.2.4 . 
[IP_ADDRESS]  Sampling, labe ling, storage and shipment  
The date and exact actual clock time of collection of each blood sample, as well as the 
exact dates and time of the study treatment administration (including the background 
therapy of CCB, ARB and diuretic) prior to and after blo od draw, will be entered in the 
eCRF.  
Details about the collection, sampling, storage, and shipment procedures can be found in 
the laboratory manual. Sites will receive required material from the central laboratory 
before the start of the study (e.g., tube s, labels, shipment materials). The site personnel will 
take care of the shipment of the plasma samples to central laboratory who will forward the 
PK samples to the Idorsia bioanalytical laboratory at time intervals agreed with the sponsor.  
[IP_ADDRESS]  Bioanalysis  
The analysis of aprocitentan in plasma will be performed using a validated liquid 
chromatography coupled to tandem mass spectrometry assay. The foreseen limit of 
Aprocitentan / ACT -132577  
Resistant hypertension  
Protocol ID -080A301  
Version 3  
27 February  2020 , page  84/[ADDRESS_930139] 2017 -004393 -33 
Doc No D-20.008  
quantification is 5 ng/mL. The analysis will be performed by [CONTACT_686086] .  
The PK analysis will be performed in a time interval which is covered by [CONTACT_686087]. 
The results will not be transferred to the study team until data base lock.  
The samples will be destroyed upon signature [CONTACT_686113] ( CSR ). 
7.2.5 Bioma rker assessments  
At Screening, end of RI (Day –1) and at the end of the DB part 1 (Week 4), plasma /serum  
samples will be collected for all subjects (if allowed per local/regulatory guidelines) to 
explore biomarkers that reflect the ET system activity. Such  biomarkers may include, but 
are not limited to, CT -proET -1, ET -1, ET -3, renin and aldosterone for ET system activity. 
These assessments will provide information whether RHT is an ET -1 driven form of 
hypertension, whether these biomarkers can be used to ch aracterize the study population , 
and whether these biomarkers are impacted by [CONTACT_204282].  
In addition, the following biomarkers wi ll be evaluated at the end of RI (Day –1), at the 
end of DB part 1 (Week 4), during SB aprocitentan part 2 (Week 20 and Week 36) and 
during DB -WD part 3 (Week 40)  to explore whether aprocitentan has an effect on 
micro - and macrovascular complications (e.g., edema,  heart overload): Such biomarkers 
may include, but are not limited to,  NT-proBNP MR-proANP,  and Troponin I.  In ad dition 
to these time  points NT-proBNP will also be measured at Screening (Visit  1), Visit 7 
(Week 6), Visit 8 (Week 12), Visit 10 (Week 28), Visit 14 (Week 44), Visit 15/EOT 
(Week  48), and Visit 16/EOS (EOT plus 30 days) as part of central laboratory assessments . 
Samples will be measured by a designated central laboratory at frequencies defined by [CONTACT_686088]. Details about the collection, sampling, storage and shipment 
procedures can be found in the laboratory manual.  If consented by [CONTACT_423], t he collected 
biomarker samples  will be stored in the sponsor´s research repository, which may be used 
for future research  on the endothelin system activity. The stored samples will be destroyed 
within [ADDRESS_930140] -STUDY TREATMEN T / 
MEDICAL CARE  
8.[ADDRESS_930141] been completed.  
8.2 Premature withdrawal from study  
Subjects may voluntarily withdraw from the study without justification for any reason at 
any time. Subjects are considered withdrawn if they state an intention to withdraw further 
Aprocitentan / ACT -132577  
Resistant hypertension  
Protocol ID -080A301  
Version 3  
27 February  2020 , page  85/[ADDRESS_930142] 2017 -004393 -33 
Doc No D-20.008  
participation in all co mponents of the study (i.e., WD of conse nt), die, or are lost to 
follow -up. If a subject withdraws consent, no further data will be collected in the eCRF 
from the date of WD onward. The investigator may withdraw a subject from the study 
(without regard to the subject ’s consent) if, on balance, he/she believes that continued 
participation in the study would be contrary to the best interests of the subject. WD from 
the study may also result from a decision by [CONTACT_134865], including 
premature te rmination or suspension of the study [see Section 8.3]. 
Subjects are considered as lost to follow -up if all reasonable attempts by [CONTACT_686089]. The site must take preventive measures to 
avoid a subject being lost to follow -up (e.g., document different ways of contact [CONTACT_42923], home address, email address, person to be contact[CONTACT_26426] e event  the 
subject cannot be reached). If the subject cannot be reached, the site must make a 
reasonable effort to contact [CONTACT_423], document all attempts (date, time and type of 
contact [CONTACT_606025]), and enter the loss of follow -up information into the eCRF.  The following 
methods must be used: at least three attempts at contacts (e.g., telephone calls, or e -mails) 
must be placed to the last available telephone number or e -mail address, and one registered 
letter must be sent by [CONTACT_215253]. Additional methods may be 
acceptable if they are compliant with local rules/regulations (e.g., a visit by [CONTACT_606026] ’s home), respecting the subject ’s right to privacy. If the subject is still 
unreachable after all contact [CONTACT_259160]/she will be considered to be lost to 
follow -up. 
The reason for premature WD from the study must be recorded in the eCRF.  
If for whatever reason (except death or loss -to-follow -up) a subject is withdrawn from the 
study, the investig ator should make his/her best efforts to schedule a last appointment / 
telephone call to assess the safety and well -being of the subject, collect unused study 
treatment and discuss follow -up medical care. Data obtained during this last appointment / 
teleph one call will be recorded in the subjects ’ medical records but it will not be collected 
in the eCRF. The investigator must provide follow -up medical care for all subjects who are 
prematurely withdrawn from the study, or must refer them for appropriate ongo ing care, as 
described in Section 8.4. 
8.3 Premature termination or suspension of the study  
The sponsor reserves the right to terminate the study at an y time globally or locally. 
Investigators can terminate the participation of their site in the study at any time.  
If a study is prematurely suspended or terminated, the sponsor will promptly inform the 
investigators, the IECs/IRBs, and health authorities, as appropriate, and provide the reasons 
for the suspension or termination.  
Aprocitentan / ACT -132577  
Resistant hypertension  
Protocol ID -080A301  
Version 3  
27 February  2020 , page  86/[ADDRESS_930143] 2017 -004393 -33 
Doc No D-20.008  
If the study is suspended or prematurely terminated for any reason, the investigator — in 
agreement with the sponsor — must promptly inform all enrolled subjects and ensure their 
appropriate treatment and follow -up, as described in Section 8.4. The sponsor may inform 
the investigator of additional procedures to be followed in o rder to ensure that adequate 
consideration is given to the protection of the subjects ’ interests.  
In addition, if the investigator suspends or terminates a study without prior agreement from 
the sponsor, the investigator must promptly inform the sponsor pe rsonnel and the IEC/IRB, 
and provide both with a detailed written explanation of the termination or suspension.  
If the IEC/IRB suspends or terminates its approval / favorable opi[INVESTIGATOR_1101] a study, the 
investigator must promptly notify the sponsor personnel a nd provide a detailed written 
explanation of the termination or suspension.  
Any suspension or premature termination of the study must be discussed with the IDMC.  
8.4 Medical care of subjects after study completion / withdrawal from study  
After the subject ’s study completion or premature WD from the study, whichever applies, 
the investigator/delegate will explain to subjects what treatment(s) / medical care is 
necessary and available according to local regulations.  
[ADDRESS_930144] 
during the course of the study, whet her or not considered by [CONTACT_42928].  
A treatment -emergent AE is any AE temporally associated with the use of study treatment 
(from study treatment initiation until 30 days after study treatment discontinuation), 
whether or not considered by [CONTACT_86190].  
AEs include:  
Exacerbation of a pre -existing disease.
Increase in frequency or intensity of a pre -existing epi[INVESTIGATOR_686019].
Disease or medical condition detected or diagnosed during the course of the study even
though it may have been present prior to the start of the study.
Continuous persistent disease or symptoms present at study start that worsen following
the start of the study (i.e., signing of informed consent) .
Aprocitentan / ACT -132577  
Resistant hypertension  
Protocol ID -080A301  
Version 3  
27 February  2020 , page  87/[ADDRESS_930145] 2017 -004393 -33 
Doc No D-20.008  
Abnormal assessments (e.g., change on physical examination, ECG findings), if they
represent a clinically significant finding that was not present at study start or worsened
during the course of the study.
Laboratory test abnormalities if they represent a clinically significant finding,
symptomatic or not, which was not present at study start or worsened during the course
of the study or led to dose reduction, interruption or permanent discontinuation of
study treatment.
9.1.[ADDRESS_930146] one of the following 
criteria:  
Fatal .
Life-threatening: Refers to an event in which the subject was at risk of death at the
time of the event. It does not refer to an event that hypot hetically might have caused
death had it been more severe.
Requiring in -patient hospi[INVESTIGATOR_1081] .
Resulting in persistent or significant disability or incapacity .
Congenital anomaly or birth defect .
Medically sign ificant: Refers to important medical events that may not immediately
result in death, be life -threatening, or require hospi[INVESTIGATOR_400379], based upon appropriate medical judgment, they may jeopardize the
subject, and may r equire medical or surgical intervention to prevent one of the
outcomes listed in the definitions above.
The following reasons for hospi[INVESTIGATOR_42863]:  
Hospi[INVESTIGATOR_180458], or social and/or convenience reason s
Hospi[INVESTIGATOR_5912] -planned (i.e., planned prior to signing ICF) surgery or standard
monitoring of a pre -existing disease or medical condition that did not worsen, e.g.,
hospi[INVESTIGATOR_42865] a subject with stable angina pectori s
However, complications that occur during hospi[INVESTIGATOR_42866] (e.g., if a 
complication prolongs hospi[INVESTIGATOR_059]).  
9.1.3 Definition of suspected unexpected serious adverse reaction  
The expectedness of a n adverse reaction is determined by [CONTACT_686090] (RSI) section provided in the most recent version of the IB. Any SAE 
that is assessed as related and unexpected against the RSI is defined  as a S[LOCATION_003]R . 
Aprocitentan / ACT -132577  
Resistant hypertension  
Protocol ID -080A301  
Version 3  
27 February  2020 , page  88/[ADDRESS_930147] 2017 -004393 -33 
Doc No D-20.008  
9.1.4 Definition of the intensity of adverse events  
The intensity of AEs is  graded on a three -point scale — mild, moderate, severe — as 
follows:  
 Mild
The event may be noticeable to the subject. It does not usually influence daily activities, 
and normally does not require intervention.  
 Moderate
The event may make the subject uncomfortable. Performance of daily activities may be 
influenced, and intervention may be needed.  
 Severe
The event may cause noticeable discomfort and usually interferes with daily activities. The 
subject may not be able to continue in the study, and treat ment or intervention is usually 
needed.  
These terms are used to describe the intensity of a specific event. Medical judgment should 
be used on a case -by-case basis.  
A mild, moderate, or severe AE may or may not be serious [see Section 9.1.2 ]. Seriousness, 
rather than intensity assessment, determines the regulatory reporting obligations see 
Section 9.3.2. 
9.1.5 Relationship to study treatment 
Each AE/SAE must be assessed by [CONTACT_180510] a 
reasonable possibility of causal relationship to the study treatment, and repor ted as either 
related or unrelated.  
9.1.6 Relationship to study design or protocol -mandated procedure  
An AE/ SAE is defined as related to study design or protocol -mandated procedure if it 
appears to have a reasonable possibility of a causal relationship to eithe r the study design 
or to a protocol -mandated procedure (e.g., discontinuation of a subject ’s previous treatment 
leading to exacerbation of underlying disease). The determination of the likelihood that the 
study design / a protocol -mandated procedure caused  the AE/SAE will be provided by [CONTACT_1275].  
9.2 Time period and frequency for AE/SAE assessment and follow -up 
The occurrence of an AE/SAE may come to the attention of study personnel during study 
visits, phone calls and interviews of study participant pr esenting for medical care. At each 
Aprocitentan / ACT -132577  
Resistant hypertension  
Protocol ID -080A301  
Version 3  
27 February  2020 , page  89/[ADDRESS_930148] 2017 -004393 -33 
Doc No D-20.008  
study visit (scheduled or unscheduled), the investigator will inquire about the occurrence 
of AE/SAEs since the last visit.  
The clinical course of AEs/SAEs will be followed according to local standard medical 
practices.  
9.2.[ADDRESS_930149] be recorded on specific  AE forms of the eCRF.  
Information to be collected on an AE form in the eCRF includes date of onset, action taken 
with the study treatment, outcome of AE, date of resolution (if applicable), as well as PI ’s 
assessment of intensity and relationship to stud y treatment , standardized background 
antihypertensive therapy , study design or protocol mandated procedures.  
If the intensity of an AE worsens during the study , a new AE should be reported  in the 
eCRF with the higher intensity. If the intensity of an AE lessens during the study , no change 
in the intensity  is required to be reported .  
Follow -up information on ongoing AE obtained after the subject ’s EOS visit will not be 
collected in the eCRF.  
9.3.[ADDRESS_930150] be reported by [CONTACT_68477] ’s Global Drug Safety 
department within 24  hours of the investigator ’s first knowledge of the event.  
All SAEs occurring after signing of the ICF  up to [ADDRESS_930151] be sent to the sponsor ’s Global Drug Safety department (see contact 
[CONTACT_259163]) . The investigator must complete the SAE form in English, and 
must assess the event ’s causal relationship to the study treatment.  
Aprocitentan / ACT -132577  
Resistant hypertension  
Protocol ID -080A301  
Version 3  
27 February  2020 , page  90/[ADDRESS_930152] also be reported within 
24 hours of receiving it. The sponsor ’s Global Drug Safety personnel may contact [CONTACT_110198].  
If the subject is  hospi[INVESTIGATOR_42868] a hospi[INVESTIGATOR_310486], it is the 
investigator ’s responsibility to contact [CONTACT_42933][INVESTIGATOR_42870] -relevant information 
and documentation.  
Follow -up information on an ongoing SAE obtained after a subject ’s EOS  visit must be 
reported to the sponsor ’s Global Drug Safety department, but is not recorded in the eCRF. 
New SAEs occurring after the [ADDRESS_930153] be reported to the sponsor ’s Global 
Drug Safety department within 24  hours of the investigator ’s knowledge of the event, only 
if considered by [CONTACT_42930].  
9.3.3 Additional reporting procedures for S[LOCATION_003]R  
The sponsor will report a ny S[LOCATION_003]R  see definition in Section 9.1.3 to concerned health 
authorities (including the EudraVigilance database if the study is conducted in Europe), 
IECs/IRBs and investigators.  
9.[ADDRESS_930154] be 
discontinued [see Section 5.1.11. The investigator must counsel the subject and  discuss 
the risks of continuing with the pregnancy and the possible effects on the fetus.  
9.4.[ADDRESS_930155] be reported to the sponsor ’s Global Drug Safety 
department within 24  hours of the investigator ’s knowledge of the event.  
Pregnancies must be reported on the sponsor Pregnancy form, which is faxed to the 
sponsor ’s Global Drug Safety department (see contact [CONTACT_686091]).  
The investigator must complete the pregnancy form in English.  
9.4.[ADDRESS_930156] be reported 
to the sponsor ’s Global Drug Safety department.  
Aprocitentan / ACT -132577  
Resistant hypertension  
Protocol ID -080A301  
Version 3  
27 February  2020 , page  91/[ADDRESS_930157] be reported 
on an SAE form as described in Section 9.3.2 . 
9.5 Reporting of study treatment overdose, misuse, and abuse  
Study treatment overdose, misuse, and abuse  will be reported as an AE  only if associated 
with signs or symptoms .  
Overdose: Administration of a dose (per intake or cumulatively) which is above the 
instructions provided in the protocol. When applying this definition, clinical judgment 
should always be applied (e.g., just because a subject took two tablets instead of one  it is 
not “overdose ” as per definition).  
Misuse: Intentional and inappropriate use which is different from the instructions provided 
in the protocol.  
Abuse: Intentional excessive use with harmful physical or psychological effects.  
9.6 Study safety monitoring 
Study safety information (AEs, SAEs, laboratory values, ECGs, vital signs, and 
study -specific examinations as required) is monitored and reviewed on a continuous basis 
by [CONTACT_456] (in charge of ensuring subjects ’ safety as well as data quality) by 
[CONTACT_686092] y monitoring clinical studies activities from protocol conception to database 
closure.  
In addition, an IDMC is monitoring safety data on a study level [see Section 3.3.2 ]. 
10 STATISTICAL METHODS  
10.1 Analysis sets  
10.1.1  Screened Set  
The Screened Set (SCR) includes all subjects who have given informed consent to 
participate in the study and have a subject number.  
10.1.2  Run-in Set  
The Run -in Set (RIS) includes all subject s from the SCR  who received at least one dose of 
SB placebo in the RI period.  
10.1.3  Full Analysis Set  (FAS)  
The FAS includes all subjects who were randomized and have a baseline SiSBP, measured 
by [CONTACT_686034]. In order to adhere to the intent -to-treat principle as much as possible, subjects  
will be evaluated according to their assigned study treatment in the DB part: aprocitentan 
25 mg, aprocitentan 12.5 mg or placebo.  
Aprocitentan / ACT -132577  
Resistant hypertension  
Protocol ID -080A301  
Version 3  
27 February  2020 , page  92/[ADDRESS_930158] 2017 -004393 -33 
Doc No D-20.008  
10.1.4  Per Protocol Set  
The PPS includes all subjects from the FAS without a major protocol deviation (to  be 
defined in the SAP).  
10.1.5  Modified FAS  
The modified FAS (mFAS) includes all subjects in the FAS who were re -randomized in 
the DB -WD part of the study and who have a Week [ADDRESS_930159] udy treatment in the DB -WD part: 
aprocitentan 25 mg or placebo.  
10.1.6  ABPM FAS  
The ABPM FAS (aFAS) includes all subjects from the FAS who have a baseline 24  h mean 
SBP, measured by [CONTACT_44117]. Subjects will be evaluated according to their assigned study 
treatment in t he DB part.  
10.1.7  Modified ABPM FAS  
The modified ABPM FAS (maFAS) includes all sub jects from the aFAS who were 
re-randomized in the DB -WD part of the study and who have a Week 36 24  h mean SBP, 
measured by [CONTACT_44117]. Subjects will be evaluated according to their assi gned study treatment 
in the DB -WD part.  
10.1.8  Safety Analysis Set 
The Safety  Analysis  Set (SAF) includes all randomized subjects who received at least one 
dose of study treatment in the DB part. Subjects will be evaluated according to the study 
treatment they re ceived in the DB part.  
10.1.9  Modified Safety Analysis Set 
The modified SAF  (mSAF) includes subjects from the SAF received at least one dose of 
study treatment in the DB -WD part. Subjects will be evaluated according to the study 
treatment they received in the DB -WD part.  
10.1.[ADDRESS_930160] one valid PK assessment and 
no major protocol deviation pertaining to PK (to be de fined in the SAP).  
10.1.11  Usage of the analysis sets  
The role of the analysis sets in each of the study parts (DB, SB  aprocitentan  and DB -WD) 
is summarized in  Table 4. 
Aprocitentan / ACT -132577  
Resistant hypertension  
Protocol ID -080A301  
Version 3  
27 February  2020 , page  93/[ADDRESS_930161] 2017 -004393 -33 
Doc No D-20.008  
Table 4 Role of the analysis sets  
ABPM = ambulatory blood pressure monitoring; aFAS = ABPM Full Analysis Set; AOBPM = automated office blood 
pressure measurement;  DB = double -bind; FAS = Full Analysis Set; maFAS= modified ABPM Full Analysis Set; mFAS 
= modified Full Analysis Set; mSAF = mo dified Safety Analysis Set; PK = pharmacokinetic(s); PPS = Per Protocol Set; 
SAF = Safety Analysis Set; SB = single -blind; WD = withdrawal.  
The SCR and RIS  will be used for subject listings.  
10.2 Variables  
10.2.1  Primary efficacy variable  
Refer to Section 6.1.1 . 
10.2.2  Secondary efficacy variables  
Refer to Section 6.1.2 . Details for the derivation of ABPM -based endpoints are given 
below. The criteria for ABPM readings to be evaluable for analysis will be listed in the 
SAP.  
Changes from baseline to Week 4 of DB treatment in 24  h mean SBP and DBP
measured by [CONTACT_44117] . At each visit the 24  h mean SBP (DBP) is derived from the area
under the SBP (DBP) -time curve, divided by [CONTACT_686093]. The area under the curve
is calculated by [CONTACT_51715]. Time points lat er than [ADDRESS_930162] time
point will be excluded from the calculation. T he change from baseline to Week  4 will
be obtained by [CONTACT_58413].
Changes from Week 36 to Week 40 of DB -WD treatment in 24  h mean SBP and DBP
measured by [CONTACT_44117] . These are d erived similarly to changes from baseline to Week  4
of DB treatment in 24  h mean SBP and DBP, with baseline and Week 4 replaced by
[CONTACT_10585] 36 and Week 40, respectively.
10.2.3  Safety variables  
Refer to Section  6.2.  Study Part  DB SB DB-WD 
Efficacy endpoints based on AOBPM  FAS (PPS)  - mFAS  
Efficacy endpoints based on ABPM  aFAS  - maFAS  
Safety endpoints  SAF SAF mSAF  
PK endpoints  PK - - 
Aprocitentan / ACT -132577  
Resistant hypertension  
Protocol ID -080A301  
Version 3  
27 February  2020 , page  94/[ADDRESS_930163] two hypotheses (H 10 and H 20) 
will be tested in parallel using the Bonferroni correction. T he third hypothesis (H 30) will 
only be tested if H10 or H [ADDRESS_930164] null hypothesis H 10 is that there is no difference between aprocitentan 25 mg and 
placebo in the DB part in the mean change from baseline to Week 4 in mean  trough SiSBP. 
The alternative hypothesis H 1a is that there is a difference between these groups:  
H10: μ1 = μ 0 vs H1a: μ1 ≠ μ 0. 
Here μ 0 and  μ1 denote the mean change from baseline to Week 4 in mean  trough SiSBP in 
the placebo and aprocitentan 25 mg group, respectively. This  hypothesis will be tested at a 
two-sided significance level of 0.025.  
The second null hypothesis H 20 is that there is no diffe rence between aprocitentan 12.5  mg 
and placebo in the DB part in the mean change from baseline to Week 4 in mean trough 
SiSBP. Th e alternative hypothesis H 2a is that there is a difference between these groups:  
H20: μ2 = μ 0 vs H2a: μ2 ≠ μ 0. 
Here μ [ADDRESS_930165] null hypothesis H 30 is that there is no difference between aprocitentan 25 mg and 
placebo in the DB -WD part in the mean change from Week 36 to Week 40 in mean  trough 
SiSBP.  The alternative hypothesis H 2a is that there is a difference between these groups:  
H30: ν1 = ν 0 vs H3a: ν1 ≠ ν0. 
Here ν 0 and  ν1 denote the mean change from Week 36 to Week 40 in mean  trough SiSBP 
in the placebo and aprocitentan 25 mg group, respectively. This hypothesis will only be 
tested if H 10 or H 20 is rejected: at a two -sided significance level of 0.[ADDRESS_930166] and second null 
hypotheses (H 10 and H 20) will be tested as described in Section 10.3.1 .  
Aprocitentan / ACT -132577  
Resistant hypertension  
Protocol ID -080A301  
Version 3  
27 February  2020 , page  95/[ADDRESS_930167] 2017 -004393 -33 
Doc No D-20.008  
[IP_ADDRESS]  Main analysis in the DB part  
AOBPM  measurements obtained after premature discontinuation of DB treatment will be 
excluded from this analysis (i.e.,  considered as missing), leading to a hypothetical strategy 
estimand in the terminology of [ ICH E9  (R1)]. This approach was chosen because it is 
anticipated that the effect of a treatment on BP will be lost soon after the treatment has 
been discontinued. In this setting,  it is not the usual practice to assess effectiveness after 
(premature) treatment discontin uation [ O’Neill 2012 ]. 
Changes from baseline to post -baseline visits up to Week [ADDRESS_930168] Squares Mean (LSM) differences vs placebo at Week 4 and their 9 7.5% CIs will be 
obtained from the model. The associated P -values will be used to test the first and second 
null hypotheses.  
[IP_ADDRESS]  Handling of missing data in the DB part  
Based on the Phase 2 study, AC -080A201, it is expected that 5% of subjects will have a 
missing Week 4 AOBPM. Missing data will not be imputed but will be handled by [CONTACT_686094] (MAR).  
[IP_ADDRESS]  Sensitivity analyses for missin g data in the DB part  
The impact of deviations from the MAR assumption underlying the mixed model will be 
investigated in sensitivity analyses assuming that in the aprocitentan groups the data are 
missing not at random (MNAR ) [Mallinckro dt 2013 ].  
Multiple imputation analyses will be performed assuming a monotone missing data pattern 
(i.e., if data are missing at a given visit, they are also missing at subsequent visits). Any 
non-monotone missing data will first be imputed under MAR, which is considered 
reasonable because the proportion of non -monotone missing data (i.e., AOBPM missing at 
Week 2, but observed at Week 4) is expected to be low.  
Two control -based multiple imputation analyses w ill be performed under MNAR: 
a Jump to Reference (J2R) and a Copy Reference (CR) approach [ Carpent er 2013 ]. 
In these approaches,  multiple imputation of missing values will be performed based 
on the assumption that subjects with missing data in the aprocitentan arms follow 
the trajectory of the placebo arm, conditional on subjects ’ data available prior to 
discontinuation (baseline SiSBP for the J2R approach; baseline as well as available 
post-baseline SiSBP for the CR approach). Imputation is performed seq uentially, 
one visit at a time [Ratitch  2013 ]. At each visit a regression model is fitted using 
Aprocitentan / ACT -132577  
Resistant hypertension  
Protocol ID -080A301  
Version 3  
27 February  2020 , page  96/[ADDRESS_930169] 2017 -004393 -33 
Doc No D-20.008  
data from the placebo arm only, so missing data in the aprocitentan arms are 
imputed based on the predicted outcome in the placebo arm. The resulting multiple 
data sets are subsequently analyzed using the same mixed model as for the main 
analysis Results from these analyses are combined using Rubin ’s methodology 
[Rubin 1987 ].  
In addition, a tippi[INVESTIGATOR_686020]. Further details 
of the sensitivity analyses are given in the SAP.  
[IP_ADDRESS]  Supportive analyses  in the DB part  
In a supportive analysis,  all AOBPM  measurements obtained after premature 
discontinuation of DB treatment will be included in  the analysis, leading to a treatment 
policy strategy estimand in the terminology of [ ICH E9  (R1)]. 
[IP_ADDRESS]  Subgroup analyses in the DB part  
The aim of the subgroup analyses is to explore the consistency of treatment effect in 
relevant subgroups:  
Age (< 65 years vs ≥ 65 years),
Sex (m ale/female),
Race (Black, Caucasian, Other),
Region (to be defined in the SAP),
UACR at randomization visit (<  30 mg/g, 30 –300 mg/g, >  300 mg/g),
Results of the subgroup analyses will be displayed in a forest plot and will include:
An estimate of the treatment effect for each aprocitentan dose vs placebo with its 95%
CI for each level of the subgroup. It will be calculated as the LSM difference vs
placebo at Week 4 obtained separately for each subgroup level as described for the
main  analysis [Section [IP_ADDRESS] ].
A p-value for the interaction test obtained from the mixed model for the main analysis
extended with factors for the  subgroup and treatment by [CONTACT_226418].
A vertical reference line displayed at the level of the overall treatment effect.
The study is not designed or powered to detect interactions but an arbitrary two-sided 
significance level of 0.[ADDRESS_930170]. No 
multiplicity adjustment is applied as these subgroup analyses are exploratory in nature.  
10.3.3  Analysis of the key secondary efficacy variable  
The main analysis for the change from Week 36 to Week 40 in mean trough SiSBP 
measured by [CONTACT_686095]. The treatment groups in this 
Aprocitentan / ACT -132577  
Resistant hypertension  
Protocol ID -080A301  
Version 3  
27 February  2020 , page  97/[ADDRESS_930171] 2017 -004393 -33 
Doc No D-20.008  
analysis are aprocitentan 25 mg and placebo. The analyses will be adj usted for the stratum 
in the re -randomization (i.e., randomized treatment in the DB part). The  third null 
hypothesis (H 30) will be tested as described in Section 10.3.1 .  
[IP_ADDRESS]  Main analysis in the DB -WD part  
For the main analysis in the DB -WD part  the same approach was chosen as for the DB part 
for the reasons given in Section [IP_ADDRESS] . In addition, the initiation of antihypertensive 
rescue m edication (which is allowed in this part of the study) could influence the BP of a 
subject [ O’Neill 2012 ]. For this reason, AOBPM measurements obtained after  premature 
discontinuation of DB -WD treatment or initiation of antihypertensive rescue medication in 
the DB -WD part will be excluded from  this analysis  (i.e., considered as missing) , leading 
to a hypothetical  strategy estimand in the terminology of [ ICH E9  (R1)]. 
Changes from Week 36 to visits up to Week 48 in mean  trough SiSBP will be analyzed 
using a mixed model with factors for stratum, treatment group, tim e, and treatment by [CONTACT_26072], covariates for Week 36 SiSBP and the interaction between Week 36 and time 
and an unstructured covariance matrix.  
LSM  differences vs placebo for the change from Week 36 to Week 40 and their 95% CI s 
will be obtained from  the model. The associated P -values will be used to test the third null 
hypothesis. LSM  differences and their 95% CIs for changes from Week 36 to Weeks 44 
and 48 will be obtained from the same model.  
[IP_ADDRESS]  Handling of missing data in the DB -WD part  
It is expecte d that 10% of subjects in the mFAS will have a missing Week 40 AOBPM. 
Missing data will not be imputed but will be handled by [CONTACT_686096].  
[IP_ADDRESS]  Sensitivity analyses for missing data in the DB -WD part  
The impact of devi ations from the MAR assumption underlying the mixed model will be 
investigated in sensitivity analyses under MNA R as described for the DB part 
[Section  [IP_ADDRESS] ]. 
[IP_ADDRESS]  Supportive analyses in the DB -WD part  
In a supportive analysis,  all AOBPM measurements obtained after premature 
discontinuation of DB -WD treatment or initiation of antihypertensive rescue medication in 
the DB -WD part  will be included in  the analysis, leading to a treatment policy strategy 
estimand in the terminology of [ ICH E9  (R1)]. Additionally, an Analysis of Covariance 
(ANCOVA) will be perfor med for the change from Week [ADDRESS_930172].  
Aprocitentan / ACT -132577  
Resistant hypertension  
Protocol ID -080A301  
Version 3  
27 February  2020 , page  98/[ADDRESS_930173] 2017 -004393 -33 
Doc No D-20.008  
[IP_ADDRESS]  Subgroup analyses in the DB -WD part  
Sub-group analyses in the DB -WD part  will be performed as described for the DB part 
[Section [IP_ADDRESS] ]. In addition,  subgroup s based on the initiation of  antihypertensive rescue 
medication prior to the DB -WD part (Y/N)  will be considered. Subjects without 
antihypertensive rescue medication are considered an enriched sub -population of the 
mFAS.  
10.3.4  Analysis of the other secondary efficacy variables  
All other secondary efficacy variables will be tested at the two-sided significance level 
of 0.05.  
 Change from baseline to Week 4 of DB treatment in mean trough SiDBP measured
by [CONTACT_686097]
(main analysis) in the DB part.
 Changes from baseline to Week 4 of DB treatment in 24  h mean SBP and DBP
measured by [CONTACT_686098] a factor
for treatment group and a covariate for baseline 24  h mean SBP (or DBP).
 Change from Week 36 to Week 40 of DB -WD treatment in mean trough SiDBP as
measured by A OBPM  will be analyzed in the mFAS using the same model as
specified for SiSBP (main analysis) in the DB -WD part.
 Changes from Week 36 to Week 40 of DB -WD treatment in 24  h mean SBP and DBP
as measured by [CONTACT_686099] A NCOVA as
described for changes from baseline to Week 4 of DB treatment in 24  h mean SBP
and DBP, but with baseline replaced by [CONTACT_10585] 36.
10.3.5  Analysis of other efficacy variables  
The analyses of other efficacy variables will be described in detail in the SAP.  
10.3.6  Analysis of the safety variables  
Safety analyses in the DB and SB aprocitentan parts will be performed on the SAF. Safety 
analyses in the DB -WD part will be performed on the mSAF.  
Only treatment -emergent safety data up to EOT  + 30 days will be considered i n tables and 
figures. All safety data will be included in listings  based on the SCR or RI (as appropriate) , 
with flags for safety data not considered to be treatment -emergent.  
[IP_ADDRESS]  Adverse events  
[IP_ADDRESS].1  Treatment -emergent AEs  
Treatment -emergent AEs will be tabulated by [CONTACT_16051] (DB, SB or DB -WD), treatment 
group (within study part), system organ class (SOC) and preferred terms within each SOC: 
the number and percentage of subjects who experienced at least one AE, at least one AE 
Aprocitentan / ACT -132577  
Resistant hypertension  
Protocol ID -080A301  
Version 3  
27 February  2020 , page  99/[ADDRESS_930174] part. If, however, the intensity of the AE increases in the second part it is counted 
in that part as well.  
[IP_ADDRESS].2  Treatment -emergent SAEs  
SAEs will be summarized in a similar manner as de scribed in Section [IP_ADDRESS].1 . 
[IP_ADDRESS].3  AEs leading to premature discontinuation of study treatment  
(S)AEs leading to premature discontinuation of study treatment will be summarized in a
similar manner as described in Section [IP_ADDRESS].1 .
[IP_ADDRESS]  Laboratory data  
[IP_ADDRESS].1  Changes from baseline and Week 36 in laboratory variables  
Changes from baseline for laboratory tests to visits in the DB and  SB parts (henceforth, 
DB+SB) will be summarized using descriptive statistics by [CONTACT_3232] (in 
the DB part). Changes from Week 36 to visits in the DB -WD part will be summarized by 
[CONTACT_3232] (in the DB -WD part). Data will be displayed in SI units whenever 
possible and graphical approaches will be applied for certain variables.  
[IP_ADDRESS].2  Treatment -emergent marked laboratory abnormalities  
The number (%) of subjects with laboratory abnormalities will be tabulated by [CONTACT_16051] 
(DB+SB and DB-WD) and treatment group (within study part). Laboratory abnormalities 
will be defined in the SAP.  
[IP_ADDRESS].3  Ratios to baseline and Week 36 of NT -proBNP  
Ratios to baseline of NT -proBNP will be log transformed (base e) and analyzed in the 
DB+SB parts using a mixed model for repeated measurements with factors for treatment 
group (in the DB part), visit (up to Week 36) and treatment by [CONTACT_686100]  (NT-proBNP) and treatment by [CONTACT_420780]. Ratios to 
Week 36 of NT -proBNP in  the DB -WD part will be analyzed similarly, but with baseline 
replaced by [CONTACT_10585] 36.  
[IP_ADDRESS]  Vital signs  
Descriptive statistics by [CONTACT_16051] (DB+SB or DB -WD), visit and treatment group (within 
study part) will be provided for observed treatment -emergent values and absolute changes 
from baseline and Week 36 in body weight and pulse rate .  
Aprocitentan / ACT -132577  
Resistant hypertension  
Protocol ID -080A301  
Version 3  
27 February  2020 , page  100/[ADDRESS_930175] 2017 -004393 -33 
Doc No D-20.008  
[IP_ADDRESS]  ECG  
Descriptive statistics by [CONTACT_16051] (DB+SB or DB -WD), visit and treatment group (within 
study part) will be provided for observed treatment -emergent values and absolute changes  
from baseline in numeric 12 -lead ECG values (HR, PR, QRS, QT, QTcB, and QTcF).  
Treatment -emergent marked abnormalities for selected 12 -lead ECG variables (HR, PR, 
QT, QTcB, and QTcF) will be summarized by [CONTACT_686101].  
In addition, summ aries of treatment -emergent morphological ECG abnormalities that were 
not present before first study treatment intake (using data from the ECG provider) will be 
provided.  
[IP_ADDRESS]  Treatment -emergent MACE  and MACE -plus 
The number (%) of subjects with MACE  and MACE -plus will be tabulated by [CONTACT_16051] 
(DB, SB or DB -WD) and treatment group (within study part). Time from Randomization  
to (first) MACE  will also be described using a Cox model with a time -dependent covariate 
for treatment. Times to event will be censored at EOT  + 30 days. MACE -plus will be 
analyzed similarly . 
[IP_ADDRESS]  Increase in dose of existing diuretic or addition of new diuretic due to fluid 
retention  
This endpoint will be analyzed similarly to MACE.  
10.3.[ADDRESS_930176] deviation for the change from Week 36 to Week 40 in mean  trough SiSBP as 
measured by [CONTACT_686102] 15 mmHg (based on study AC -080A201). 
A diff erence vs placebo ( ‘delta ’) of at least 5 mmHg is considered clinically relevant.  
With a type I error of 0.05 (two -sided ; if both H [ADDRESS_930177] been rejected ), the size of 
the mFAS needed for 90% power to detect a difference of 5 mmHg between aprociten tan 
25 mg and placebo would be 380 subjects (190 in each of the two groups in the DB -WD 
part). The sample size is based on the t -test but provides similar  power for the mixed model. 
The anticipated drop -out rate is 37% in the 9 months between Randomizatio n and start of 
the DB -WD part  (based on the AC -080A201 study) . In order to have 380 subjects in the 
Aprocitentan / ACT -132577  
Resistant hypertension  
Protocol ID -080A301  
Version 3  
27 February  2020 , page  101/[ADDRESS_930178] 2017 -004393 -33 
Doc No D-20.008  
DB-WD part a total of 600 subjects need to be randomized (200 in each of the three groups 
in the DB part of the study).  
For the change from baseline to Wee k 4 in mean  trough SiSBP as measured by [CONTACT_686034] 
(primary endpoint) the clinically relevant difference vs placebo is around [ADDRESS_930179] this difference is well over 90 %. 
Table  [ADDRESS_930180] a treatment difference for the primary endpoint  
Delta (mmHg)  5.5 6.0 6.5 
Power (alpha=0.025 two -sided)  92% 96% 98% 
In case only one of the two doses in the DB part is statistically significantly better than 
placebo on the primary endpoint, the secondary endpoint must be tested at alpha=0.025 
(two-sided). In that case the power for the DB -WD part is 84%. However, testin g at 
alpha=0.025 is less likely than testing at alpha=0.05 ( under the assumptions made in the 
sample size calculations the probabilities are approximately 80% and 20%, respectively). 
On average, the power for the DB -WD part is approximately 88%.  
If the drop -out rate is greater than anticipated the sample size may be increased in order to 
ensure sufficient power for the DB -WD part. The sample s ize will not be decreased 
below  600. 
11 DATA HANDLING  
11.1 Data collection  
The investigator/delegate is responsibl e for ensuring the accuracy, completeness and 
timelines of the data reported. All source documents should be completed in a neat, legible 
manner to ensure accurate interpretation of the data. Data reported in the eCRF derived 
from source documents must be consistent with the source documents.  
eCRF data will be captured via electronic data capture. The investigator and site personnel 
will be trained to enter and edit the data via a secure network, with secure access features 
(username, password, and identification – an electronic password system). A complete 
electronic audit trail will be maintained. The investigator/delegate will approve the data 
(i.e., confirm the accuracy of the data recorded) using an electronic signature (ref. to US 
21 CFR Part 1 1). 
For each subject enrolled, regardless of study treatment initiation, an eCRF must be 
completed and signed by [CONTACT_093]/delegate. This also applies to those subjects who 
fail to complete the study.  
Aprocitentan / ACT -132577  
Resistant hypertension  
Protocol ID -080A301  
Version 3  
27 February  2020 , page  102/[ADDRESS_930181] 2017 -004393 -33 
Doc No D-20.008  
11.2 Maintenance of data confidentiality  
The investi gator/delegate must ensure that data confidentiality is maintained. On eCRFs or 
other documents (e.g., documents attached to SAE forms / Pregnancy forms) submitted to 
the sponsor and any vendors or CROs, subjects must be identified only by [CONTACT_686103], date of birth, hospi[INVESTIGATOR_42871], or any other personal 
identifier. The investigator/delegate must keep a subject identification code list at the site, 
showing the screening/randomization number, the subject ’s name, date of birth , and 
address or any other locally accepted identifiers. Documents identifying the subjects (e.g., 
signed ICFs) must not be sent to the sponsor, any vendor or CROs, and must be kept in 
strict confidence by [CONTACT_093]/delegate.  
11.[ADDRESS_930182] status at any time point during the course of the study.  
While entering the data, the investigator/delegate will be instantly alerted to data queries 
by [CONTACT_42940]. Additional data review will be performed by [CONTACT_686104]. If discrepant data are detected, a query specifying the issue and requesting 
clarification will be issued and visible to the investigator/delegate via the  eCRF. All 
electronic queries visible in the system either require a data correction (when applicable) 
and a response from the investigator/delegate to clarify the queried data directly in the 
eCRF, or simply a data correction in the eCRF. The investigator /delegate must, on request, 
supply the sponsor with any required background data from the study documentation or 
clinical records. This is particularly important when errors in data transcription are 
suspected. In the case of health authority queries, it i s also necessary to have access to the 
complete study records, provided that subject confidentiality is protected.  
This process will continue until database lock.  
Laboratory samples, ECGs , AOBPM and ABPM  will be processed through a central 
laboratory or ve ndor and the results of the randomized subjects will be electronically sent 
to the sponsor.  
AEs and medical history are coded according to the latest MedDRA  version used by [CONTACT_103]. Medications are coded according to the latest WHO Drug Dictionary ver sion used 
by [CONTACT_456].  
After the database has been declared complete and accurate, the database will be locked. 
Any changes to the database after that time may only be made as described in the 
Aprocitentan / ACT -132577  
Resistant hypertension  
Protocol ID -080A301  
Version 3  
27 February  2020 , page  103/[ADDRESS_930183] igator will receive the CRFs 
of the subjects of his/her site (including the audit trail)  as a portable document format file. 
12 PROCEDURES AND GOOD CLINICAL PRACTICE  
12.1 Ethics and Good Clinical Practice  
The sponsor personnel and the investigators will ensure tha t the study is conducted in full 
compliance with ICH -GCP Guidelines, the principles of the “Declaration of Helsinki ”, and 
with the laws and regulations of the country in which the study is conducted.  
12.2 Independent Ethics Committee / Institutional Review Boar d (IEC/IRB)  
The investigator will submit this protocol and any related document(s) provided to the 
subject (such as the ICF) to an IEC/IRB. Approval from the committee/board must be 
obtained before starting the study, and must be documented in a dated lett er to the 
investigator, clearly identifying the study, the documents reviewed, and the date of 
approval.  
Modifications made to the protocol or the ICF after receipt of the approval must also be 
submitted as amendments by [CONTACT_42942]/IRB in accordance with local 
procedures and regulations [see Section 12.6]. 
A list of members participating in the IEC/IRB meetings must be provided, inclu ding the 
names, qualifications, and functions of these members. If that is not possible, the attempts 
made to obtain this information along with an explanation as to why it cannot be obtained 
or disclosed must be documented in the study documentation.  
If a member of the site study personnel was present during an IEC/IRB meeting, it must be 
clear that this person did not vote.  
12.3 Informed consent  
It is the responsibility of the investigator/delegate to obtain informed consent according to 
ICH-GCP and Declarati on of Helsinki guidelines and local regulations from each 
individual subject participating in this study and/or his/her legally designated 
representative. The investigator/delegate must explain to subjects that they are completely 
free to refuse to enter t he study, or to voluntarily withdraw from the study at any time for 
any reason without having to provide any justification. Special attention shall be paid to 
the information needs of specific subject populations and of individual subjects, as well as 
to the methods used to give the information. Adequate time shall be given for the subject 
to consider his or her decision to participate in the study and it shall be verified that the 
subject has understood the information (e.g., by [CONTACT_686105]).  
The ICF will be provided in the country local language(s).  
Aprocitentan / ACT -132577  
Resistant hypertension  
Protocol ID -080A301  
Version 3  
27 February  2020 , page  104/[ADDRESS_930184] 2017 -004393 -33 
Doc No D-20.008  
Site personnel authorized (according to local regulation) to participate in the consent 
process and/or to obtain consent from the subject will be listed on the Delegat ion of 
Authority form.  
The subject and authorized site personnel listed on the Delegation of Authority form must 
sign, personally date, and time (if the first study -mandated procedure is to be performed on 
the same day informed consent is obtained) the ICF  before any study -related procedures 
(i.e., any procedures required by [CONTACT_760]) begin.  
The informed consent process must be fully documented in the subject ’s medical records. 
This must include at a minimum the study reference, the subject number, the  date and, if 
applicable, time when the subject was first introduced to the study, the date and, if 
applicable, time of consent, who participated in the consent discussion, who consented the 
subject, and any additional person present during the consent pro cess (e.g., subject ’s family 
member[s]), and the information that a copy of the signed ICF was given to the subject.  
12.4 Compensation to subjects and investigators  
The sponsor provides insurance in order to indemnify (with both legal and financial 
coverage) the investigator/site against claims arising from the study, except for claims that 
arise from malpractice and/or negligence.  
The compensation of the subject in the event of study -related injuries will comply with 
applicable regulations.  
12.5 Protocol adherence /compliance  
The investigator must conduct the study in compliance with the IEC/IRB and/or the 
regulatory authority -approved version of the protocol and must not implement any 
deviation/change from the protocol, except when deviation is necessary to elimina te an 
immediate hazard to the subject.  
If a protocol deviation occurs, the investigator/delegate will inform the sponsor or its 
representative in a timely manner. The investigator/delegate must document and explain 
any deviation from the approved protocol.  Deviations considered to be a violation of 
ICH-GCP must be reported to the IEC/IRB and regulatory authorities according to the 
sponsor or (overruling) local requirements.  
All protocol deviations will be reported in the CSR. IECs/IRBs will be provided with  
listings of protocol deviations as per local requirements.  
12.[ADDRESS_930185] be submitted to the IEC/IRB and regulatory authorities, according 
to their requirements.  
Aprocitentan / ACT -132577  
Resistant hypertension  
Protocol ID -080A301  
Version 3  
27 February  2020 , page  105/[ADDRESS_930186] 2017 -004393 -33 
Doc No D-20.008  
12.7 Essential documents and retention of documents  
The investigator/delegate must maintain adequate records necessary for the reconstruction 
and evaluation of the study. Several attributes are considered of universal importance to 
source da ta and the records that hold those data. These include that the data and records 
are accurate, legible, contemporaneous, original (or certified copy), attributable, complete, 
consistent, enduring, and available when needed.  
These records are to be classifi ed into two different categories of documents: ISF and 
subjects ’ source documents.  
These records must be kept by [CONTACT_259178] ’s requirements (i.e., as specified in the clinical study agreement), an d national 
and/or international regulations, whichever would be the longest period. If the investigator 
cannot guarantee this archiving requirement at the site for any or all of the documents, 
special arrangements, respecting the data confidentiality, must  be made between the 
investigator and the sponsor to store these documents outside the site, so that they can be 
retrieved in the event  of a regulatory inspection. No study document should be destroyed 
without prior written approval from the sponsor. Should the investigator wish to assign the 
study records to another party, or move them to another location, the sponsor must be 
notified in  advance.  
If the site is using an electronic/computerized system to store subject medical records, it 
can be used for the purpose of the clinical study if it is validated (as per [ADDRESS_930187]) and if the CRA has been provided  with personal and restricted access 
to study subjects only, to verify consistency between electronic source data and the eCRF 
during monitoring visits.  
If the site is using an electronic/computerized system to store subject medical records but 
it could not be c onfirmed that the system is validated or if the CRA could not be provided 
access to the system, the site is requested to print the complete set of source data needed 
for verification by [CONTACT_2689]. The print -outs must be numbered, stapled together with a 
cove rsheet, signed and dated by [CONTACT_093]/delegate to confirm that these certified 
copi[INVESTIGATOR_215182]. The 
printouts will be considered as the official clinical study records and must be filed  either 
with the subject ’s medical records or with the subject ’s eCRF.  
In order to verify that the process the site uses to prepare certified copi[INVESTIGATOR_42874], the 
CRA must be able to observe this process and confirm that the comparison of the source 
documents and the certified copy did not reveal inconsistencies. The CRA does not need 
to verify this process for all data of all subjects but at least for some of them (e.g., first 
subject; regular check during the study of critical data like inclusion/exclu sion criteria, 
endpoints for some subjects) as per the sponsor instructions. If it were not possible for the 
Aprocitentan / ACT -132577  
Resistant hypertension  
Protocol ID -080A301  
Version 3  
27 February  2020 , page  106/[ADDRESS_930188] 2017 -004393 -33 
Doc No D-20.008  
CRA to observe this process, it would not be possible to rely on the site ’s certified copi[INVESTIGATOR_686021].  
12.[ADDRESS_930189] be obtained. A site initiation visit 
(SIV) will be performed after the required essential study documents are approved by [CONTACT_103]. The study treatment will be shipped t o the site upon approval of the required 
essential documents.  
The PI [INVESTIGATOR_223138]. Site Information Technology support should also be 
available duri ng the SIV to assess the use of the eCRF.  
The SIV must be completed before the site can start the screening of study subjects. 
Following the SIV, a copy of the completed initiation visit report and follow -up letter will 
be provided to the PI [INVESTIGATOR_686022] t he ISF.  
During the study, the CRA will contact [CONTACT_42947], 
on request, to have access to study facilities and all source documents needed to verify 
adherence to the protocol and the completeness, consistency, and acc uracy of the data being 
entered in the eCRFs and other protocol -related documents. The sponsor monitoring 
standards require full verification that informed consent has been provided, verification of 
adherence to the inclusion/exclusion criteria, documentat ion of SAEs, and the recording of 
the main efficacy, safety, and tolerability endpoints. Additional checks of the consistency 
of the source data with the eCRFs will be performed according to the study -specific 
monitoring guidelines. The frequency of the mo nitoring visits will be based on subject 
recruitment rate and critical data -collection times.  
The PI [INVESTIGATOR_223139] a subject ’s visit (site visit or telephone 
call), and that all requested subject files (e.g., ICFs, medical no tes/charts, other 
documentation verifying the activities conducted for the study) are available for review by 
[CONTACT_2689]. The required site personnel must be available during monitoring visits and allow 
adequate time to meet with the CRA to discuss study -related issues.  
The investigator agrees to cooperate with the CRA(s) to ensure that any issues detected in 
the course of these monitoring visits are resolved. If the subject is hospi[INVESTIGATOR_42878] a 
hospi[INVESTIGATOR_42869], the investigator is r esponsible for contact[CONTACT_42948][INVESTIGATOR_42879], in accordance with local regulations.  
A close -out visit will be performed for any initiated site when there are no more active 
subjects and all follow -up issues have been resolved. If a site does not enroll any subjects, 
the close -out visit may be performed prior to study closure at the discretion of the sponsor.  
Aprocitentan / ACT -132577  
Resistant hypertension  
Protocol ID -080A301  
Version 3  
27 February  2020 , page  107/[ADDRESS_930190] be kept by [CONTACT_606046] ’s 
requirements (i.e., as specified in the clinical study agreement), ICH -GCP and national 
and/or international regu lations, whichever would be the longest period. If the site needs 
to transfer the ISF to another location and/or if site facility can no longer store the ISF, the 
PI [INVESTIGATOR_400384].  
If the PI [CONTACT_48599] s or if the site relocate s the CRA must be notified as soon as possible.  
12.10  Audit  
The sponsor representatives may audit the investigator site (during the study or after its 
completion). The purpose of this visit will be to determine the investigator ’s adherence to 
ICH-GCP, the protoco l, and applicable regulations; adherence to the sponsor requirements 
(e.g., standard operating procedures ) will also be verified. Prior to initiating this audit, the 
investigator will be contact[CONTACT_461692] a time for the audit.  
The investi gator and site personnel must cooperate with the auditor(s) and allow access to 
all study documentation (e.g., subject records) and facilities.  
12.11  Inspections  
Health authorities and/or IEC/IRB may also conduct an inspection of this study (during the 
study or after its completion) at the site.  
Should an inspection be announced by a health authority and/or IEC/IRB, the investigator 
must immediately inform the sponsor (usually via the CRA) that such a request has been 
made.  
The investigator and site personnel mus t cooperate with inspector(s) and allow access to 
all study documentation (e.g., subject records) and study facilities.  
Aprocitentan / ACT -132577  
Resistant hypertension  
Protocol ID -080A301  
Version 3  
27 February  2020 , page  108/[ADDRESS_930191] the key elements of this protocol and the summary of results within 
the required timelines on publicly  accessible databases (e.g., clinicaltrials.gov, EU 
database), as required by [CONTACT_42951].  
Study results will be documented in a CSR that will be signed by [CONTACT_456] ’s 
representatives  and the Coordinating Investigato r. 
In accordance with the Good Publication Practices and ethical practice as outlined in 
internationally recognized guidance documents (e.g., European Medical Writers 
Association, American Medical Writers Association, International Society for Medical 
Publication Professionals), the results of the study will be submitted for publication in a 
peer-reviewed journal. Study results can be submitted for presentation at a congress before 
submission to a peer -reviewed journal.  
Authorship will be determined in acco rdance with the International Committee of Journal 
Editors criteria, and be based on:  
substantial contributions to the conception or design of the study, or the acquisition,
analysis, or interpretation of data; and
drafting of the publication or critical r eview for important intellectual content; and
providing final approval of the version to be published; and
agreement to be accountable for all aspects of the work in ensuring that questions
related to the accuracy or integrity of  any part of the work are a ppropriately
investigated and resolved.
The list of authors of any publication of study results may include representatives of the 
sponsor and will be determined by [CONTACT_11402].  
Any study -related publication written independently by [CONTACT_686106] [ADDRESS_930192] 
alterations and/or deletions for the sole purpose of protecting its confidential information 
and/or patent rights. Neither the institution nor the investigator should permit publication 
during such a review period.  
Aprocitentan / ACT -132577  
Resistant hypertension  
Protocol ID -080A301  
Version 3  
27 February  2020 , page  109/[ADDRESS_930193] 2017 -004393 -33 
Doc No D-20.008  
13 REFERENCES  
[D-18.046] A single -center, double -blind, randomized, placebo -controlled, two -way 
crossover study to evaluate potential body weight increase induced by [CONTACT_686107]‒132577 in healthy male subjects on a high -sodium diet . 
Idorsia Pharmace uticals Ltd; Clinical Study Report AC -080-102. Report in 
preparation.  
[Aprocitentan  IB] Investigator ’s Brochure for aprocitentan, version 5. Idorsia  
Pharmaceuticals Ltd; March 2018. 
[Bangalore  2014] Bangalore S, Fayyad R, Laskey R, Demicco DA, Deedwania P,  
Kostis  JB, et al. Prevalence, predictors, and outcomes in treatment -resistant 
hypertension in patients with coronary  disease. Am J Med. 2014;127:71 –81. 
[Bhatt  2014]  Bhatt DL, Kandzari DE, O ’Neill WW, D ’Agostino R, Flack JM, Katzen  BT, 
et al. A controlled trial of renal denervation for resistant hypertension. N Eng J Med. 
2014;370:1393 –401.  
[Cai 2017] Cai A, Calhoun DA. Resistant Hypertension: An Update of Experimental and 
Clinical Findings. Hypertension.  2017 Jul;  70(1):5 –9. 
[Calhoun  2008] Calhoun DA, Jon es D, Textor S, Goff DC, Murphy TP, Toto RD , et al. 
Resistant Hypertension: Diagnosis, Evaluation and Treatment. A Scientific 
Statement from the American Heart Association Professional Education Committee 
of the Council for High Blood Pressure Research. Hy pertension 2008:51:1403 –19. 
[Carpent er 2013] Carpenter JR, Roger JH, Kenward MG. Analysis of longitudinal trials 
with protocol deviation: a framework for relevant, accessible assumptions, and 
inference via multiple imputation. Journal of Bio pharmaceutical Statistics 
2013; 23:1352 –71. 
[Chobanian 2003] Chobanian AV, Backris GL, Black HR, Cushman WC, Green LA, 
Izzo JL Jr, et al. National Heart Lung and Blood Institute Joint National Committee 
on Prevention, Detection, Evaluation, and Treatment of High Blood Pres sure; 
National High Blood Pressure Education Progr am Coordinating Committee. The 
Seventh Re port of the Joint National Committee on Prevention, Detection, 
Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 
2003;289:2560 –72. 
Aprocitentan / ACT -132577  
Resistant hypertension  
Protocol ID -080A301  
Version 3  
27 February  2020 , page  110/[ADDRESS_930194] 2017 -004393 -33 
Doc No D-20.008  
[Chrysant  1979]  Chrysant SG, Danisa K, Kem DC, Dillard BL, Smith WJ, Frohlich ED. 
Racial differences in pressure, volume and renin interrelationships in essential 
hypertension. Hypertension. 1979;(2):136 –41. 
[Daskalopoulou  2012] Daskalopoulou SS, Khan NA, Quinn RR, et al. The 2012 Canadian 
Hypertension Education Program recommendations for the management of 
hypertension: blood pressure measurement, diagnosis, assessment of risk, and 
therapy. Can J Cardiol 2012;28:270 –87. 
[Daugherty  2012] Daugherty SL, Powers JD, Magi d DJ,  Tavel HM, Masoudi FA, 
Margolis  KL, et al. Incidence and prognosis of resistant hypertension in hypertensive 
patients. Circulation. 2012 Apr 3;125(13):1635 –42. 
[Davenport  2016 ] Davenport AP, Hyndman KA, Dhaun N, Southan C, Kohan  DE, Pollock 
JS, et al. Endothelin. Pharmacol 2016;68:357 –418. 
[De Nicola  2013] De Nicola L, Gabbai FB, Agarwal R, Chiodini P, Borrelli S, Bellizzi V, 
et al. Prevalence and prognostic role of resistant hypertension in chronic kidney 
disease patients. J Am Coll Cardiol. 2013;61(24):2461 –7. 
[DeFelice  2008] DeFelice A, Willard J, Lawrence J, Hung J, Gordon MA, Karkowsky A, 
et al. The risks associated with short -term placebo -controlled antihypertensive 
clinical trials: a descriptive meta -analysis. J Hum Hypertens. 2008 ;22(10):659 –68.  
[Denolle  2014 ] Denolle  T, Chamontin B , Doll G, Fauvel JP , Girerd X , Herpin D , et al 
[Management of resistant hypertension. Expert consensus statement from the French 
Society of Hypertension, an affiliate of the French Society of Cardiology ]. Presse 
Med.2014;43:1325 –31. French  
[Desai 2006] Desai M, Stockbridge N, Temple R. Blood pressure as an example of a 
biomarker that functions as a surrogate. AAPS J. 2006;8(1):146 –52. 
[Dhaun 2 008] Dhaun N, Goddard J, Donald E, Pollock DM, Schiffrin EL, Webb DJ. Role 
of Endothelin -1 in Clinical Hypertension – 20 Year s on. Hypertension. 2008;52:  
452–59. 
[EMA  2016a] European Medicines Agency.  Guideline on clinical investigation of 
medicinal produc ts in the treatment of hypertension  
(EMA/CHMP/[ZIP_CODE]/2013/Rev.4), 23 June 2016. [accessed on 8  March  2018]. 
Available from:   
http://www.ema.europa.eu/ema/pages/includes/document/open_document.jsp?web
ContentId=WC500209943  
Aprocitentan / ACT -132577  
Resistant hypertension  
Protocol ID -080A301  
Version 3  
27 February  2020 , page  111/[ADDRESS_930195] 2017 -004393 -33 
Doc No D-20.008  
[EMA  2016b] European Medicines Agenc y. Reflection paper on assessment of 
cardiovascular safety profile of medicinal products ( EMA/CHMP/[ZIP_CODE]/2015 ) 
25 February 2016. [accessed 8 March  2018]. Available from:   
http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/201
6/03/WC500203804.pdf  
[Ergul 1996]  Ergul S, Parish DC, Puett D, Ergul A . Racial differences in plasma 
endothelin -1 concentrations in individuals with essential hypertension. 
Hyper tension. 1996;28(4):652 –5. 
[Gaddam 2008]  Gaddam KK, Nishizaka MK, Pratt Ubunama MN, Pi[INVESTIGATOR_274650] E, Aban I, 
Oparil S, et al. Characterization of resistant hypertension: association between 
resistant hypertension, aldosterone, and persistent intravascular volume  expansion. 
Arch Intern Med. 2008;168(11):1159 –64. 
[Go 2013] Go AS, Mozzaffarian D, Roger VL , Benjamin EJ, Berry JD, Borden WB , et al. 
Heart Disease and Stroke statistics - 2013 update: a Report from the American Heart  
Association. Circulation 2013; 127:e6 -e245.  
[ICH E9  (R1)] International Council for Harmonisation Guideline E9 (R1) Estimands and 
sensitivity analysis in clinical trials to the guideline on statistical principles for 
clinical trials.  Available from:   
http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/
E9/E9 -R1EWG_Step2_Guideline_2017_0616.pdf  
[Juurlink  2004] Juurlink DN, Mamdani MM, Lee DS, Kopp A, Austin PC, Laupacis A, 
et al. Rates of hyperkalemia after publication of the Ra ndomized Aldactone 
Evaluation Study. N Engl J Med 2004;351:543 –51. 
[Kassel 2015] Kassel LE, Odum LE. Our Own Worst Enemy: Pharmacologic  Mechanisms 
of Hypertension . Adv Chronic Kidney D is. 2015 May;22(3):245 –52. 
[Kellum  2013] Kellum JA, Lameire N, KDIGO AKI  Guideline Work Grou p. Diagnosis, 
evaluation, and management of acute kidney injury: a kdigo summary (Part 1). Crit 
Care 2013  4;17(1):204.  
[Kohan  2011] Kohan DE, Rossi NF, Inscho EW, Pollock DM. Regulation of blood 
pressure and salt homeostasis by [CONTACT_686108]. Physiol Rev 2011 ;91(1):1 –77. 
[Krogager 2017] Korgager ML, Torp -Pedersen C, Mortensen RN, Køber L, Gislason G, 
Søgaard P, et al. Short -term mortality risk of serum potassium levels in hypertension: 
a retrospective analysis of nationwide registry data. Eu Heart J 2017;38:104 –12. 
Aprocitentan / ACT -132577  
Resistant hypertension  
Protocol ID -080A301  
Version 3  
27 February  2020 , page  112/[ADDRESS_930196] 2017 -004393 -33 
Doc No D-20.008  
[Kumbhani 2013] Kumbhani DJ, Steg PG, Cannon CP, Eagle KA, Smith SC, Crowley K, 
et al. Resistant hypertension: a frequent and ominous finding among hypertensive 
patients with atherothrombosis. Eu Heart J. 2013;34(16):1204 –14. 
[Lancet 1981] Adverse reactions to bendrofluazide and propranolol for the treatment of 
mild hypertension. Report of Medical Research Council Working Party on Mild to 
Moderate Hypertension. Lancet. 1981 ;12;(8246):539 –43. 
[Leung 2017] Leung AA, Daskalopoulou SS , Dasgupta K, McBrien K, Butalia S, Zarnke 
KB, et al.  Hypertension Canada ’s 2017 guidelines for d iagnosis, r isk assessment, 
prevention, and treatment of hypertension in a dults . Can J Cardiol. 2017;33(5):  
557–76. 
[Levey  2009] Levey AS, Cattran D , Friedman A , Miller WG, Sedor J, Tuttle K , et al. 
Proteinuria as a Surrogate Outcome in CKD: Report of a Scientific Workshop 
Sponsored by [CONTACT_686109]. Am J kidney Diseases 2009; 54:205 –26.  
[Lim 2012] Lim SS, Vos T, Flaxman AD, Danaei G, Shibuya K, Adair -Rohani H, et al. A 
comparative risk assessment of burden of disease and injury attributable to 67 risk 
factors and risk factor clusters in 21 regions, 1990 –2010: a systematic analysis for 
the Global Burden of D isease Study 2010. Lancet 2012;380:2224 –60. 
[Luft 1979] Luft FC, Grim CE, Fineberg N, Weinberger MC. Effects of volume expansion 
and contraction in normotensive whites, blacks, and subjects of different ages. 
Circulation. 1979 Apr;59(4):643 –50. 
[Mallinckro dt 2013]  Mallinckrodt C, Roger J, Chuang -stein C, Molenberghs G, Lane PW, 
O’Kelly M. Missing data: turning guidance into action. Statistics in 
Biopharmaceutical Research 2013; 4:369 –82. 
[McCormack  2013] McCormack T, Arden C, Begg A, Ca ulfield M, Griffith K,  
Williams  H. Optimising hypertension treatment: NICE/BHS guideline 
implementation and audit for best practice. Br J Cardiol. 2013;20(suppl 1):S1 –S16. 
[Myat  2012] Myat A, Redwood SR, Qureshi AC, Spertus JA, Williams B. Resistant 
hypertension. BMJ 2012;345:e 7473.  
[Myers 2010] Myers MG, Godwin M, Dawes M, Kiss A,  Tobe SW, Kaczorowski J.  et al. 
Measurement of blood pressure in the office recognizing the problem and proposing 
the solution. Hypertension. 2010;55:195 -200. 
Aprocitentan / ACT -132577  
Resistant hypertension  
Protocol ID -080A301  
Version 3  
27 February  2020 , page  113/[ADDRESS_930197] 2017 -004393 -33 
Doc No D-20.008  
[O’Neill 2012] O’Neill RT, Temple R.  The p revention and treatment of missing data in 
clinical trials: an FDA perspective on the importance of dealing with it.  Clin 
Pharmacol Ther. 2012 Mar;91(3):550 –4. 
[Oparil 2015] Oparil S, Schmieder RE. New approaches in the treatment of hypertension. 
Circ Res.  2015 Mar 13;116:1074 –95. 
[Palmer  2002]  Palmer BF. Renal dysfunction complicating the treatment of hypertension.  
N Engl J Med 2002;347(16):1256 –61. 
[Pellicori 2017] Urbinati A, Shah P, MacNamara A, Kazmi S, Dierckx R, Zhang J, et al. 
What proportion of pa tients with chronic heart failure are eligible for 
sacubitril -valsartan?  Eur J Heart Fail. 2017 Jun;19(6):768 –78. 
[Pi[INVESTIGATOR_11721] 2005] Pi[INVESTIGATOR_65528], Hall JE, Appel LJ , Falkner BE, Graves J, Hill MN , et al. 
Recommendations for blood pressure measurement in huma ns and experimental 
animals part 1: Blood pressure measurement in humans, a statement for professionals 
from the subcommittee of professional and public education of the American Heart 
Association council on high blood pressure research. Circulation. 2005; 111: 
697–716. 
[Poulter  2015] Poulter NR, Prabhakaran D, Caulfield M. Hypertension. Lancet. 
2015;386:801 –12. 
[Ratitch  2013] Ratitch B, O ’Kelly M, Tosiello R. Missing data in clinical trials: from 
clinical assumptions to statistical analysis using pattern mixture models in SAS. 
Pharmaceutical Statistics 2013; 12:337 –47. 
[Rimoldi 2013] Rimoldi SF, Scherrer U, Messerli FH. Secondary arterial hypertension: 
when, who, and how to screen? Eur Heart J. 2014 May 14; 35(19):1245 –54. 
[Rossignol  2015] Rossignol P, Massy ZA, Azizi M, Bakris G, Ritz E, Covic A, et. al. The 
double challenge of resistant hypertension and chronic kidney disease. Lancet. 
2015;386([ZIP_CODE]):15 88–98. 
[Rubin 1987] Rubin DB. Multiple imputation for nonresponse in surveys. John Wiley  & 
Sons, Inc. [LOCATION_003]; 1987.  
[Schiffrin 1998] Schiffrin EL. Endothelin and endothelin antagonists in hypertension. J 
Hypertens. 1998;16(12 Pt 2):1891 –5. 
Aprocitentan / ACT -132577  
Resistant hypertension  
Protocol ID -080A301  
Version 3  
27 February  2020 , page  114/[ADDRESS_930198] 2017 -004393 -33 
Doc No D-20.008  
[Sheppard 2017] Sheppard JP, Martin U, McManus RJ. Diagnosis and management of 
resistant hypertension. Heart 2017;103:1295 –302. 
[Solini 2014] Solini A, Zoppi[INVESTIGATOR_9384] G, Orsi E, Fondelli C, Trevisan R, Vedovato M, et al. 
Resistant hypertension in patients with type 2  diabetes: clinical correlates and 
association with complications. J Hypertens. 2014;32(12):2401 –10. 
[Strauss  1951] Strauss MB, Davies RK, Rosembaum JD , Rossmeisl EC.  Water d iuresis 
produced during recumbency by [CONTACT_686110]. 
J Clin Invest 1951:30;862 –8. 
[Thomopoulos  2016a]  Thomopoulos C, Parati G, Zanchetti A.  Effects of 
blood -pressure -lowering treatment in hypertension: 9. Discontinuations for adverse 
events attributed to different classes of antihypertensive drugs:  meta -analyses of 
randomized trials. J Hypertens.  2016  34(10) :1921 –32.  
[Thomopoulos  2016b ] Thomopoulos C, Parati G, Zanchetti A.  Effects of blood pressure 
lowering treatment in hypertension: 8. Outcome reductions vs. discontinuations 
because of adverse dr ug events - meta -analyses of randomized trials. J Hypertens. 
2016;34(8):1451 –63. 
[Tsioufis 2014] Tsioufis C, Kasiakogias A, Kordalis A, Dimitriadis K, Thomopoulos C, 
Tsiachris D, et al. Dynamic resistant hypertension patterns as predictors of 
cardiovascula r morbidity: a 4 -year prospective study. J  Hypertens 2014;32:415 –22. 
[Václavík 2011] Václavík J, Sedlák R, Plachy M, Navrátil K , Plásek J, Jarkovsky J , et al. 
Addition of spi[INVESTIGATOR_686023] 
(ASPI[INVESTIGATOR_686024]): a randomized, double -blind, placebo -controlled trial. Hypertension 
2011;57(6):1069 –75.  
[Weber 2009]  Weber MA, Black H, Bakris G, Krum H, Linas S, Weiss R, et a l. A selective 
endothelin -receptor antagonist to reduce blood pres sure in patients with 
treatment -resistant hypertension: a randomized, double -blind, placebo -controlled 
trial. Lancet. 2009;347:1423 –31. 
[Weber 2014] Weber MA, Schiffrin EL, White WB, Mann S,  Lindholm LH, Kenerson JG, 
et al. Clinical Practice Guidelines for the Management of Hypertension in the 
Community. J Clin Hypertens . 2014 ;16(1):14 –26. 
Aprocitentan / ACT -132577  
Resistant hypertension  
Protocol ID -080A301  
Version 3  
27 February  2020 , page  115/[ADDRESS_930199] 2017 -004393 -33 
Doc No D-20.008  
[Whelton  2017]  Whelton PK, Carey RM, Aronow WS, Casey DE Jr, Co llins KJ, Dennison 
Himmelfarb C.  2017 ACC /AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/  
ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and 
Management of High Blood Pressure in Adults: A Report of the American College 
of Cardiology/American Heart Association Task Force on Clinical Practice 
Guidelines.  Hypertension. 2017  Nov 13  PMID: 29133356 . ePub ahead of print.  
[White  2014] White WB, Turner JR, Sica DA, Bisognano JD, Calhoun DA, Townsend  RR, 
et al. Detection, evaluation, and treatment of severe and resistant hypertension: 
Proceedings from a n American Society of Hypertension Interactive Forum held in 
Bethesda, MD, [LOCATION_003], October 10th 2013. J Am Soc Hypertension. 
2014;8(10);743 -57. 
[Williams  2012] in BMJ 2012;345:e7473 doi: 10.1136/bmj.e7473 (Published 20 
November 2012).  
[Williams  2015] William s B, MacDonald TM, Morant S , Webb DJ, Sever P, McInnes G , 
et al. Spi[INVESTIGATOR_310592], bisoprolol, and doxazosin to determine the 
optimal treatment for drug -resistant hypertension (PATHWAY -2): a randomised, 
double -blind, crossover trial. Lancet. 2 015;386([ZIP_CODE]):2059 –68. 
[Williams  2018] Williams B, Mancia G, Spi[INVESTIGATOR_110971] W, Agabiti Rosei E, Aziz M, Burnier M, 
et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur 
Heart J 2018;39(33):3021 –3104.  
[Wright 2015]  Wright JT Jr, Williamson JD, Whelto n PK, Snyder JK, Sink KM, 
Rocco  MV, et al. A Randomized Trial of Intensive versus Standard Blood -Pressure 
Control.  N Engl J Med. 2015;373(22):2103 –16. 
Aprocitentan / ACT -132577  
Resistant hypertension  
Protocol ID -080A301  
Version 3  
27 February  2020 , page  116/[ADDRESS_930200] 2017 -004393 -33 
Doc No D-20.008  
14 APPENDICES  
Appendix 1 Forbidden drugs 
A)Medication which may affect BP:
Inhibitors of vascular endothelial growth factor such as  bevacizumab , or tyrosine
kinase inhibitors  such as sunitinib and sorafenib ,
Immunosuppressive agents : cyclosporine  and tacrolimus  (topi[INVESTIGATOR_59407] s of
tacrolimus  are permitted) ,
Sympathomimetics (any formulation),
oIntermittent (not daily) use of topi[INVESTIGATOR_2855]  (nasal /inhalers /drops ) decongestants
is permitted, except within 3 days prior to a study visit.
Diet pi[INVESTIGATOR_3353]: phenylpropanolamine and sibutramine ,
Stimulants : amphetamines and cocaine (topi[INVESTIGATOR_686025] ),
Herbal supplements : ephedra, ma huang, Yohimbine,
Systemic c orticosteroids (topi[INVESTIGATOR_686026] /inhalers/drops/ local  injection  applications
are permitted ),
CYP17A1 inhibitors  such as abiraterone ,
Phosphodiesterase type 5  inhibitors: except intermittent (not daily) use of sildenafil,
vardenafil or tadalafil (e.g., ®, ®, ®) within 5 days prior to a
study visit ,
Licorice .
For details information, please refer t o Kassel et al [Kassel 2015 ]. 
B) Antihypertensive therapi[INVESTIGATOR_686027] ,
rescue medication  including diuretics, and diuretics for treatment of clinically relevant
fluid retention  [see Section 5.2.2 , [IP_ADDRESS] , and [IP_ADDRESS] ], such as:
Drugs that target the renin -angiotensin system ;
oACEIs  (e.g., benazepril, captopril, enalapril, fosinopril, lisinopril,
moexipril, perindropril, quinapril, ramipril, trandolapril).
oARBs  (e.g., azilsartan, candesartan, eprosartan, ibresartan, losartan,
olmesartan, telmisartan).

Aprocitentan / ACT -132577  
Resistant hypertension  
Protocol ID -080A301  
Version 3  
27 February  2020 , page  117/[ADDRESS_930201] renin inhibitor (e.g., a liskiren ).  
 Diuretics ;  
o Thiazide and thiazide like diuretics (e.g., bendrofluazide, 
bendroflumethiazide, chlorthalidone, hydroflumethiazide, indapamide, 
methylclothiazide, metolazone, polythiazide ),  
o Loop diuretics (e.g., bumetanide,  furosemide, pi[INVESTIGATOR_28967], torsemide ),  
o Potassium -sparing diuretics (e.g., amiloride, eplerenone, spi[INVESTIGATOR_8407], 
triamterene).  
 CCBs ; 
o Dihydropyridines (e.g.,  felodipi[INVESTIGATOR_050], isradipi[INVESTIGATOR_050], nicardipi[INVESTIGATOR_050], nifedipi[INVESTIGATOR_050], 
nitrendipi[INVESTIGATOR_050], nisoldipi[INVESTIGATOR_050]).  
o Non dihydropyridines (e. g., diltiaz em, verapamil).  
 
 Alpha -adrenergic receptors blockers (e.g ., doxazosin, phenoxybenzamine, 
phentholamine, prazosin, terazosin), with the exception of alfuzosin  and tamsulosin 
for prostatic symptoms  [see Section  5.2.3], 
 Vasodilators (e.g., hydralazine, minoxidil ), 
 Central alpha -agonists  (e.g., clonidine, clonidine patch, guanfacine, methyldopa, 
rilmenidine ), 
 Adrenergic depleters (e.g., reserpi[INVESTIGATOR_050]).  
 
C) ERA s (e.g., bosentan, macitentan, ambrisentan) . 
For detailed information, please refer to American Society of Hypertension guidelines 
[Weber 2014 ]. 